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 Resumen 
ix 
 
There is increasing evidences showing that cancer is not only a genetic disease but also an 
epigenetic disease. The most important epigenetic regulators are the Polycomb and trithorax 
complexes and DNA methylation. Moreover several cancers show altered expression of 
microRNAs that also deregulate several genes. In this work, we have undertaken the study of 
SUZ12, a Polycomb group protein and the microRNAs (miRNA) expressed by the oncogenic 
Epstein Barr Virus (EBV) in different B-cell lymphoma types. 
SUZ12 is a component of the Polycomb PRC2 complex, along with EZH2, that has been 
involved in embryonic stem cell differentiation. Various results coincide in showing that EZH2 
plays an essential role in many cancer types, but this has not been as fully demonstrated for 
SUZ12. In the first part of this work, we report SUZ12 protein expression and genetic 
alterations in several tumors and especially in Mantle Cell Lymphoma (MCL), a tumor whose 
pathogenesis is not completely understood. Additionally, functional and genomic studies 
demonstrate that SUZ12 targets genes involved in central oncogenic pathways are associated 
with MCL pathogenesis and SUZ12 deficiency results in reduced viability of MCL cells. Our 
results support the hypothesis that the abnormal expression of SUZ12 in MCL may account for 
some of the still unexplained features of MCL, and lead us to propose a putative oncogenic 
role for SUZ12. These data suggest that drugs targeting the PRC2 complexes, such as LBH589, 
could be a rational therapeutic approach for MCL patients. 
EBV is a very successful virus that infects B cells, inducing proliferation of EBV carrying B-
lymphocytes. EBV infection disrupts the normal B cell program and abrogates the formation of 
normal germinal centers by infected B cells. BCL6 is a key transcriptional repressor required for 
germinal centre reaction and it has been shown to repress NF-κB in DLBCL. However, EBV 
positive DLBCL are usually BCL6-negative.  
In the second part of this work, we have found a restricted cluster of viral microRNAs that is 
expressed in EBV-positive patients. By immunohistochemical studies we have found an almost 
perfect inverse correlation between EBV infection and BCL6 protein expression in cases of 
DLBCL. Using a bioinformatic approach we have found that several of these miRNAs can 
potentially target the 3’UTR of BCL6. Functional experiments have allowed us to demonstrate 
the effect of these miRNAs on BCL6. With these results we hypothesize that BCL6 
downregulation might be necessary for DLBCL cells to survive in the context of EBV infection, 
probably in order to allow the activation of the NF-κB pathway. 
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Cada vez hay más evidencias que demuestran que el cáncer no es sólo una enfermedad 
genética, sino también epigenética. Los reguladores epigenéticos más importantes son los 
complejos Polycomb y Trithorax y la metilación del ADN. Además muchos tumores presentan 
una expresión alterada de microARNs que desorganizan la expresión de varios genes. En el 
presente trabajo, hemos abordado el estudio de SUZ12, una proteína del grupo Polycomb y de 
microARNs expresados por el virus de Epstein Barr en diferentes tipos de linfomas B. 
SUZ12 es un componente del complejo Polycomb PRC2, junto a EZH2, que ha sido 
implicado en la diferenciación de células troncales embrionarias. Varios resultados coinciden 
en mostrar que EZH2 interpreta una función esencial en muchos tipos de cáncer, pero esto 
mismo no se ha demostrado totalmente para SUZ12. En la primera parte de este trabajo, 
mostramos alteraciones genéticas y en la expresión de SUZ12 en varios tumores, 
especialmente en linfoma de célula del manto, un tumor cuya patogenia no se entiende 
totalmente. Además, estudios genómicos y funcionales demostraron que SUZ12 regula genes 
implicados en vías de señalización oncogénicas asociadas con la patogenia del linfoma de 
célula del manto y que la deficiencia de esta proteína reduce la viabilidad de las células de este 
linfoma. Nuestros resultados avalan la hipótesis de que la expresión anormal de SUZ12 en 
linfoma del manto da cuenta de algunas de las características sin explicación de este tumor y 
nos permiten proponer una función oncogénica para SUZ12. Por otro lado, estos datos 
sugieren que fármacos que interfieren con los complejos PRC2, tales como el LBH589, pueden 
suponer una aproximación terapéutica alternativa para los pacientes de linfoma del manto. 
El virus de Epstein Barr es un virus que infecta de manera muy eficiente células B induciendo la 
proliferación de estos linfocitos. Esta infección interfiere con el programa normal de desarrollo 
de las células B e impide la participación de estas células en la formación de centros 
germinales normales. BCL6 es un represor transcripcional clave requerido para la reacción del 
centro germinal y se ha demostrado que es capaz de inhibir la vía de NF-κB en linfoma difuso 
de células B grandes. Sin embargo, los casos de linfoma difuso positivos para el virus de 
Epstein Barr suelen ser negativos para BCL6.  
En la segunda parte de este trabajo, hemos encontrado un grupo restringido de microARNs 
que se expresa en los casos de linfoma difuso positivos para el virus de Epstein Barr. Mediante 
estudios inmunohistoquímicos hemos encontrado una correlación inversa casi perfecta entre 
la presencia del virus y la expresión de BCL6 en estos casos. Mediante un análisis 
bioinformático hemos podido comprobar que muchos de estos microARNs pueden, 
potencialmente, inhibir BCL6. Experimentos funcionales nos ha permitido demostrar el efecto 
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de estos microARNs sobre BCL6. Con estos resultados podemos especular que la inhibición de 
BCL6 podría ser necesaria para la supervivencia de los linfomas difusos en el contexto de una 
infección por el virus de Epstein Barr, permitiendo la activación de la vía de NF-κB.
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1.1 HEMATOLOGIC MALIGNANCIES: LYMPHOMAS 
 
1.1.1 GENERAL ASPECTS 
The word lymphoma encompasses a series of B and T cell derived malignancies with very 
different courses and prognosis. They constitute around 4-5% of all newly diagnosed cancers in 
developed countries and its incidence has followed an increasing tendency in the last years 
(Altekruse et al., 2009).  
Lymphomas are classified attending to their morphology, immunophenotype, clinical 
course as well as genetic and cytogenetic characteristics. Although lymphoma classification is 
dynamic and frequent revisions are published, there are two major categories recognized: 
Hodgkin lymphoma (HL, discovered by Thomas Hodgkin in 1832, being the first lymphoma to 
be described) and non-Hodgkin lymphoma (NHL). Non-Hodgkin lymphomas constitute 87.5% 
of all lymphomas and include neoplasms derived from B and T/NK cells. B cell lymphomas 
account for nearly 85% of all non-Hodgkin lymphomas though (Altekruse et al., 2009). 
Lymphoma classification is complex (Table 1.1) and its extension is out from the scope of 
this work. Thus, due to their relevance for this doctoral thesis, only two lymphoma subtypes 
are going to be described: mantle cell lymphoma and diffuse large B cell lymphoma. 
 
1.1.2 MANTLE CELL LYMPHOMA 
Mantle cell lymphoma (MCL) is a type of high-grade (i.e. fast-growing or aggressive) small 
B cell lymphoma characterized by an abnormal proliferation of mature B lymphocytes. This 
lymphoma was first described in the 70’s by Lennert (Stansfeld et al., 1988) and the concept of 
MCL was first introduced by Weisenburger and collaborators (Weisenburger et al., 1981). 
However it was not until 1992 that the International Lymphoma Study Group (ILSG) agreed on 
the denomination of this tumor as MCL (Banks et al., 1992). There are different morphologic 
variants: blastoid, pleomorphic, small cell and marginal zone-like. The blastoid and 
pleomorphic variants are larger cell types, have higher proliferation rates and are normally 
associated to a shorter survival (Argatoff et al., 1997; Bosch et al., 1998; Lardelli et al., 1990; 
Pileri and Falini, 2009; Swerdlow et al., 2008). High tumor cell proliferation is another factor 
that is associated to poor prognosis in MCL (Argatoff et al., 1997; Bosch et al., 1998). 
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1.1.2.1  EPIDEMIOLOGY 
MCL is a relatively rare disease that constitutes only about 8-10% of all NHL in Europe and 
more frequently affecting middle-aged to elderly men (mean age at diagnosis: 60 years; 
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Figure 1.1. Comparison of the structure of a reactive follicle (A) and an early phase of 
mantle cell lymphoma (B). Despite of the tumoral cells that are invading the germinal 
center, the structure of the follicle, centered by a reactive germinal centre, can still be 
recognized. 
male:female ratio = 2-7:1) (Meusers et al., 1997; Swerdlow et al., 2008). It is thought to arise 
from the malignant transformation of B lymphocytes in the mantle zone of the lymphoid 
follicle (Figure 1.1). Most MCL patients (>70%) are diagnosed in a stage III-IV (i.e. with 
extranodal dissemination, bone-marrow involvement and leukemic spread). MCL is regarded 
as an aggressive incurable disease with a median survival of patients being 3-4 years and less 
than 15% of long-term survivors (Weigert et al., 2009). However, individual clinical behavior 
can vary substantially and survival times range between few months only to more than 10 
years (Fernandez et al., 2010; Jares et al., 2007; Meusers et al., 1997; Orchard et al., 2003; 
Rosenwald et al., 2003b). 
 
 
1.1.2.2 IMMUNOPHENOTYPE AND GENETIC FEATURES 
MCL is characterized by expression of the B-cell markers CD19, CD20, CD22, CD79a, 
SOX11 and BSAP/PAX5 (Jaffe, 2009; Jares and Campo, 2008; Mozos et al., 2009). MCL normally 
expresses high levels of IgM/D with more frequent lambda restriction (Jaffe, 2009; Jares and 
Campo, 2008). Most cases of MCL do not show mutation in V-gene sequences of Ig(VH) genes 
but 15-40% of MCLs may carry somatic hypermutation, indicating a different origin in cells that 
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has passed through the germinal centre reaction (Camacho et al., 2003; Kienle et al., 2003; 
Orchard et al., 2003; Welzel et al., 2001). 
Table 1.2. Common genetic alterations in mantle cell lymphoma (from Jares et al. 2007) 
Chromosomal 
region* 
Frequency (%) Candidate 
gene 
Functional process 
BAC array SNP array 
(10 K) 
Metaphase 
CGH 
Gains      
3q25-qter 31–50 27 32–70‡ ? ? 
4p12-13 57 ? 7‡ ? ? 
7p21-22 16-34 ? 27‡ ? ? 
8q21-qter 16-36 ? 11–30‡ MYC Cell growth, proliferation, 
apoptosis 
9q22 ? ? 16 SYK Cell signaling 
10p11-12 17 12 5-7‡ BMI1 Cell cycle, DNA damage 
response and anti-senescence 
12q13 ? ? 16-30 CDK4 Cell cycle 
18q11-q23 15-17 18 11–26‡ BCL2 Anti-apoptosis 
Losses      
1p13-p31 29–52 18 24-52 ? ? 
2q13 17 ? ? BIM§ Pro-apoptosis 
6q23-q27 23-38 18 ? ? ? 
8p21-pter 17–34 ? 13-30 ? ? 
9p21-p22 18–31 27 16-30 CDKN2A Cell cycle and anti-senescence 
9q21-qter 29 ? 18 ? ? 
10p14-15 18-31 18 18 ? ? 
11q22-q23 21-59 23 16-30 ATM DNA damage response 
13q11-q13 25-55 27 17-74 ? ? 
13q14-q34 43-51 ? 44-70 ? ? 
17p13-pter 21-45 18 13-16 TP53 Cell cycle, DNA damage 
response and anti-senescence 
22q12 17-50 ? ? ? ? 
*Minimal altered regions vary slightly among different studies. ‡High-level DNA amplifications have 
been identified in these regions. §Homozygous deletions of this gene have been identified in mantle 
cell lymphoma cell lines but not in primary tumors. BAC, bacterial artificial chromosome; CGH, 
comparative genomic hybridization; SNP, single nucleotide polymorphism; ?, not known. 
The main distinguishable feature of MCL is the overexpression of nuclear cyclin D1. This is 
caused by a translocation between chromosomes 11 and 14 that puts the CCND1 gene under 
the control of the enhancer of the heavy chain of the immunoglobulins (Raffeld and Jaffe, 
1991). The t(11;14)(q13;q32) translocation is found in the vast majority of MCL patients, it is 
considered the hallmark of the disease (Jares et al., 2007) and probably facilitates the 
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deregulation of the cell cycle at the G1-S transition. In those patients that do not carry the 
t(11;14) translocation, other genetic abnormalities seem to cause excess production of cyclin 
D1. However, there are rare examples in which MCL seems to initiate from the overexpression 
of other cyclins (e.g., cyclin D2 and cyclin D3) (Fu et al., 2005). However, this characteristic 
molecular event does not explain fully the clinical and biological features of the tumor and is 
not sufficient for malignant transformation, as has been demonstrated in experimental models 
(Bodrug et al., 1994). 
Moreover, several secondary chromosomal gains and losses are found in MCL samples 
and surely account for the varying survival of these patients (Table 1.2). The most frequently 
altered chromosomal regions in MCL identified up to now are gains of chromosomal fragments 
in 3q, 7q and 8q and losses in 1p, 6q, 8p, 9p, 9q, 11q, 13q and 17p (Ferrer et al., 2007; Jares et 
al., 2007). These alterations affect the expression of several proteins involved in regulation of 
cell cycle (BMI1, INK4a, ARF, CDK4 and RB1), proteins involved in DNA damage repair (ATM, 
CHK2 and p53) and apoptosis (BCL2, BIM) (Jares et al., 2007). NF-κB activation has been also 
implied in the pathogenesis of MCL (Martinez et al., 2003). Nevertheless, there are still various 
MCL oncogenic features that are not explained by the alterations so far identified. 
 
1.1.3 DIFFUSE LARGE B CELL LYMPHOMA 
Diffuse large B cell lymphoma (DLBCL) is a high-grade large cell lymphoma. It is 
characterized by the proliferation of mature B cells that can have different origins.  
However, classical DLBCL is already a heterogeneous disease. The molecular 
heterogeneity of DLBCL has been explored through the use of microarrays and has lead to the 
definition of three different molecular subtypes of DLBCL: germinal centre B-like DLBCL (GCB 
DLBCL), activated B-like DLBCL (ABC DLBCL) and primary mediastinal B cell lymphoma (PMBL) 
(Lenz et al., 2008b). Each subtype has different prognosis and survival rates. 
1.1.3.1 EPIDEMIOLOGY 
DLBCL is the most common form of lymphoma accounting for 30-40% of all newly 
diagnosed lymphomas. Approximately 5-6 DLBCL new cases per 100,000 people are diagnosed 
in Europe each year. Median age at presentation for the two most common subtypes is around 
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60 years old with male predominance. It often involves the lymph nodes, spleen, liver, and 
bone marrow, though this differs from patient to patient (Swerdlow et al., 2008).  
The cell of origin is thought to be a B cell in different stages of differentiation depending 
on the DLBCL subtype. GCB subtype is thought to arise from germinal-center B cells whereas 
de ABC subtype may arise from a post-germinal center B cell that is blocked during plasmacytic 
differentiation. The cells of origin for PMBL are probably rare thymic B cells. 
DLBCL is considered curable with anthracycline-based chemotherapy regimens such as a 
combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (Fisher et 
al., 1993), but addition of rituximab immunotherapy (R-CHOP) increases significantly the 
survival rate of patients (Coiffier et al., 2002). However only 50% of patients achieve complete 
response (Lenz and Staudt). The prognosis depends mainly on the molecular subtype of DLBCL. 
Thus, overall survival is favorable for GCB and PMBL subtypes and worse for those patients 
with the ABC subtype (Lenz et al., 2008a) (Figure 1.2). 
1.1.3.2 MOLECULAR PATHOGENESIS 
Chromosomal translocations involving the BCL6 gene on band 3q27 are the most 
common genetic abnormalities in DLBCL, occurring in 35% to 40% of cases (Pasqualucci et al., 
2003). The chromosomal partner is usually the immunoglobulin heavy-chain promoter on 
chromosome 14, thus the consequence is the overexpression of BCL6 which is normally tightly 
regulated during B cell differentiation. Dysregulated constitutive expression of BCL6 may lead 
to maturation arrest and confer a proliferative advantage.  
However, each DLBCL subtype relies in a different oncogenic program. Although some 
alterations are common for more than one subtype there are several features that are 
Figure 1.2. Kaplan-Meier plot of overall survival of PMBL, GCB, and ABC DLBCL patients after 
chemotherapy (reproduced from Rosenwald A et al., 2003) 
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exclusive of one subtype. For instance the GCB subtype is characterized by the t(14;18) 
translocation that puts the anti-apoptotic gene BCL2 under the control of the promoter of 
immunoglobulins (Lenz et al., 2008b; Rosenwald et al., 2002). Other genetic aberrations are 
p53 mutations (Young et al., 2008), deletion of the tumor suppressor gene PTEN and the 
amplification of the oncogenic miR-17-92 cluster (which also downregulates PTEN) (Xiao et al., 
2008).  
In the case of ABC lymphomas, some of them bear amplification of the BCL2 locus and 
almost all overexpress BCL2 protein (Lenz et al., 2008b). Other frequent cytogenetic alterations 
are the deletion of the CDKN2A locus (Lenz et al., 2008b; Tagawa et al., 2005) which encodes 
for two different proteins INK4a and ARF both of which are able to restrict cell proliferation 
upon aberrant mitotic signaling. However the mechanism is different for each protein. 
Whereas INK4a acts through the activation of RB, ARF inhibits the function of MDM2, a known 
repressor of p53. Thus, deletion of the CDKN2A locus provides resistance to cell cycle arrest 
and p53-induced apoptosis.  
The third entity, PMBL is characterized by the 9p24 amplification, an alteration that is 
common to HL (Joos et al., 2000; Lenz et al., 2008b; Rosenwald et al., 2003a). This region 
encompasses several megabases of DNA and involves many genes, but it is thought that one of 
the most important targets of this amplification is JAK2 which encode for a tyrosine kinase 
involved in the inhibition of apoptosis among other functions (Meier et al., 2009). 
 
1.1.3.3 RELATIONSHIP WITH EPSTEIN BARR VIRUS 
Epstein Barr virus (EBV) is a virus belonging to the γ-herpesvirus family that infects 90% 
population worldwide and persists for life in the infected host. Its genome is constituted by a 
172 kb molecule of double stranded DNA. The main target of the virus is the subpopulation of 
B cells but it can also infect other cell types, especially epithelial cells. The virus exploits the 
physiological hierarchy of the normal B cell differentiation to ensure its permanence in 
memory B cell pool of the immunocompetent host where the viral DNA stays as an episome in 
the nucleus of the infected cell (Kurth et al., 2000). Sometimes the virus switches to a lytic 
cycle and new viruses are produced resulting in death of the infected cell.  
In most cases the infection is harmless, however EBV has been associated to the 
development of many cancers including nasopharyngeal cancer (Young and Rickinson, 2004) 
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and several lymphomas such as Burkitt lymphoma (BL), post-transplant lymphoproliferative 
disease (PTLD) and HL (Kuppers, 2003). EBV positive DLBCLs are normally associated to 
circumstances of immunosupression such as in PTLD; however the WHO has recently included 
a new entity as a variant of DLBCL, the Epstein-Barr virus positive DLBCL of the elderly which is 
also closely related to EBV infection (Swerdlow et al., 2008).  
The virus preferentially infects B lymphocytes through the binding of the major viral 
envelope glycoprotein gp350 to the CD21 receptor on the surface of B cells (Nemerow et al., 
1987) and through the binding of a second glycoprotein, gp42, to human leukocyte antigen 
(HLA) class II molecules as a co-receptor (Borza and Hutt-Fletcher, 2002). However, as 
mentioned before, other cell types can be infected such as epithelial cells but in a much lower 
efficient process. 
The expression pattern of EBV-encoded genes depends on the differentiation stage of the 
infected B-cell. This has led to the description of different types of latency that also apply to 
tumor cells (Babcock et al., 2000).  
The oncogenic potential of the EBV resides in several of the virus-encoded proteins and 
RNAs. For instance, the latent membrane protein 1 (LMP1), which is able to block B cells from 
differentiating into germinal-centre B cells, has been shown to mimic a constitutively active 
CD40 receptor and activate the NF-κB pathway that protect the cells from apoptosis (Gires et 
al., 1997; Kilger et al., 1998; Mosialos et al., 1995; Uchida et al., 1999). Moreover, its 
expression inversely correlates with the expression of BCL6, a key transcriptional repressor 
that is essential for germinal centre differentiation, in B-cell lymphomas (Capello et al., 2003; 
Carbone et al., 1997). The viral protein LMP2a functionally resembles a B cell receptor (BCR) 
and has immunoreceptor tyrosine-based motifs (ITAMs) in its cytoplasmic domain that can 
replace the survival signals for B cells that are normally provided by the BCR (Caldwell et al., 
1998). This is especially important for Hodgkin and Reed-Sternberg (HRS) cells which are 
thought to be rescued from apoptosis by this viral BCR-mimicry phenomenon (Kuppers and 
Rajewsky, 1998). EBV also expresses several transcripts that do not translate into protein. 
These are the EBV-encoded RNAs (EBERs), the BamH1-H Right Fragment 1 (BHRF1) RNAs and 
the BamH1-A rightward transcripts (BARTs). The function of these RNAs is not as well-studied 
as the coding sequences, however on one hand, EBERs have been associated to the induction 
of IL-10 expression (Kitagawa et al., 2000), the relocalization of the ribosomal L22 protein from 
nucleoli to the nucleoplasm (Houmani et al., 2009) and the resistance to interferon-α (IFN-α) 
(Nanbo et al., 2002). It is thought that the antiapoptotic activity of EBERs can counteract the 
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proapoptotic effect of the MYC translocation in BL (Niller et al., 2003). On the other hand, 
BHFR1 RNAs and BARTs have been demonstrated to be microRNAs (miRNAs), being EBV the 
first virus discovered to express miRNAs (Pfeffer et al., 2004).  
 
1.2 MECHANISMS OF EPIGENETIC REGULATION 
The enormous complexity of life even at the cellular level requires a complex traffic of 
information between external and internal signals and a coordinated response mediated by 
systems to read the information and execute the response. Although the genetic information 
that determines the response is contained in the sequence of nucleotides of DNA, the 
structure of chromatin is crucial in the way this information is read. The effective organization 
of the genomic information is the object of study of epigenetic. 
There are several existing definitions of epigenetic and more than one sense is given to 
this word. In this work, the concept of epigenetic refers to the heritable changes (heritable in 
the sense of transmissible over rounds of cell divisions, but in some cases also over 
generations of organisms) that do not involve changes in DNA sequence. In other words, 
epigenetic defines all the heritable information that is not directly codified in the sequence of 
nucleotides. 
The most fundamental epigenetic mechanisms are DNA methylation and histone tail 
modification. There are additional epigenetic mechanisms such as the presence of histone 
variants, and displacement and reposition of nucleosomes. Non-coding RNAs (ncRNAs) are also 
considered an epigenetic mechanism because in some organisms they can direct DNA 
methylation (Bao et al., 2004) and participate in some epigenetic processes such as the 
inactivation of X chromosome in mammals. However, in mammals the relationship between 
miRNAs and DNA methylation is still under debate although some examples are described in 
the literature (Kim et al., 2008).  
1.2.1 LEVELS OF EPIGENETIC REGULATION 
The functional unit for epigenetic regulation is chromatin. Chromatin is a highly ordered 
structure consisting of DNA molecules organized in nucleosomes. Chromatin is constituted by 
DNA, histones and non-histone proteins. It adopts two main structures: heterochromatin and 
euchromatin. Heterochromatin is a densely compacted conformation that impedes the 
transcription for those loci contained in it. In contrast, euchromatin is characterized by a 
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decondensed conformation and is normally associated to active transcription (Huisinga et al., 
2006). The main mechanisms of epigenetic regulation rely on two different levels: modification 
of histone tails and DNA methylation. 
The best known epigenetic mechanism of gene regulation is DNA methylation. DNA 
methylation does not occur in a stochastic manner. It is targeted to specific bases in the 
genome. In the mammalian genome DNA methylation takes place only at the 5 position of the 
pyrimidine ring of a cytosine and is mediated by DNA methyl transferases (DNMTs) (Bird, 2002; 
Goll and Bestor, 2005). This cytosine must be followed by a guanosine in the 3’ direction 
forming the so called CpG dinucleotides (Weber et al., 2007). DNA methylation is executed by 
DNMTs. DNMT3A and DNMT3B are responsible for de novo methylation whereas DNMT1 is 
responsible for maintenance of DNA methylation during DNA replication (Okano et al., 1999) 
by methylating the hemimethylated strands. In healthy cells, DNA methylation represses the 
expression of deleterious sequences that have been incorporated to our genomes over the 
time such as transposons and viral sequences. It is also important for the regulation of 
development and cell differentiation (Li et al., 1992), genomic imprinting (Li et al., 1993) and X-
chromosome inactivation in females (Heard et al., 1997). Having these global functions it is not 
surprising that DNA methylation has been implicated in several diseases, especially in cancer. 
Regarding DNA methylation, two different phenomena occur in cancer cells: first there is a 
global DNA hypomethylation that affects mainly repetitive sequences, coding regions and 
introns and produces chromosomal instability (Feinberg et al., 1988; Tuck-Muller et al., 2000); 
second there is a DNA hypermethylation at special CpG-rich sites called CpG islands that are 
present at the promoter of many genes. The CpG islands are normally unmethylated in normal 
cells but become methylated in cancer leading to the repression of tumor suppressor genes 
(Toyota et al., 1999). 
Another epigenetic mechanism of transcriptional regulation is histone modification. 
Histones are the small basic proteins that form the core of the nucleosomes. A typical 
nucleosome contains an octamer of histones composed of two copies of each of the core 
histones i.e. H2A, H2B, H3 and H4 that is wrapped by 146 base pairs of DNA (Luger et al., 
1997). Nucleosomes are connected by stretches of linker DNA which can vary on their 
extension and the linker histone H1. Histones contain a globular domain and a flexible tail with 
a charged NH2 terminus that projects out of the nucleosome and is the main substrate of 
histone modifications. There are more than 60 different modification sites but histone 
modifications can be classified in eight categories: lysine acetylation, lysine and arginine 
methylation, serine and threonine phosphorylation, lysine ubiquitination, lysine sumoylation, 
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arginine deimination, proline isomerization, and glutamate poly-ADP ribosylation (Kouzarides, 
2007). They suppose a highly dynamic regulatory process that act either by disrupting 
chromatin contacts or by modifying the recruitment of non-histone proteins and ATP-
dependent chromatin remodeling complexes to chromatin. All these modifications constitute a 
complex language that governs the structure of chromatin and the transcriptional status of the 
genes contained in a particular locus. In terms of transcription, modifications can be grouped 
in those that correlate with activation of transcription and those that correlate with repression 
of transcription. Thus, acetylation, methylation, phosphorylation and ubiquitination have been 
associated to active transcription whereas methylation, ubiquitination, sumoylation, 
deimination and proline isomerization have been implicated in gene repression. However, 
each modification has its own meaning in a defined context and the same modification can be 
associated to gene activation or repression depending on the context. Two good examples are 
methylation of H3K36 and H3K9 that have a positive effect on gene transcription when they 
are located in the coding region but a negative effect if they are located in the promoter of the 
gene (Vakoc et al., 2005).  
Some authors claim that all these modifications, acting alone or in combinations, 
constitute a histone code that provide a binding platform for chromatin-associated proteins 
that initiates or block the transcription (Turner, 2007). Nevertheless, this concept probably 
only defines the need for specific histone modifications to carry on a specific function, and 
does not reflect the presence of a real code of modifications with a predictable outcome (Liu 
et al., 2005). In the end, the crosstalk between the histone modifications and the status of DNA 
methylation is what determines if a particular gene is going to be transcriptionally active or 
not. Similar to DNA methylation, histone modification has several important functions 
including DNA repair, replication and chromosome condensation, but the most versatile 
function is regulation of transcription (Kouzarides, 2007).  
 
1.2.2 THE POLYCOMB GROUP AS A REGULATOR OF GENE EXPRESSION 
There are several enzymes involved in histone modification such as histone acetylases, 
methylases, demethylases, deacetylases, ubiquitinases and so on. Nevertheless most of them 
act in the form of (or associated to) complexes. The Polycomb (PcG) and trithorax (trxG) 
complexes are major modifiers of chromatin structure through histone modification and have 
opposing roles. They were first described in Drosophila as systems that regulate body 
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segmentation during fly development through the direct control of HOX genes (Lewis, 1978) 
and alterations in these proteins provoke homeotic transformations. On one hand trxG 
activates gene expression through the methylation of lysine 4 of histone H3 (H3K4) and 
through the chromatin remodeling activity of some of their members. On the other hand PcG 
proteins, the repressive counterpart of trxG, induce two different histone modifications 
associated to repression counteracting the nucleosome remodeling activity of SWI/SNF 
complex (Shao et al., 1999) and blocking the association of RNA polymerase II to the gene 
promoter (Dellino et al., 2004; Stock et al., 2007), preventing gene transcription 
(Schuettengruber et al., 2007). The regulation of HOX genes is a PcG function that is conserved 
from flies to human. Notwithstanding in Drosophila there are specific consensus sequences 
called PRE (Polycomb Repressed Elements) to which PcG proteins bind (Muller and Kassis, 
2006) but these sequences have not been identified in mammals yet although a recent work 
shows the existence of a genomic region in the human genome that shares some 
characteristics with the PREs (Woo et al., 2010). Polycomb proteins form DNA-binding 
complexes to exert their function. Expression studies as well as the use of 
immunoprecipitation assays has led to the postulation that the composition of these 
complexes is variable and dynamic depending on the cell or tissue type or the differentiation 
status of the cell (Gunster et al., 2001; Otte and Kwaks, 2003; Sanchez-Beato et al., 2006) but 
at least two different complexes have been clearly identified: the Polycomb Repressive 
Complex 1 (PRC1) and the Polycomb Repressive Complex 2 (PRC2) (Lund and van Lohuizen, 
2004).  
The PRC2 is thought to be the first complex acting on gene promoters. It has as core 
members EZH2, EED and SUZ12. EZH2 carries the histone methyl transferase activity in its SET 
domain that trimethylates the lysine 27 of histone H3 (H3K27me3 mark) (Kuzmichev et al., 
2002). The composition of this complex is variable and some authors have proposed the 
existence of a PRC3 and PRC4 regarding the molecular partners of the core proteins that 
include several EED isoforms and the proteins RBBP4, RBBP7, PHF1, AEBP2, SIRT1, HDAC1 and 
HDAC2 amongst others (Kuzmichev et al., 2004; Kuzmichev et al., 2005) but its presence is 
associated to specific differentiation status or malignant conditions (Kuzmichev et al., 2005).  
The composition of PRC1 is also highly variable but it is constituted by combinations of 
member of the PC (CBX2, CBX4, CBX7 and CBX8), PSC (BMI1, MEL18, MBLR, NSPC1, PCGF5 and 
PCGF3), RING (RING1 and RNF2), PH (HPH1, HPH2 and HPH3) and SCML (SCML1 and SCML2) 
families (Bracken and Helin, 2009). The PRC1 is recruited to the H3K27me3 mark through the 
chromodomain of PC proteins (Min et al., 2003) and ubiquitinates histone H2A at lysine 119 
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(H2AK119Ub) thanks to the ubiquitin E3 ligase activity of RNF2 (Wang et al., 2004). This 
ubiquitination is thought to be important for gene repression (Cao et al., 2005; Wang et al., 
2004). The PRC1 eventually provokes changes in chromatin structure (Francis et al., 2004).  
In embryonic stem (ES) cells PRC1 and PRC2 are both present at the promoters of several 
key developmental regulators. In these promoters the Polycomb-mediated H3K27m3 mark co-
exist with the methylation of lysine 4 of histone H3 (H3K4me) associated to trxG activity 
(Bernstein et al., 2006a). This bivalent mark keeps the genes poised to rapidly switch gene 
status upon differentiation. This is not exclusive of ES cells and some adult cells also harbor 
bivalent promoters such as T cells and fibroblasts (Araki et al., 2009; Barski et al., 2007; Roh et 
al., 2006; Wei et al., 2009). 
As suggested by this model the activities of PRC2 and PRC1 are closely related and it has 
been demonstrated high levels of co-occupancy of proteins belonging to the PRC1 and PRC2 
complexes at promoters with the H3K27me3 mark (Bernstein et al., 2006b; Lee et al., 2007; 
Terranova et al., 2008). However, this is a simplistic description of reality. Even though the 
H3K27me3 mark has been demonstrated to recruit the PRC1 to gene promoters, 
independence from this mark has also been described for PRC1 recruitment (Pasini et al., 
2007; Schoeftner et al., 2006). Moreover there are additional complexes that contain PcG as 
well as non-PcG proteins. For instance, several factors of the E2F family can be found 
associated to PcG proteins such as E2F6 (Trimarchi et al., 2001), MGA, MAX and TFDP1. The 
formation of these complexes can be regulated in a cell cycle-dependent manner (Ogawa et 
al., 2002) revealing the limitations of the model in which the action of PRC2 and PRC1 
complexes is sequential. Probably it will be more correct to say that gene repression mediated 
by PcG proteins rely on the activity of PRC1 and PRC2 alone or in association. 
Moreover there are additional enzymatic activities associated to PRCs that are not 
directly executed by PcG members. For instance, EED is able to interact with histone 
deacetylases (HDACs) that collaborate to repress gene expression (van der Vlag and Otte, 
1999). It seems that PcG proteins can also regulate DNA methylation, although this question is 
now under active debate. Two main direct evidences support the role of PcG in DNA 
methylation. First, murine Bmi1 has been found to interact directly with Dmap1 and form a 
ternary complex with Dmap1 and Dnmt1. In this interaction, Bmi1 collaborate with Dmap1 to 
repress target genes as demonstrated by the fact that Hox genes are derepressed not only in 
the absence of Bmi1 but also in the absence of Dmap1 (Negishi et al., 2007). Second, EZH2 by 
GST pull-down assays and immunoprecipitation has been shown to interact directly with the 
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three DMNTs in the context of PRC2/3 and to be required for DNA methylation at EZH2-target 
promoters (Vire et al., 2006). However it does not mean that DNA methylation is required for 
PcG activity since the H3K27me3 mark can be found out of CpG islands (Kondo et al., 2008). 
 
1.2.2.1 POLYCOMB TARGETING TO GENE PROMOTERS 
Despite the huge advance in the understanding of the mechanism of action of PcG 
proteins, there are still many facts that remain obscure. For instance it is still a mystery how 
PcG complexes are driven to the correct places in the mammalian genome. Neither PRC1 nor 
PRC2 contain DNA-binding domains and, as commented before, human PREs have been only 
recently described in the HOXD cluster. One of the best candidates to drive PcG function is 
YY1. YY1 is the human homologue of Drosophila Pho and can interact with several PcG 
proteins. In fact, YY1 knockdown in mouse myoblasts impedes the recruitment of Ezh2 to 
target promoters and prevents H3K27 trimethylation (Caretti et al., 2004). However, studies in 
mouse ES cells showed very limited overlap suggesting that recruitment by YY1 might not be a 
general mechanism. In fact, in ES cells OCT4 could be more important for PcG function since 
OCT4 knockdown diminishes the binding capacity of PRC1 and PRC2 in these cells (Endoh et al., 
2008; Squazzo et al., 2006). However, the biochemical evidence for the interaction between 
OCT4 and PcG members is very weak (Lee et al., 2006). Other transcription factors that can 
recruit PcG complexes are E2F6 and BCOR. E2F6 is a repressor member of the E2F family of 
transcription factors. E2F6 can repress its targets by direct interaction with RING1, RNF2, YAF2 
and DP1 (Ogawa et al., 2002). BCOR (BCL-6 interacting co-repressor) is a co-repressor that is 
essential for repression of BCL6 targets. It has been associated to several PcG members such as 
RING1, RNF2 and RYBP (Gearhart et al., 2006). 
Another type of molecules, the ncRNAs, have also been implicated in PcG targeting 
(Bernstein et al., 2006b; Grimaud et al., 2006; Kanhere et al., 2010; Pandey et al., 2008; Rinn et 
al., 2007; Yap et al., 2010). For instance the long ncRNAs HOTAIR (encoded in HOXC cluster) 
interacts directly with PRC2 and is required for SUZ12 recruitment, and trimethylation of 
H3K27 in HOXD loci (Rinn et al., 2007). Another long RNA, Kcnq1ot1 functions in placenta 
interacting with PRC2 and chromatin (Pandey et al., 2008). This interaction correlates with the 
presence of the repressive marks H3K27me3 and H3K9me3. Another long ncRNA, ANRIL which 
is codified in a region that overlaps the INK4b/ARF/INK4a loci is bound by the PRC1 protein 
CBX7 in order to repress the INK4a/ARF locus. CBX7 uses distinct regions and residues of its 
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chromodomain for binding RNA or H3K27me3 (Yap et al., 2010). The RepA RNA that is 
transcribed from Xist has also been shown to interact with PRC2. This interaction is necessary 
for H3K27me3 and X chromosome inactivation (Zhao et al., 2008). Two reports indicate that 
this mechanism might be general and long ncRNAs (Khalil et al., 2009) as well as short RNAs 
(Kanhere et al., 2010) can physically interact with PcG members and influence the activity of 
PRCs. It seems that these RNAs frequently form stem loop structures that serve as a docking 
platform for PcG binding. 
Finally, RNAi machinery adds even more complexity to the PcG system. RNAi when 
directed to gene promoters has been associated to PcG activity. For instance, in Drosophila 
AGO1, a protein which plays an important role in RNAi, is able to drive gene silencing of 
promoters targeted by specific small interfering RNAs (siRNAs) by recruiting EZH2 (Kim et al., 
2006). 
 
1.2.2.2 POLYCOMB FUNCTIONS 
Polycomb genes are highly conserved through plants, flies and vertebrates. The best 
studied function of PcG is the regulation of HOX gene expression through cell division and 
during development and this function is also conserved in the aforementioned groups. 
Actually, most of PcG members were initially identified because their mutations produce 
homeotic phenotypes.  
However PcG functions go far beyond the regulation of HOX genes. Several genome-wide 
studies have revealed the numerous target genes regulated by the PRCs (Boyer et al., 2006; 
Bracken et al., 2006; Lee et al., 2006; Schwartz et al., 2006; Squazzo et al., 2006; Tolhuis et al., 
2006). Among the PcG targets there is an evident enrichment in transcription factors and 
proteins that regulate development, differentiation, stemness, and cell fate decisions. The role 
of PcG in the self renewal of stem cells has been widely demonstrated not only in ES cells but 
also in a variety of adult stem cells (for a review see (Sparmann and van Lohuizen, 2006)).  
PcG play a major role in the regulation of adult hematopoietic stem cells (HSC) and 
several alterations in PcG proteins affect this cellular compartment (Jacobs and van Lohuizen, 
2002; Kajiume et al., 2004; Ohta et al., 2002; Orlando, 2003; Park et al., 2003). Levels of BMI1 
and MEL18 determine to a great extent the capability of HSCs to function as progenitors 
(Kajiume et al., 2009) with opposing roles. BMI1 enhances HSC potential whereas MEL18 
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restricts HSC self renewal and is increased in differentiated cells which agrees with the fact 
that BMI1 is expressed in more primitive cells and during differentiation, there is an 
upregulation of MEL18, RAE28, and EZH2 (Lessard et al., 1998). Moreover, mouse models using 
Bmi1 knockout (Lessard and Sauvageau, 2003; Park et al., 2003; van der Lugt et al., 1994) and 
transgenic mice (Iwama et al., 2004) have demonstrated the key role of Bmi1 in the function of 
HSCs. Many of the Bmi1 effects on HSC function are mediated through the repression of the 
Ink4a/Arf locus. Bmi-/- HSCs have markedly higher levels of Ink4a and Arf (Jacobs et al., 1999) 
two proteins that induce cell cycle arrest and p53-mediated apoptosis in HSCs (Park et al., 
2003). In fact, deletion of the Cdkn2a locus in Bmi1-/- mice partially restores the proliferative 
capacity of HSCs (Oguro et al., 2006). In accordance to the opposed role of Mel18 in HSC 
activity, Mel18 downregulation in bone marrow-derived HSCs promotes their self-renewal, 
while its forced expression reduces the self-renewal capacity of HSCs (Kajiume et al., 2004). 
However Mel18 is still necessary for the development of the hematopoietic system as shown 
in Mel18-/- mice (Akasaka et al., 1997). Many other PcG proteins are important for HSC 
function such as EZH2 (Kamminga et al., 2006) and EDD (Lessard et al., 1999). Likewise, Rnf2 
affects hematopoiesis, but this time in a dual way. On one hand Rnf2 is able to restrict 
proliferation of progenitor cells; on the other hand it enhances the proliferation of the 
maturing progeny (Cales et al., 2008). 
Polycomb also regulates cell proliferation as demonstrated by several facts. First, as 
mentioned before, the formation of some PRC complexes is dependent on the cell cycle 
suggesting a role in proliferation (Ogawa et al., 2002); second, among PcG targets there are 
some cell cycle regulators including INK4a/ARF, MYC, JUN, FOS, CDC25, hTERT, several cyclins 
and CDKs, CHEK1, MAD2L1, and BUB3 (Bruggeman et al., 2005; Jacobs et al., 1999). Some 
recent works also show the implication of PcG proteins in the regulation of proliferation 
through the control of the JAK/STAT pathway in Drosophila (Classen et al., 2009; Gonzalez et 
al., 2009). 
 
1.2.2.3 POLYCOMB AND CANCER 
Cancer is a complex disease in which cells are transformed by genetic and epigenetic 
alterations and proliferate in an uncontrolled way. There is increasing evidence that many 
cancer cells present some characteristics of stem cells including unlimited self renewal capacity 
and activation of several pathways that are active in stem cells. This is supported by the fact 
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Table 1.3. Common members of PRCs and their alterations in cancer. Bold text indicates members known to be frequently altered in cancer. 
Human Mouse homologue Alteration in cancer Tumor type 
PRC1 complex 
BMI1 Bmi1 Overexpression/Amplification  
Acute myeloid leukemia, Hodgkin lymphoma, B cell non-Hodgkin lymphoma, 
gastrointestinal tumors, pituitary adenoma, parathyroid adenoma, breast 
cancer, glioma, neuroblastoma, medulloblastoma, non-small cell lung cancer, 
skin cancer 
MEL18/RNF110/PCGF2 Mel18 Loss Cutaneous squamous-cell carcinoma
, 
gynecological tumors, prostate cancer 
RING1A Ring1a 
Overexpression Large B cell lymphoma 
Loss Clear-cell renal-cell carcinoma and testicular germ-cell tumors 
RNF2 Ring1b Overexpression 
Gastric and colonic tumors, melanoma, lung cancer, gynecological tumors, 
diffuse large B cell lymphoma, follicular lymphoma, Burkitt lymphoma, Hodgkin 
lymphoma  
HPH1, HPH2, HPH3 Rae28/Mph1, Phc2, Phc3 
Lack of expression Acute lymphocytic leukemia 
Overexpression Large B cell lymphoma, central nervous system tumors 
CBX2, CBX4, CBX6, CBX7, 
CBX8 
M33/Cbx2, Cbx4, Cbx6, 
Cbx7, Cbx8 
Loss Pancreatic cancer, aggressive thyroid carcinomas 
Overexpression Follicular lymphoma 
PCGF6 Pcgf6 Loss Mantle cell lymphoma 
RYBP Rybp Overexpression Oligodendroglioma, pituitary adenoma, T cell lymphoma, Hodgkin Lymphoma 
PRC2 complex 
EZH2/EZH1 Ezh2/Ezh1 
Overexpression/Amplification 
Prostate carcinoma, breast carcinoma, melanoma, bladder cancer, glioma, 
endometrial carcinoma, lymphomas, colon carcinoma, glioblastoma, Ewing 
tumor 
Deletion/Mutation/Uniparental disomy Linfomas, myeloid malignancies. 
Altered localization Acute myeloid leukemia 
SUZ12 Suz12 
Overexpression/Amplification/ 
Translocation 
Gastrointestinal tumors, lung tumors, thyroid follicular carcinoma, pituitary 
adenoma, parathyroid adenoma, skin tumors, breast and gynecological tumors, 
mantle cell lymphoma, chronic myeloid leukemia, endometrial stromal tumor 
EED Eed Overexpression Salivary gland adenoid cystic carcinoma, Hodgkin lymphoma, prostate cancer 
 
RBBP7 
 
Rbbp7 
Lack of expression Prostate cancer 
Overexpression Non-small cell lung cancer, breast cancer 
RBBP4 Rbbp4 Downregulation Cervical cancer 
PCL3 Phf19 Overexpression Cancers of colon, skin, lung, rectum, cervix, uterus, and liver  
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that tumors contain heterogeneous population of cells although they originate from a single 
clone. It is also true that several pathways that are aberrantly activated in tumors, such as 
Sonic Hedgehog (Shh), Notch, and Wnt, also regulate self-renewal in stem cells (reviewed in 
(Taipale and Beachy, 2001)), and some embryonic genes are re-expressed in human cancers 
(Monk and Holding, 2001). 
Taking into account the role of Polycomb in the control of stem cell properties, 
development and cell cycle, it is not surprising that several reports have linked this system to 
cancer and that the expression of many PcG proteins is altered in several malignancies (Table 
1.3). A plausible model is that alterations in PcG could allow malignant cells to acquire stem 
cell properties (Figure 1.3). The first example is BMI1. It was initially described in mice to 
collaborate with c-MYC in the development of lymphomas (Haupt et al., 1991; van Lohuizen et 
al., 1991) and it has been found to be deregulated in some lymphoid malignancies such as 
MCL, HL and DLBCL (Bea et al., 2001; Dukers et al., 2004; Raaphorst et al., 2004; Sanchez-Beato 
et al., 2004; Sanchez-Beato et al., 2006). Anomalous expression of EZH2 has been described in 
prostate cancer where EZH2 levels also correlate with the progression of the tumor. Moreover, 
EZH2 is also important for the neopastic transformation of breast epithelial cells (Kleer et al., 
2003; Varambally et al., 2002). Other PRC2 members such as EED and RbAp48 are upregulated 
in colon and breast tumors (Kirmizis et al., 2003), and SUZ12 is translocated in endometrial 
stromal tumors (Koontz et al., 2001b). The oncogenic role of BMI1 might rely on the 
aforementioned repression of INK4a/ARF, a role that seems to be shared with other PcG 
members such as EZH2 (Paul et al., 2010) and CBX7 (Dimri et al., 2002; Gil et al., 2004). 
Noteworthy, EZH2 plays a major role in hematologic malignancies. It is upregulated in 
MCL (Visser et al., 2001) and other non-Hodgkin lymphomas (Dukers et al., 2004; Raaphorst et 
al., 2001; Raaphorst et al., 2000). More importantly there are mutations that affect the 
catalytic domain of this protein in follicular lymphoma and DLBCL of GCB origin (Morin et al., 
2010). Since these mutations reduce the enzymatic activity of EZH2 one may think that the 
oncogenic mechanism of EZH2 in these tumors might be different from that of prostate cancer 
and, in this case, EZH2 would behave as a tumor suppressing gene. However it remains to be 
explored whether these mutations alter the target specificity of this protein. Two very recent 
studies also report genetic alterations at the EZH2 locus in myeloid malignancies (Ernst et al., 
2010; Nikoloski et al., 2010). Both studies show that EZH2 is the target of deletion, uniparental 
disomy and mutation. In all cases, the alterations were EZH2-inactivating and, taking into 
account that many of them are deletions, the major effect must be a loss of function rather 
than a change in the target specificity. This means that EZH2 may have a tumor suppressor role 
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in these malignancies. In line with this, recent investigations show that the Drosophila E(z) and 
other PRC2 and PRC1 components play a tumor suppressor role through the suppression of 
the oncogenic JAK-STAT (Classen et al., 2009) and Notch (Martinez et al., 2009) pathways.  
 
 
There are also alterations described in PcG-regulating genes. For instance, several miRNAs 
that regulate the expression of PcG components are altered in cancer. Two examples are miR-
101 and miR-26a which target EZH2, but are downregulated in prostate cancer and in BL 
(Friedman et al., 2009; Sander et al., 2008). The downregulation of miR-26a comes from the 
upregulation of MYC due to a common translocation in BL. MYC represses miR-26a and 
therefore EZH2 can be expressed at higher levels. MiR-200c, miR-203, and miR-183 target 
BMI1 and are downregulated in cancer cells and mouse embryonic stem cells (Shimono et al., 
2009; Wellner et al., 2009). 
Figure 1.3. Cancer cells can originate from a stem cell such as a HSC that acquire an altered 
phenotype through chromosomal aberrations and/or mutations. PcG aberrant activity 
promotes tumor development. Alternatively, the first chromosomal aberration and/or 
mutation occur in a commited progenitor cell in which the abnormal PcG activity confers 
stem cell properties. 
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In the last few years several studies that have come up suggest a more profound impact 
of Polycomb in cancer. In fact, among the genes that are repressed in cancer there is a 
significant enrichment in those which are PcG targets in ES cells. This has led to propose the 
existence of a “Polycomb signature” in cancer.  
 
 
This molecular signature consists of those PRC2 target genes identified by chIP-on-chip 
analysis in cancer (most of which coincide with PcG targets identified in ES cells) that are also 
found downregulated in tumors by gene expression profile analysis. 
This Polycomb fingerprint can predict clinical outcome in several tumors (Yu et al., 2007). 
Other reports have studied the methylation pattern of promoters in human tumors in a 
genome-wide scale. In these studies, among the genes that suffer promoter hypermethylation 
Figure 1.4. Cell identity is reflected by changes in chromatin status. In HSCs PRCs repress 
genes involved in differentiation to allow a stem cell phenotype. During differentiation PcG 
proteins target genes involved in stemness. In cancer the aberrant PcG activity blocks 
differentiation and repress tumor suppressor genes. In this case the recruitment of DNMTs 
induces permanent repression of the genes. 
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in human tumors, there is an enrichment for PcG target genes described in ES cells (Dunwell et 
al., 2010; Martin-Subero et al., 2009a; Martin-Subero et al., 2009b; O'Riain et al., 2009; Richter 
et al., 2009; Schlesinger et al., 2007; Wang et al., 2010; Wu et al., 2010a). Some examples of 
PcG target genes that accumulate DNA methylation at their promoters in cancer are WT1, 
RARB, KLF4, ID4, GATA3, CHD5 and SPI1 (Bracken and Helin, 2009). This can be explained, as 
commented before, because EZH2 can directly control DNA methylation in some models by 
serving as a recruitment platform for DNA methyltransferases (Vire et al., 2006), and suggests 
a model in which PcG proteins recruits DNA methylation machinery to induce permanent 
repression of target genes (Figure 1.4).  
 
1.2.3 MicroRNAS AND REGULATION OF GENE EXPRESSION 
MiRNAs are one of the most abundant regulatory gene families. They are endogenously 
codified as long transcripts from RNA polymerase II promoters (Lee et al., 2004). These long 
transcripts called primary miRNAs (pri-miRNA) form imperfect stem loop structures that are 
processed by the RNAse III-type complex Drosha-DGCR8 (Lee et al., 2003) to remove the 
flanking sequences, and liberate the stem–loop precursor miRNA (pre-miRNA). At this step the 
pre-miRNA needs to be transported to the cytoplasm. This step is carried out by the Ran-
dependent nuclear transport receptor exportin-5 (Bohnsack et al., 2004; Lund et al., 2004; Yi et 
al., 2003). Once in the cytoplasm the pre-miRNA is processed by the RNAse III-type Dicer into 
approximately 22-nucleotides long double stranded RNAs that constitute the mature miRNA. 
The mature miRNA is now loaded into the miRISC (miRNA-containing RNA-induced silencing 
complex). During incorporation to the RISC complex, the miRNAs are converted into single 
stranded molecules. The strand that do not enter into the RISC complex is usually short-lived 
and rapidly disappears whereas the other strand remains as mature miRNA (Khvorova et al., 
2003).  
The mature miRNA guides the miRISC complex to the target mRNA through sequence 
complementarity to the 3’ UTR. If the miRNA have perfect or nearly perfect complementarity 
to the 3’ UTR it normally induces mRNA cleavage (Llave et al., 2002; Yekta et al., 2004) 
whereas in those cases where complementarity is not perfect, translation blockade is normally 
achieved (Pillai et al., 2005) (Figure 1.5). As an exception to this biogenesis pathway, the less 
abundant “mirtrons” bypass the normal nuclear Drosha processing and are processed 
exclusively by Dicer (Okamura et al., 2008). From the point of view of evolution, miRNAs are 
only expressed by plants and animals and the viruses that infect them(Bartel and Chen, 2004). 
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Most miRNAs are phylogenetically conserved between several species and their number 
correlates with the complexity of the organism. 
Actually, expansions of the miRNA repertoire appear to be associated with major body-
plan innovations during animal evolution (Niwa and Slack, 2007). Until the elaboration of this 
work, 940 human miRNAs can be found at the miRbase (www.mirbase.org). Each miRNA can 
regulate hundreds of target genes, so this group of short sequences can actually regulate a big 
part of the transcriptome even though the system seems to be redundant (Lim et al., 2005). 
The consequence is that miRNAs are virtually implicated in every cellular process. In fact 
miRNAs have been shown to regulate quite different functions such as development, cell 
proliferation, cell death, fat metabolism, pattering of the nervous system and modulation of 
hematopoietic differentiation (Ambros, 2004; Bartel and Chen, 2004; Niwa and Slack, 2007). 
Many miRNAs are tissue specific, highlighting their role in the development and 
differentiation. 
 
MiRNAs have been also implicated in several diseases including cancer. The first evidence 
of the role of miRNAs in cancer came from a study on B-cell chronic lymphocytic leukemia 
Figure 1.5. Scheme of miRNA biogenesis (reproduced from (He and Hannon, 2004)) 
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where miR-15 and miR-16 were downregulated due to hemi- or homozygous chromosomal 
deletion at 13q14 (Calin et al., 2002). Several miRNA loci reside on chromosomal fragile sites 
that are frequently altered in cancer: for instance the aforementioned miR-15a/16 cluster 
which is also deleted in pituitary adenomas; miR-143 and miR-145 that are located in the 5q33 
region which is deleted in lung cancer (Calin and Croce, 2006) and the miR-17-92 cluster which 
is frequently amplified in B-cell lymphomas (Ota et al., 2004) and lung cancers (Hayashita et al., 
2005). Methylation is another cause of abnormal miRNA expression in cancer. 
Hypomethylation of miR-21, miR-203 and miR-205 has been suggested as the mechanism by 
which these miRNAs are overexpressed in ovarian carcinomas (Iorio et al., 2007). The 
decreased miR-124a expression has been attributed to DNA hypermethylation in colon, breast 
and lung carcinomas (Lujambio and Esteller, 2007). Several oncogenic viruses also express 
miRNAs although the function of most of these miRNAs is largely unknown. This is especially 
important in oncogenic viruses like EBV. EBV expresses more than 20 miRNAs that are 
organized in two clusters within the EBV genome: one in the intronic region of the BART 
(BamH1-A Rigthward Transcript) gene, and another in the untranslated regions (UTRs) of the 
BHRF1 (BamHI-H right reading frame) gene (Cai et al., 2006; Grundhoff et al., 2006; Pfeffer et 
al., 2004). These miRNAs are important for the biological cycle of the virus and control several 
viral genes such as BALF5, LMP1 and LMP2a (Barth et al., 2008; Lo et al., 2007; Lung et al., 
2009). Some of these viral miRNAs promote survival of the host cell by targeting cellular 
transcripts. An example is ebv-miR-BART5 which targets the p53 up-regulated modulator of 
apoptosis (PUMA) rendering the infected cells less sensitive to apoptosis (Choy et al., 2008). 
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Cancer arises from the accumulation of both genetic and epigenetic events. Much attention 
has been paid to the molecular events that cause cancer from the genetic point of view (e.g. 
mutations, translocations, deletions, amplifications), but there is increasing evidence that 
epigenetic alterations play also a very important role in cancer. 
Two main epigenetic mechanisms could play a key role in the development of lymphomas: 
the Polycomb group of proteins and the microRNAs.  
Further investigation in these areas may be useful to elucidate new mechanisms of 
oncogenesis, thus helping to the understanding of the disease and proposing new therapeutic 
targets. 
Initial studies with several members of the Polycomb Repressive Complex 1 highlighted the 
importance of this system in lymphomas therefore promoting investigation of the Polycomb 
Repressive Complex 2. The objectives of the first part of this work are the following: 
 
a) To analyze the SUZ12 expression pattern in normal and malignant lymphoid tissues, 
investigating a possible oncogenic role for SUZ12. 
b) To analyze SUZ12 target genes in order to elucidate the exact mechanism by which 
SUZ12 can confer advantages to tumor cells or influence the tumorigenic process. 
 
On the other hand, the unexplained mutually exclusive relationship observed between the 
presence of the Epstein Barr Virus and the expression of the BCL6 protein in diffuse large cell 
lymphomas pointed to new mechanisms of regulation to explain this phenomenon. 
Hence, the objectives of the second part of this work are the following: 
 
c) To investigate the role of Epstein Barr virus and its correlation with BCL6 in diffuse 
large B cell lymphomas. 
d) To search microRNAs encoded by the Epstein Barr virus that could repress the 
expression of BCL6 protein and test functionally this hypothesis. 
  
  
 
 
   
 
 
 
 
  
2. MATERIAL 
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2.1 HUMAN TISSUE SAMPLES. ORIGIN, PROCESSING AND DIAGNOSIS 
All human tissue samples used in this work were collected through the archive of the CNIO 
tumor bank with the collaboration of the hospitals integrating the tumor bank network. The 
complete protocol for sample collection can be found in the following web address 
http://www.cnio.es/ing/programas/progTumor11.asp and are summarized in the following 
lines. Immediately after the surgery the tumor is divided in several pieces and processed in 
two different ways: 
Fixation in 10% formalin for 16-48 hours followed by inclusion in paraffin by standard 
techniques 
Freezing: The sample is properly identified in plastic cryomolds (Cryomold standard; Tissue-
Tek 4557) and embedded in a cryosolidifiable medium (OCT-Compound, Tissue-Tek 4583, 
Bayer S.A). The sample is subsequently fast-frozen through immersion in isopentane at -160º 
C. 
In this work formalin-fixed, paraffin-embedded (FFPE) tissue sections were used for 
immunohistochemical (IHC) studies as well as analysis of microRNA expression by RT-PCR. 
Frozen tissues were used for gene expression profiling by microarray hybridization. Diagnosis 
of all samples was revised in a centralized manner using FFPE tissue sections by means of 
hematoxylin/eosin and immunohistochemical staining according to the WHO criteria 
(Swerdlow et al., 2008). For the first project, we used in total, 154 non-malignant and 550 
malignant samples of human tissues. Three different samples of each of the following non-
malignant human samples were collected: 
· Central nervous system: parietal lobes, cerebellum, basal nuclei, brain stem, choroid plexus. 
· Gastrointestinal tract: esophagus, stomach, small bowel, colon, appendix, liver, pancreas, 
gallbladder. 
·  Respiratory tract: parotid, larynx, trachea, lung (pleura and bronchi). 
·  Endocrine system: pituitary, thyroid, parathyroid and adrenal glands. 
·  Skin and soft tissue: skin, muscle. 
·  Lymphoid tissue: tonsil, spleen, thymus. 
·  Breast and gynecological tissue: breast, ovary, uterus (cervix, endometrium, myometrium), 
fallopian tubes, placenta, umbilical cord. 
·  Male reproductive system and urinary tract: kidney, bladder, prostate, testis, seminal vesicles, 
epididymis. 
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·  Hyperplasic and inflammatory tissue: nodular thyroid hyperplasia, parathyroid hyperplasia, 
seborrheic keratosis, ulcerative colitis, hyperplasic polyp of the colon. 
 
The following tumors were represented in the malignant samples: 
· Central nervous system: low- and high-grade astrocytomas, oligodendroglioma, ependymoma, 
meningioma (10 cases per type). 
· Gastrointestinal tract and annexes: gastric adenocarcinoma (10 well differentiated and eight 
poorly differentiated cases); gastric signet-ring adenocarcinoma (10 cases), colonic villous 
adenoma (10 low-grade and 10 high-grade dysplasia cases); colonic tubular adenoma (10 
cases); well-differentiated colorectal adenocarcinoma (10 cases); mucinous colorectal 
adenocarcinoma (10 cases), poorly differentiated colorectal adenocarcinoma (5 cases); 
hepatocellular carcinoma (10 cases); gallbladder adenocarcinoma (9 cases); carcinoid tumor of 
the appendix (3 cases); endocrine pancreatic tumor (5 cases); exocrine pancreatic 
adenocarcinoma (5 cases). 
· Respiratory tract tumors: parotid pleomorphic adenoma (10 cases), squamous cell carcinoma of 
the larynx (10 cases), lung adenocarcinoma (10 cases), lung squamous cell carcinoma (10 
cases), lung undifferentiated large-cell carcinoma (10 cases), lung neuroendocrine small-cell 
carcinoma (6 cases), mesothelioma (10 cases). 
· Endocrine tumors: pituitary adenoma (10 cases), thyroid papillary carcinoma (10 cases), thyroid 
follicular carcinoma (8 cases), thyroid medullary carcinoma (9 cases), adrenal cortex carcinoma 
(3 cases), adrenal pheochromocytoma (8 cases), parathyroid adenoma (10 cases). 
· Skin and soft tissue tumors: cutaneous basal cell carcinoma (10 cases), cutaneous squamous 
cell carcinoma (10 cases), malignant melanoma (10 cases), capillary haemangioma (10 cases), 
Kaposi’s sarcoma (10 cases), fibrous solitary tumor (4 cases), leiomyosarcoma (6 cases), 
liposarcoma (7 cases) and atypical lipomas (3 cases). 
· Lymphomas: non-Hodgkin’s lymphomas (FL, MCL, DLBCL, BL and peripheral T-cell lymphomas) 
and Hodgkin’s lymphomas (HL) (10 cases of each type). 
· Breast and gynecological tumors: breast ductal carcinoma (10 cases), breast lobular carcinoma 
(8 cases), squamous cell carcinoma of the cervix (10 cases), endometrial adenocarcinoma (8 
cases) and serous endometrial carcinoma (2 cases), uterus leiomyoma (4 cases); ovary 
mucinous cystadenoma (5 cases) and cystadenocarcinomas (4 cases), ovary serous 
cystadenomas (4 cases) and cystadenocarcinomas (6 cases), ovary endometrioid 
adenocarcinoma (7 cases) and cystadenocarcinomas (3 cases), ovary clear-cell carcinoma (10 
cases). 
· Tumors of the urinary and male reproductive system: bladder urothelial carcinoma, clear-cell 
renal-cell carcinoma (10 cases), prostate adenocarcinoma (10 cases), seminoma (10 cases), 
embryonal carcinoma (5 cases), teratocarcinoma (5 cases). 
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Additional samples of MCL were used for the second TMA (76 samples) and the 
hybridization onto miRNA microarrays (24 samples, frozen tissues). 
In the second project, a first series of 36 cases of DLBCL (frozen tissues) was used to 
perform the analysis of miRNA expression and a second series of 149 DLBCL patients (FFPE 
tissues) was used for the immunohistochemical analysis as well as for the validation of miRNA 
expression. All the studies were carried out under the supervision of the institutional review 
board of the Instituto de Salud Carlos III. 
 
2.2 CELL CULTURE 
 
2.2.1 CELL LINES 
HEK293T (Graham et al., 1977) cells derived from human embryonic kidney were obtained from the 
American Type Culture Collection. Human cell lines derived from MCL patients Jeko-1 (Jeon et al., 1998) 
and Z-138 (Estrov et al., 1998) and from DLBCL patients HBL1 (Nozawa et al., 1988), HLY-1 (Al Saati et al., 
1989), MD901 (Miki et al., 1994), OCI-LY10 (Alizadeh et al., 2000), OCI-LY3 (Yee et al., 1989), RIVA and 
U2932 (Amini et al., 2002) were kindly provided by Dr. Martínez-Climent from the Centro de 
Investigación Médica Aplicada, Navarra. Human cell line derived from BL patient AKATA (Takada et al., 
1991) was a kind gift of Dr. Campanero from the Instituto de Investigaciones Biomédicas “Alberto Sols”, 
Madrid. NAMALWA (Henderson et al., 1983), RAJI (Pulvertaft, 1964), RAMOS (Benjamin et al., 1982) and 
TOLEDO (Gabay et al., 1999) cell lines were purchased from the American Type Culture Collection 
(Rockville, MD) and GRANTA-519 (Jadayel et al., 1997), DB (Beckwith et al., 1990), DOHH-2 (Kluin-
Nelemans et al., 1991), FARAGE (Baruch et al., 1996), KARPAS-422 (Dyer et al., 1990), OCI-LY19 (Chang 
et al., 1995), SU-DHL-4 (Epstein et al., 1978) and SU-DHL-6 (Epstein et al., 1978) from the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany).  
Table 2.1 summarizes all the characteristics of the cell lines used in this work including the origin, 
description and culture conditions for each one. 
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Cell line Species Source Culture medium Growth Origin 
HEK293T  Human Embryonic kidney DMEM + 10% FBS Adherent ATCC 
GRANTA-519  Human Mantle Cell Lymphoma DMEM + 10% FBS Suspension DSMZ 
Jeko-1  Human Mantle Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
Z-138  Human Mantle Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
AKATA  Human Burkitt’s Lymphoma RPMI 1640 + 10% FBS Suspension Campanero 
NAMALWA  Human Burkitt’s Lymphoma RPMI 1640 + 10% FBS Suspension ATCC 
RAJI  Human Burkitt’s Lymphoma RPMI 1640 + 10% FBS Suspension ATCC 
RAMOS  Human Burkitt’s Lymphoma RPMI 1640 + 10% FBS Suspension ATCC 
DB  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 20% FBS Suspension DSMZ 
DOHH-2  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension DSMZ 
FARAGE  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension ATCC 
HBL-1  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
HLY-1 Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
KARPAS-422  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 20% FBS Suspension DSMZ 
MD901  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
OCI-LY10  Human Diffuse Large B Cell Lymphoma IMDM + 10% FBS Suspension Martínez-Climent 
OCI-LY19  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 20% FBS Suspension DSMZ 
OCI-LY3  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 20% FBS Suspension Martínez-Climent 
RIVA Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
SU-DHL-4  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension DSMZ 
SU-DHL-6  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension DSMZ 
TOLEDO  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension ATCC 
U2932  Human Diffuse Large B Cell Lymphoma RPMI 1640 + 10% FBS Suspension Martínez-Climent 
 
2.2.2 CULTURE AND CONSERVATION OF CELL LINES 
All cell lines were grown in RPMI 1640 (Sigma Chemical, St Louis, MO), DMEM (Sigma Chemical) or 
IMDM medium (Gibco, Billings, MT) supplemented with 10-20% heat-inactivated fetal bovine serum – 
FBS (Euroclone, Ltd, UK), 2mM L-glutamine (Life Technologies, Inc., Grand Island, NY), 40 units/mL 
Table 2.1. Description of all cell lines used in this study. 
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penicillin (Gibco), 40 µg/mL streptomycin (Gibco) and 1 µg/mL fungizone (amphotericin B, Gibco) in a 
humidified incubator (Nuaire, Inc., Plymouth, MN) at 37º C with a 5% CO2 atmosphere. Cell lines in 
suspension were grown in 25-150 cm
2
 flasks (Corning, Corning, NY) and were subcultured by diluting 
cells 1:3 to 1:6 every other day. All cell manipulations were performed in a Telstar Biological Safety 
Cabinets (Bio IIA) with the laminar air flow systems. For long storage, cells were preserved in a liquid 
nitrogen container using DMSO as a cryoprotectant to avoid crystal formation and rupture of cell 
membrane. Briefly, 2.5-5 million cells were resuspended in 1 mL of freezing medium (90% FBS, 10% 
DMSO) and aliquoted in cryotubes. Aliquots where then put into a chilling jar and stored for 24 h in a -
80º C freezer to achieve a -1º C/minute cooling rate. To defrost the cells, a cryotube was quickly thawed 
in a 37º C water bath and DMSO was removed by a 5 minutes centrifugation step at 1,200 rpm. Cells 
were then resuspended in the proper amount of fresh medium. 
 
2.3 ANTIBODIES 
The antibodies utilized in the present work together with its origin, type, clone, application, dilution 
and manufacturer are shown in table 2.2. 
 
Antibody Species Type Clone Dilution Manufacturer 
BCL6 Mouse Monoclonal PG-B6p 1:500 (WB) DAKO 
BCL6 Mouse Monoclonal GI 191E/A8 1:300 (IHC) CNIO 
EZH2 Rabbit Polyclonal ZMD.309 1:25 (IHC) Zymed 
Histone H3 Mouse Monoclonal 6.6.2 1:1000 (WB) Upstate 
H3K27me3 Rabbit Polyclonal 07-499 1:1000 (WB) Upstate 
Ki67 Mouse Monoclonal MIB-1 Ready to use (IHC) DAKO 
LMP-1 Mouse Monoclonal CS.1-4 Ready to use (IHC) DAKO 
PARP Mouse Monoclonal P248 1:1000 (WB) Sigma-Aldrich 
SUZ12 Mouse Monoclonal 220A/A3 
1:2000 (WB & ChIP, concentrated) 
1:2 (IHC, supernatant) 
CNIO 
SUZ12 Mouse Monoclonal 07-379 1:1000 (ChIP) Upstate 
Tubulin Mouse Monoclonal DM1A 1:10000 (WB) Sigma-Aldrich 
 
Table 2.2. Characteristics of the antibodies used. 
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2.3.1 PRODUCTION OF SUZ12 MONOCLONAL ANTIBODY 
A cDNA encoding the full-length human SUZ12 protein was obtained from the laboratory of Dr Yi 
Zhang (pGEX-KG-SUZ12). The human SUZ12 gene was amplified by polymerase chain reaction (PCR) and 
introduced into the pDEST-TH1 expression vector (Invitrogen, Carlsbad, CA, USA) by means of Gateway® 
technology. The MBP-SUZ12 fusion protein was then expressed in E. coli strain BL21 (DE3) with 0.4 mM 
IPTG overnight at 30ºC. The bacteria were lysed with BugBuster reagent. The soluble fraction was 
purified with amylase resin (New England Biolabs, Ipswich, MA, USA), and the joined protein was eluted 
with 10 mM maltose. The protein-containing fractions were concentrated by Vivaspin ultrafiltration and 
used as an immunogen. 
Three BALB/c mice were injected intraperitoneally (three times at 14-day intervals) with 100 μg 6 x 
MBP-SUZ12 fusion protein and Freund's adjuvant. A 150-μg booster of the recombinant SUZ12 protein 
was injected intraperitoneally, and fused three days later, as described previously (Garcia et al., 2006; 
Montes-Moreno et al., 2008) 
To confirm that 220A/A3 mAb recognized the human SUZ12 protein, immunohistochemistry on 
frozen cytospin preparations of V5-tagged human SUZ12 expressed in HEK-293T cells was performed. 
Labeling with the anti-V5 mAb confirmed the efficiency of transfection. A Cytospin preparation of V5-
tagged human SOX4 protein was used as a negative control (Figure 3.1). Hybridoma supernatants were 
screened by ELISA. The mouse mAb raised against SUZ12 (220A/A3) was cloned by the limiting dilution 
technique. Animal experiments were performed under the experimental protocol approved by the 
Institutional Committee for Care and Use of Animals, CEUCA nº 001/02. 
 
2.4 IMMUNOHISTOCHEMISTRY 
In general, immunohistochemical staining was performed in the Histology and 
Immunohistochemistry Core Unit at the CNIO as follows. Immunohistochemical staining was carried out 
on FFPE tissue slides using a robotized system (Techmate 500; DAKO) and the LSAB Visualization System 
protocol (labeled streptavidin-biotin; DAKO). The slides were dried at 56º C and paraffin removed by 
successive immersion in xylene (2 x 10 minutes), 100% ethanol (5 minutes), 95% ethanol (5 minutes), 
70% ethanol (5 minutes) and water (2 minutes). A Heat-Induced Epitope Retrieval (HIER) step was 
performed in a 10mM solution of sodium citrate buffer pH 6.5 with 0.01M tri-sodium citrate solution, 
and heated for 2min in a conventional pressure cooker. After heating, slides were rinsed in cool running 
water for 5min. They were then quickly washed in Tris-buffered-saline pH 7.4, and incubated with 
monoclonal primary antibodies at appropriate dilutions for approx. 40min. The primary monoclonal 
antibodies used in this study and their dilutions are included in the table 2.7. 
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Following incubation with the primary antibody, immunodetection was performed with biotinylated 
secondary antibody (25 minutes), followed by peroxidase-labelled streptavidin-biotin (DAKO-
Cytomation, Glostrup, Denmark) with diaminobenzidine chromogen as substrate and contra stained 
with hematoxilin (1 minute and washed with distilled water). The preparations were dehydrated 
through consecutive incubations with ethanol 95% (30 seconds), ethanol 100% (30 seconds) and xylene 
(1 hour), and mounted using automatic mounting Tissue-Tek SCA. Incubation omitting the specific 
antibody and incubation with unrelated antibodies was used as a control of the technique. 
 
2.5 TISSUE MICROARRAYS 
Tissue Microarrays (TMA) technology allows for the simultaneous analysis of multiple individual 
tissue samples on a single slide through immunohistochemistry, in situ hybridization and fluorescence in 
situ hybridization techniques (Kallioniemi et al., 2001; Kononen et al., 1998). A TMA consist of the 
arrayed disposition of a variable number of circular biopsies (0.6-2 mm diameter) originated from 
different PFFE blocks into a unique block. This technology takes advantage of the possibility of analyzing 
a big number of samples in homogeneous experimental conditions with a minimum destruction of the 
original tissue sample and a low time and money consumption. The possibility of bias due to non-
representative tissue sections is overcame by the number of tumors analyzed as demonstrated by 
several studies (Camp et al., 2000). 
To construct the TMAs we used a Tissue Arrayer device (Beecher Instruments, Sun Prairie, WI) as 
previously described (Kallioniemi et al., 2001; Sanchez-Beato et al., 2006). All cases were histologically 
reviewed and representative areas were selected. In each case, 2 selected 1-mm-diameter cylinders 
from 2 different areas were included, along with 43 different controls to ensure the quality, 
reproducibility, and homogenous staining of the slides.  
Two independent researchers evaluated the staining of TMA sections for SUZ12, EZH2, and Ki67 
proteins using uniform criteria. Discrepancies in the scoring of cases were resolved after joint 
examination on a multi-headed microscope. To ensure the reproducibility of this method, we employed 
straightforward, clear-cut criteria, and cases were scored as positive (1) or negative (0) for SUZ12 and 
EZH2 antibodies. The threshold was 5% of positive cells for both antibodies. For Ki67, the values were 
scored as negative (0) for fewer than 5% of proliferating cells, positive (1) for 5-25%, and strongly 
positive (2) if more than 25% of cells were positive for Ki67. 
Whole-tissue sections from reactive lymph node, thymus, spleen, and tonsillectomy specimens were 
used for the examination of benign lymphocyte subpopulations. 
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2.6 BACTERIAL STRAINS AND CULTURE 
 
2.6.1 PROPAGATION CONDITIONS 
All Gateway™ destination vectors with the ccdB toxic gene were propagated in Escherichia coli One 
Shot® ccdB Survival™ T1 Phage-Resistant Cells (Invitrogen, San Diego, CA) which genotype is: F- mcrA 
Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araΔ139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG tonA::Ptrc-ccdA. 
All other vectors including Gateway™ destination vectors without the ccdB toxic gene were 
propagated in One Shot® TOP10 Chemically Competent E. coli (Invitrogen) which genotype is: F- mcrA 
Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 
nupG. 
All bacteria strains were normally growth in Luria-Bertani (LB) broth (10 g/L tryptone, 5 g/L yeast 
extract, 200 mM NaCl, pH 7.0) at 37º C in continuous shaking (225 rpm) for 16-20 hours approximately. 
Low salt LB broth (10 g/L tryptone, 5 g/L yeast extract, 100 mM NaCl, pH7.0) was used for propagating 
those bacteria carrying lentiviral plasmids. 
 
2.7 POLYMERASE CHAIN REACTION (PCR) 
The amplification of DNA fragments was carried out following a standard procedure. A general 
mixture was prepared with the following components: 1X polymerase buffer, 1.5 mM MgCl2, 0.2 mM 
dNTPs, 0.2 mM of each primer, 100 ng of DNA and 1 unit of polymerase. The typical reaction volume 
was 25 µL. The polymerase was different depending on the use of the PCR product and will be described 
in the proper section. PCR reactions took place in a GeneAmp® PCR System 9700 (Applied Biosystems, 
Foster City, CA). The conditions for each reaction will be described in the corresponding section. 
 
2.8 CLONING OF PCR PRODUCTS 
 
2.8.1 CLONING IN PENTR/D-TOPO VECTOR 
The pEntr/D-TOPO (Invitrogen) is a linear vector with a 5’ overhang in one side that contains the 
sequence GGTG and allows the directional cloning of a PCR product with a CACC 5’ end. Moreover it 
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contains a molecule of topoisomerase I covalently bound to each end of the vector that catalyzes the 
formation of a phosphodiester bond. The reactions were carried out in a volume of 3 µL that contained 
1 µL of PCR product (in which one of the primers contained the CACC 5’ end), 0.5 µL of salt solution (1.2 
M NaCl, 0.06 M MgCl2), 0.3 µL of the vector and 1.2 µL of water. This mix was incubated at room 
temperature for 5 minutes and 2 µL were used to transform chemocompetent TOP10 cells. The plasmid 
DNA of the resulting colonies was extracted by the miniprep procedure and analyzed by restriction 
analysis and sequencing. 
 
2.8.2 CLONING IN PGL3 CONTROL VECTOR 
The pGL3 Control vector (Promega) is an expression vector that contains the luc+ gene from the 
Firefly luciferase under the control of the SV40 promoter and enhancer sequences, resulting in the 
strong expression of the luc+ gene in many types of mammalian cells. For cloning of PCR products, the 
vector was digested with the XbaI restriction enzyme (New England Biolabs, Ipswich, MA). The vector 
was separated by electrophoresis in a 0.8 % agarose gel to ensure the correct digestion and purified. 
Vector was then subjected to blunting using the T4 DNA polymerase. For this, 1 unit of T4 polymerase 
was mixed with 1 µg of digested vector and 100 µM dNTPs in a final volume of 50 µL. This mix was 
incubated at 12º C for 20 minutes and then T4 DNA polymerase was inactivated by heating at 75º C for 
10 minutes. Then the blunt PCR product was ligated overnight at 16º C. 
 
2.9 CLONING OF shRNA IN LENTIVIRAL VECTORS 
The lentiviral vector pA179.Helix (Figure 2.1) was developed by the Genomics Unit at the CNIO by 
introducing a Gateway cassette into the pFUGW vector (Lois et al., 2002) deposited by David Baltimore 
to Addgene's plasmid repository (http://www.addgene.org/14883). Different shRNAs were designed 
using the SIDE program (http://side.bioinfo.cipf.es). The shRNAs were designed within the ORF 
sequence of the gene to avoid off-target effects associated with imperfect matching in the 3’ UTR of the 
target gene.  
As a first step for cloning, the H1 promoter is added to a shRNA-coding oligo by overlap extension 
PCR using the pSUPER vector (Brummelkamp et al., 2002) (Oligoengine, Seattle, WA) as a mold. The 
shRNA-coding oligo carries a CACC sequence at the 5’ end to allow the cloning into the pENTR/D-TOPO 
vector. The PCR is normally carried out using the Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA) 
derived from the DNA polymerase of the hyperthermophilic archaeon Pyrococcus furiosus or the KOD 
DNA polymerase (Toyobo Co., Osaka, Japan) derived from the DNA polymerase of the 
hyperthermophilic archaeon Thermococcus kodakaraensis if reaction with Pfu Turbo was unproductive. 
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The constructions are separated by gel electrophoresis, extracted and cloned into the pENTR/D-TOPO 
vector as described in the sections 2.9 and 2.10.1.  
 
 
After successful cloning in the pENTR/D-TOPO vector, the plasmid is propagated, isolated and 
sequence-verified as described in the sections 2.6.1 and 2.7.2.  
The insert is then subcloned into the pA179.Helix vector by using the Gateway® LR Clonase™ II 
enzyme mix (Invitrogen). This enzyme mix contains the Int (Integrase), IHF (Integration Host Factor) and 
Xis (Excisionase) enzymes that catalyze the in vitro recombination between the pENTR/D-TOPO and 
pA179.Helix vectors. For the reaction to occur 150 ng of each vector were mixed and TE buffer (10 mM 
Tris, pH 8.0; 1 mM EDTA) was added up to 8 µL. Then 2 µL of enzyme mix were added and the mixture 
was briefly vortexed and spun down. The reaction was incubated at room temperature overnight and 2 
µL of the mix were used to transform TOP10 chemocompetent cells. 
 
2.10 TRANSFECTION AND TRANSDUCTION TECHNIQUES 
 
2.10.1 TRANSFECTION WITH FUGENE® HD 
HEK293T cells were transfected with FuGene® HD (Roche, Basel, Switzerland) for the production of 
viral particles. FuGene® HD is a multi-component reagent for the transient and stable transfection of 
animal and insect cells. It contains lipids and other components that form complexes with DNA that are 
Figure 2.1. Vector map for the lentiviral vector pA179 
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transported into the cells. The HD formulation allows transfection of cells cultured at high density (80-
90% confluence). The transfection was done following the manufacturer’s recommendations. Briefly, 
the day before the assay 4.5 million cells were seeded in a 10 cm plate. The next day the medium was 
replaced by 10 mL of fresh medium and the cells were put back into the incubator. 9 µg of plasmid were 
mixed in 500 µL of prewarmed OPTIMEM® (Invitrogen) with 27 µL of FuGene® HD. The mixture was 
incubated for 30 minutes with gentle shaking every 5-10 minutes at room temperature. The mixture was 
added drop by drop to the cells and the cells were cultured normally. 
 
2.10.2 CALCIUM PHOSPHATE PRECIPITATION 
For transfection of luciferase plasmids and/or microRNAs in HEK293T cells calcium phosphate 
precipitation protocol was used since it showed superior performance than FuGene for simultaneous 
transfection of plasmids and microRNAs. In this case 1 million cells were seeded the day before 
transfection in a 35 mm diameter plate. The following day the old medium was removed and 2 mL of 
fresh medium were added. Cells were put back again into the incubator at least for 30 minutes to allow 
pH equilibration. In the meantime the following mix was prepared (per sample): 
· 400 ng of pGL3 derived vector. 
· 50 ng of pRL-CMV vector containing the Rluc gene coding for the Renilla luciferase. 
· The proper amount of microRNA. 
· Up to 87 µL of distilled water. 
· 13 µL of 1M CaCl2 
Prior to transfection cells were taken out the incubator and 100 µL of 2X HBS were added to the 
CaCl2 mix. The blend was mixed by directly bubbling for 15 seconds with the pipette. Then, it was added 
drop by drop to the cells. 16-20 hours after the transfection the cells were washed twice with 1X PBS 
(NaCl 137 mM, Na2HPO4 10 mM, KCl 2.7 mM, KH2PO4 2 mM, pH 7.4) to remove calcium phosphate 
precipitates and 2 mL of fresh medium were added. 
 
2.10.3 MICROPORATION 
Microporation is a novel electroporation technique that achieves high levels of transfection while 
keeping high levels of cell viability. Electroporation is an effective technique for transfection in which an 
electric field is applied to increase the permeability of the cell membrane. The increased permeability 
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allows the nucleic acids to pass through the cell membrane and enter into the cell. However, during the 
electroporation there are some processes that affect cell viability such as heat generation, dissolution of 
metal ions, variations in pH and oxide formation avoiding its use for sensitive cell lines such as lymphoid 
ones. The microporator (Digital Bio Technology, Seoul, Korea) is an electroporation device that uses a 
pipette tip as the electroporation space. This allows the generation of a uniform electric field with 
minimum heat generation, dissolution of metal ions, variation in pH or oxide formation. Thus we were 
able to get high transfection efficiency and survival rates with this method.   
For microporation one day prior to the assay the cells were cultured in a fresh growth medium 
without antibiotics in order to reach 60 to 80% confluence. The following day 2x10
6
 cells (100 µL tips) or 
3x10
5
 cells (10 µL tips) were harvested and washed with PBS. The pellet was resuspended in 110 µL (100 
µL tip) or 11 µL (10 µL tip) of buffer R and mixed with the proper amount of nucleic acids. 3 mL of buffer 
E2 (100 µL tip) or E (10 µL tip) were added to the microporation tube. 100 µL or 10 µL were taken with 
the gold tip, the pipette was inserted in the microporation tube and the electric field was applied. For 
microporation of the cell lines used in this study the following conditions were applied: 1250 volts, 30 
ms, 2 pulses. 
 
2.10.4 TRANSDUCTION WITH LENTIVIRAL PARTICLES 
Retroviral vectors are attractive tool for gene delivery. They have three characteristics that make 
them an ideal tool for stable expression of DNA elements. First, they stably integrate their cargo in the 
target cell which is important for the stable expression of the gene. Second, they have a large capacity 
(close to 10 Kb) that allows the expression of most cDNAs. Last, current retroviral vectors are free of 
pathogenic sequences and they do not transfer genes encoding for viral proteins thus minimizing the 
risk for the operator. Lentiviruses are a subtype of retroviruses with some specific features that render 
them very interesting for gene transduction of difficult-to-transfect cell lines. Transduction with 
lentiviruses also allows the stable delivery of DNA elements in a wide variety of cell lines, including 
primary cells and lymphoid cells. They are more efficient than other retroviral vectors because they are 
able to transduce both dividing as well non dividing cells. Lentivectors are derived from the HIV-1 
genome and have evolved to increase their safety and versatility.  
Production of lentiviral particles requires the use of a packaging cell line. In this case the HEK293T 
cell line was used to produce the viruses. This cell line allows the production of non-replicative units of 
the virus that are able to infect target cells but do not have the potential of producing more viral 
particles as normal viruses.  
There are several genes that are needed to produce the virus but are not codified by the 
lentivector. These are structural and enzymatic genes (gag, pol and env; necessary for the formation and 
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the replication of the virus that are provided in separate vectors for safety reasons). In lentiviruses, the 
efficient expression of Gag and Pol also requires a virally-encoded post-transcriptional activator called 
Rev. The gene gag-pol encodes for the capside, nucleocapside, integrase and retrotranscriptase of the 
virus whereas the env gene encodes for the glycoprotein that is present in the envelope of the virus. 
This protein determines the tropism of the virus since it is recognized by cell surface receptors and 
mediates the entry of the vector particle on its target. In this work we used the G protein of vesicular 
stomatitis virus (VSV-G) to pseudotype lentiviral vector particles because it is highly stable and because 
its receptor is ubiquitously expressed in mammalian cells (Salmon and Trono, 2007). 
 
 
The first step to produce the viruses is to co-transfect the lentivector (pA179.Helix, described 
above) with the structural vectors (pCMVdeltaR8.91 derived from the pCMVdeltaR8.9 (Lois et al., 2002) 
and encoding the gag-pol gene and pMD.G codifying for the env gene encoding the VSV-G protein) 
following the protocol described in the section 2.14.1.1 of this thesis. 48 hours after the transfection the 
cell supernatant already contains a high viral titer and can be used to infect target cells. For this, the 
supernatant is recovered and filtered through 0.45 µm cellulose acetate filter and 1 mL of viral 
supernatant was mixed with 10
6
 lymphoid target cells in a 6-well plate (NUNC, Roskilde, Denmark). 
Several protocols include the addition of polybrene (a polycation that reduces the electrostatic repulsion 
between the virus and the cell membrane) at this step, however it is not necessary when viral particles 
are pseudotyped with the VSV-G protein (Salmon and Trono, 2007). Then the cells are centrifuged with 
the viruses at 1,000 xg for 90 minutes (spinoculation). The cells are recovered and centrifuged to 
remove the viral supernatant and resuspended in 2 mL of fresh medium. The protocol is summarized in 
figure 2.2.  
Figure 2.2. Schematic representation of the steps followed for viral production and 
transduction of lymphoid cell lines. 
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2.11 LUCIFERASE ASSAYS 
To measure luciferase activity, 5x10
5
 cells were transfected with 400 ng of pGL3 vector and 40 ng of 
Renilla vector. 48h later, cells were lysed in 250 µL of Passive Lysis Buffer for 15 minutes (Promega) and 
cell debris was removed by brief centrifugation. 50 µL of Luciferase Assay Reagent II (LARII, Promega) 
were added to 50 µL of cell lysate and the firefly luciferase activity was measured in a lumminometer. 
Then, 50 µL of STOP&Glo reagent (Promega) were added to measure the activity of the Renilla 
luciferase. Total luciferase activity was represented as the ration between firefly and Renilla signals. 
 
2.12 CHROMATIN IMMUNOPRECIPITATION (CHIP) AND CHIP-ON-CHIP 
Chromatin immunoprecipitation (ChIP) is a technique that allows the analysis of protein binding to 
DNA sequences in a physiological context. It has been widely used to identify specific proteins or protein 
modifications in a region of the genome or the other way around, i.e. to identify regions of the genome 
associated with specific proteins. The technique is based on the immunoprecipitation of proteins that 
have been previously fixed with a cross linking agent and sonicated to shear DNA, allowing the 
precipitation of DNA sequences bound by these proteins. Standard PCR is commonly used to identify the 
DNA sequences associated to the immunoprecipitated protein. ChIP-on-chip, also known as location 
analysis (LA) is a variant of the ChIP assay that complements ChIP with hybridization in an 
oligonucleotide microarray. Both techniques have four common steps: 
· Fixation: It is one of the most critical steps. By fixing cells, proteins are cross linked to the 
molecules with which they are interacting. This permits protein-DNA complexes to keep their 
interactions throughout the entire process.  
· Cell lysis and sonication: It is necessary not only to release the DNA-protein complexes but also 
to shear DNA in adequate size fragments that are suitable for subsequent analysis.  
· Immunoprecipitation (IP): It is the differential step that will purify the protein-DNA complexes. 
The use of a high-quality antibody is crucial to get high signal-to-noise ratios.  
· Hydrolysis: Once the DNA fragments are co-immunoprecipitated with the protein, it is 
necessary to reverse the cross-links as a previous step to the analysis. 
After this point, in standard ChIP, DNA fragments are analyzed by standard PCR. In the case of ChIP-
on-chip, DNA is amplified to get enough starting material and later on labeled and hybridized in an 
oligonucleotide microarray (Figure 2.3). 
The detailed protocol is described below. All used buffers are described at the end of the protocol. 
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2.12.1 CHROMATIN IMMUNOPRECIPITATION (CHIP) 
First of all, 1-2 x 107 cells are harvested in a Falcon tube to have enough material for 5-10 
immunoprecipitations (approximately 2 x 106 cells are used per antibody). Cells are fixed by directly 
adding fresh 18.5% formaldehyde to get a final concentration of 1% formaldehyde. After addition of the 
fixating agent, cells are incubated for 15 minutes in a rotating platform. Afterwards, the cross linking 
reaction is stopped by direct addition of glycine powder to a final concentration of 0.125M. The samples 
are incubated 5 more minutes in a rotating platform, centrifuged for 5 minutes at 2,000 rpm to remove 
medium and washed twice with 10 mL of ice cold 1X PBS supplemented with 1X Protease Inhibitor 
Cocktail II (Milipore, Billerica, MA) and transferred to a 2 mL eppendorf tube. The pellet is disrupted by 
addition of SDS Lysis Buffer supplemented with 1X Protease Inhibitor Cocktail II (Milipore) and 
incubation for 10 minutes on ice. The amount of SDS Lysis Buffers depends on cell density and size but in 
this protocol 300 µL of lysis buffer is added to every 5 x 106 cells. Lysates can be frozen at -80º C at this 
step.  
The second step is to sonicate the cells. For this, lysates were divided in 300 µL aliquots and 
sonicated in a Bioruptor sonication device (Diagenode, Liège, Belgium) under the following conditions:  
· Intensity: High (H). 
· Time: 20 minutes. 
· Intervals: 30 seconds on, 30 seconds off. 
 Prior to sonication, half of the water of the Bioruptor was replaced with ice to avoid sample heating. 
These conditions have been previously optimized to yield chromatin fragments between 200-1000 bp 
with an average of 400 bp.  
Sonicated samples were centrifuged for 10 minutes at 15,000 xg to precipitate cell debris and 
insoluble chromatin. The chromatin can be stored at this point at -80º C. The third step is the 
immunoprecipitation. For this chromatin was measured in a NanoDrop (NanoDrop) just as an estimation 
of the yield and all the samples were put at a concentration of 750 ng/µL by diluting with SDS Lysis 
Buffer supplemented with protease inhibitors. 200 µL of chromatin were diluted with 1800 µL of 
Dilution Buffer supplemented with protease inhibitors and pre-cleared by addition of 60 µL of Salmon 
sperm DNA/Protein A/G 50% Slurry (Millipore). The samples were incubated for 1 hour in a rotating 
platform at 4º C. Agarose beads were pelleted by brief centrifugation (3000-5000 x g for 1 minute) and 
the supernatants were collected. 5 µg of the antibody were added to the sample (For the negative 
control, normal mouse IgG was used) and incubate overnight in a rotating platform at 4º C. After this, 
antibody-protein-DNA complexes are collected by addition of 80 µL of Salmon sperm DNA/Protein A/G 
50% Slurry (Millipore) for 1 hour at 4º C with rotation. . Agarose beads were pelleted by brief 
centrifugation (3000-5000 x g for 1 minute). 1 mL of supernatant of the negative control was collected 
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as the input. The beads were washed in 1ml each of the cold buffers in the order listed below and 
incubating for 3-5 minutes on a rotating platform followed by brief centrifugation (3000-5000 x g for 1 
minute) and careful removal of the supernatant fraction: 
 
· Low Salt Immune Complex Wash Buffer 
· High Salt Immune Complex Wash Buffer 
· LiCl Immune Complex Wash Buffer 
· TE Buffer (two washes)  
 
 
To elute the protein-DNA complexes, Elution Buffer was prepared prior to the elution step. 250 µL 
of elution buffer were added to each sample and incubated for 15 minutes in a rotating platform. 
Agarose was pelleted by brief centrifugation (3000-5000 x g for 1 minute) and supernatants were 
collected into new microfuge tubes. This step was repeated and eluates were combined to get a final 
volume of 500 µL. 
To reverse the cross linking, 20 μL 5M NaCl were added to each tube (40 µL for inputs) and 
incubated at 65°C for 4-5 hours or overnight. After this, 10 μl 0.5M EDTA, 20 μl 1M Tris-HCl and 2.5 μl of 
10 µg/µL Proteinase K were added to each sample (double for the inputs) and incubated at 45°C for 1-2 
hours. DNA was extracted by phenol:chlorophorm extraction as described in section 2.18 resuspending 
the DNA in a final volume of 20 µL.  
Figure 2.3. Schematic representation of the ChIP and ChIP-on-chip protocols with the four 
common steps. 
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For ChIP analysis, 1 µL of immunoprecipitated material was subjected to PCR using 1 unit of 
EcoStart Taq polymerase (Ecogen). The PCR program is described in table 2.3: 
 
  
Temperature Time Step 
95º C 5 minutes Denaturation 
94º C 30 seconds Denaturation 
35 cycles 60º C 30 seconds Annealing 
72º C 30 seconds Extension 
72º C 10 minutes Final extension 
Gene name Sense strand Antisense strand 
ATM GTTGTGCAAAGGGGTCAACT TTGGCGGAACTGAAAGAAG 
BCOR GCAAAAGACAGGCGAGCAAG ACCCCCAGAAAGACCAGGAA 
BIRC2 CCCAGGTGCATTTTTGGAAG TGCCTGCCAGTCAGTCACAG 
CBX2 TTCTCCCCGCTGTAACCTGA GCCCGAGATCCAGAACAATG 
E2F5 TGGATTGCAGTGGCAGGA CGTGGTAGTGCACACTTG 
GADD45G GTGCCAGCGTGTATGGTCAA CGAGTAAGGGCTGCAAAACG 
H2AFZ AGGGCCTGGGAGTTTTCTTG CTGTGTACAGCGCAGCCATC 
HDAC2 CTGGAGAAGGAGGCCGTTTC GCAGACCTGAGGGGGAGAAC 
JMJD2D AAATATGTACGGGGCAACCA TGACATCTCCCCTCCCACTA 
VAV3 GCTCAGCGCACCTAGACGTT GGCTCAGGTGTTCGACCTTG 
Table 2.3. PCR conditions for ChIP analysis. 
Table2.4 List of PCR primers used for ChIP analysis. 
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Buffers composition and preparation of other reagents. 
· SDS Lysis Buffer: 1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1. 
· ChIP Dilution Buffer: 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, pH 8.1, and 
167 mM NaCl. 
· Low Salt Immune Complex Wash Buffer: 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 150 mM NaCl. 
· High Salt Immune Complex Wash Buffer: 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 500 mM NaCl. 
· LiCl Immune Complex Wash Buffer: 0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid 
(sodium salt), 1 mM EDTA, 10 mM Tris, pH 8.1. 
· TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH 8.0. 
· Preparation of fresh 18.5 % formaldehyde: 0.925g paraformaldehyde (Sigma-Aldrich) was 
dissolved in a 50 mL Falcon tube with 4.8 mL of distilled water and 35 µL of 1N KOH. The tube 
was put in a glass beaker with 400-600 mL of water and heated in the microwave until the 
water in the beaker began boiling. The dissolved paraformaldehyde was cooled down on ice. 
 
2.12.2 CHIP-ON-CHIP 
For ChIP-on-chip immunoprecipitated DNA was amplified using the GenomePlex Whole Genome 
Amplification kit (Sigma-Aldrich) following the protocol described by O’Geen and colleagues (O'Geen et 
al., 2006): 
Library preparation: 10 µL of immunoprecipitated material or 10 ng of the input were mixed with 2 
µL of 1X Library Preparation Buffer and 1 µL Library Stabilization Solution. Samples were incubated at 
95º C for 2 minutes and immediately cooled on ice. Then 1 µL Library Preparation Enzyme was added 
and the samples were incubated as follows in a thermal cycler: 
· 16° C for 20 minutes (cycler should be precooled to this temperature) 
· 24° C for 20 minutes 
· 37° C for 20 minutes 
· 75° C for 5 minutes 
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· 4° C hold 
Amplification: A master mix was prepared containing 7.5 µL of 10X Amplification Master Mix, 47.5 
µL Nuclease-free H20 and 5 µL WGA DNA polymerase per sample. 60 µL of this master mix were added 
to each sample and incubated in a thermal cycler as follows: 
· 95° for 3’ , then 14 cycles of 
· 94° for 15” 
· 65° for 5’, then 
· 4° hold 
DNA was purified using the QIAquick PCR Purification Kit (Qiagen) and 15 ng of amplified material 
were subjected to a second amplification step as described above. Biological triplicates were amplified 
with this method. The same quantity of each replicate was mixed in a single tube. 2µg of DNA were 
labeled with the Bioprime Total Genomic Labeling System (Invitrogen) following the manufacturer’s 
recommendations. Briefly, input material and samples were labeled through random primer extensions 
by Exo-minus Klenow DNA polymerase in the presence of either Alexa Fluor 5 or Alexa Fluor 3 propargyl 
linked fluorophores. Labeled samples were purified with silica-based PureLink spin columns (Invitrogen). 
The samples were hybridized onto the Human Promoter ChIP-on-chip Microarray Set (Agilent 
Technologies Inc., Santa Clara, CA) that covers -5.5 kb upstream to +2.5 kb downstream of the 
transcriptional start sites of every gene with a total of 487,008 probes, following the instructions 
provided by the manufacturer. Briefly the samples were hybridized on a SureHyb hybridization chamber 
(Agilent Technologies) for 40 hours at 10 rpm and 65º C. 
 
2.12.3 DATA ANALYSIS 
Raw data from the images was extracted using the Feature Extraction software (v. 9.5.3.1, Agilent 
Technologies). ChIP Analytics program (v. 1.3.1, Agilent Technologies) was used for the analyses. A 
whole-chip error model was used to calculate confidence values from the enrichment ratio and the 
signal intensity of each probe (probe p-value) and of each set of three neighboring probes (probe set p-
value). Probe sets with significant probe-set p-values (p < 0.001) and significant individual probe p-
values (p < 0.01) were judged to be bound. Bound regions were assigned to genes if they were within 1 
kb of the transcription start site registered in at least one of five genomic databases. 
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2.13 FLOW CYTOMETRY TECHNIQUES 
 
2.13.1 ANALYSIS OF TRANSDUCTION EFFICIENCY 
For analysis of transduction efficiency, cells were counted and 200,000 cells were washed twice 
with 1X PBS (NaCl 137 mM, Na2HPO4 10 mM, KCl 2.7 mM, KH2PO4 2 mM, pH 7.4) by centrifugation at 
300 xg for five minutes. The cells were resuspended in 200 µL of PBS and acquired in a FACScalibur 
(Becton Dickinson, Franklin Lakes, NJ). Acquisition and analysis was carried out using the CellQuest™ Pro 
software (Becton Dickinson). 10,000 events were acquired and EGFP signal was detected in the FL-1 
channel. 
 
2.13.2 CELL COMPETITION ASSAYS 
To determine if viability or proliferative capacity of cells infected with a lentivirus carrying a shRNA 
against SUZ12 or a scramble control, we designed a competitive proliferation assay similar to that 
previously described (Ivanova et al., 2006). In short, GFP expression was analyzed by FACS 72 hours after 
infection of the cell lines with lentivirus carrying either the empty vector, or a scrambled control or 
either of the two shRNAs against SUZ12. This was done every 2 to 4 days. The evolution of GFP 
expression was compared with the third day using the following formula: 
?????????????? ? ?????? ???? ????? ???????????? ???? ????? ?????? ? ??? 
 
2.13.3 ANALYSIS OF APOPTOSIS BY ANNEXIN V STAINING 
Double staining with annexin V and propidium iodide (PI) was carried out in order to measure 
apoptosis. Annexin V is a 35-36 kDa Ca
2+
 dependent phospholipid-binding protein that has a high affinity 
for phosphatidylserine (PS), and binds to cells with exposed PS. Loss of plasma membrane asymmetry, 
that includes flipping of PS from the inner to the outer leaflet of the plasma membrane, is an early event 
in apoptosis. Thus annexin V stains cells that are undergoing apoptosis. PI is a DNA intercalating 
molecule that stains nucleic acids. It is used to stain death cells that have lost their membrane integrity. 
Since PI is a cell membrane impermeable compound, it is excluded from alive and early apoptotic cells 
while staining late apoptotic and necrotic cells. Double staining with these two compounds allows the 
discrimination between alive (double negative), early apoptotic (annexin V positive, PI negative) and late 
apoptotic/necrotic cells (double positive). In brief, 200,000 cells were washed twice with 1X PBS and 
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resuspended in 200 µL of 1X binding buffer (10 mM HEPES, pH 7.4; 140 mM NaCl; 2.5 mM CaCl2). To this 
suspension, 2 µL of Annexin V (BD Pharmingen) plus 2 µL of 1 mg/mL PI (Sigma-Aldrich, ST. LOUIS, 
MO) were added and cells were incubated for 30 minutes prior to acquisition in a FACScalibur (Becton 
Dickinson). Acquisition and analysis was carried out using the CellQuest™ Pro software (Becton 
Dickinson). 10,000 events were acquired. Propidium iodide signal was detected in the FL-2 channel and 
annexin V signal was detected in the FL-4 channel. 
 
2.13.4 CELL CYCLE ANALYSIS BY PI STAINING 
Cell distribution in cell cycle stages was analyzed by PI staining in a flow cytometer. PI is able to 
indicate the amount of DNA in permeabilized cells. PI fluorescence signal is directly proportional to the 
amount of DNA inside the cell. For the experiments, 10
6
 cells were washed once with 1X PBS and 
resuspended in 330 µL of cold PBS. Then 670 µL of chilled absolute ethanol was added drop by drop 
with continuous and gentle vortex. The cells were kept in this suspension for a minimum of 30 minutes 
and up to several days. Prior to analysis the cells are washed twice with 1X PBS and resuspended in 500 
µL of PBS plus 1 µL of RNAse A (100 mg/mL, Qiagen) and incubated at room temperature for 30 minutes. 
10 µL of 1mg/mL PI were added prior to acquisition in a FACScalibur (Becton Dickinson). Acquisition and 
analysis was carried out using the CellQuest™ Pro software (Becton Dickinson). 20,000 events were 
acquired. Propidium iodide signal was detected in the FL-2 channel. 
 
2.14 GENOMIC DNA EXTRACTION 
1-2 x 10
6
 cells were washed twice with 1X PBS centrifugating at 300 xg for 5 minutes. The pellet was 
disrupted by addition of 500 µL of Tissue and Cell lysis solution (Epicentre, Madison, WI) and 4 µL of 50 
µg/µL proteinase K and incubated overnight at 65º C. After the digestion the solution was observed to 
ensure that the entire pellet is digested. If that was not the case, 2 µL of proteinase K were added and 
the solution was incubated for 10 minutes at 65º C. After successful digestion of the samples, the 
solution was transferred to a 2 mL phase lock gel light tube (Eppendorf, Hamburg, Germany) and DNA 
was extracted by addition of 500 µL of phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich), 
inverting the tube for 2 minutes to mix and centrifugation for 5 minutes at 10,000 rpm in a 
microcentrifuge. Aqueous phase was then extracted and 500 µL of chloroform:isoamyl alcohol 24:1 
(Sigma-Aldrich) were added. The tubes were inverted again for a couple of minutes and centrifuged 5 
minutes at 10,000 rpm in a microcentrifuge. Organic phase was discarded and 1 mL of ice cold ethanol, 
50 µL of 7.5 M sodium acetate and 0.5 µL of linear acrylamide were added to the aqueous phase. The 
solution was inverted several times to mix and kept at -20º C to allow DNA precipitation for 30 minutes 
to one hour. DNA was subsequently pelleted by centrifugation at 12,000 rpm for 15 minutes and 
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washed with 1 mL of cold 70% ethanol. After washing, pellet was left to dry and later resuspended in 
100-200 µL of water. DNA concentration and quality was measured using a NanoDrop (Nanodrop 
Technologies, Wilmington, DE). 
 
2.15 RNA EXTRACTION 
 
2.15.1 CELL LINES 
 
2.15.1.1 EXTRACTION OF mRNA 
RNA was extracted using the RNAeasy Mini-Kit (Qiagen) following the manufacturer’s 
recommendations. Briefly, 10
6
 cells were harvested and washed twice in 1X PBS. The pellet was lysed 
and homogenized using 350 µL of the highly denaturing RLT buffer (containing guanidine isothiocyanate 
that inhibits RNAse activity) supplemented with 10 µL of ß-mercaptoethanol. Cells were homogenized in 
a QIAshredder spin column (Qiagen) by centrifugation at top speed for 1 minute in a microfuge. Ethanol 
was added to the samples and the sample was passed through an RNeasy mini column that contains a 
silica-gel membrane that selectively binds RNA. The contaminant DNA is then digested using DNAse I 
(RNase-free DNase I Set; Qiagen) for 20 minutes and RNA is washed with an ethanol-containing buffer. 
As a last step, RNA is eluted in 50 µL of RNAse-free water.  
If RNA concentration or quality was not optimal, RNA was precipitated by addition of 0.5 µl of linear 
acrylamide, 25 µL of 7.5 M ammonium acetate and 125 µL of chilled absolute ethanol. The mix was kept 
at -20º C for 12-16 hours and RNA was recovered by centrifugation at top speed for 30 minutes in a 
microfuge. The RNA was washed twice with 70% cold ethanol, air-dried and resuspended in 20-30 µL of 
RNAse-free water. Purified RNA was stored at -80º C in all cases. 
 
2.15.1.2 EXTRACTION OF microRNA 
RNA extraction protocol described in section 2.19.1.1 is not suitable when analyzing small RNAs 
because small RNAs are lost through the RNAeasy column. Thus, for analysis of miRNA expression, a 
different protocol was used. Since the detection of microRNA expression was performed using TaqMan 
miRNA probes (Applied BioSystems) that can discriminate mature from immature miRNAs and do not 
bind the microRNA gene, no DNA removal step is done in this protocol.  
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First, 1-2 x 10
6
 cells were washed twice with 1X PBS and the pellet was disrupted by addition of 1 
mL of TRIzol reagent (Invitrogen) and 5 minutes incubation at room temperature. TRIzol is a mono-
phasic solution of phenol and guanidine isothiocyanate that maintains the integrity of the RNA, while 
disrupting cells and dissolving cell components. Then, 200 µL of chloroform were added, mixed and the 
sample was centrifuged at 1,200 rpm for 15 minutes at 4º C. Aqueous phase was recovered and the 
same volume of isopropanol is added to precipitate the RNA. The sample is then centrifuged and 
washed with 70% ethanol.  
The pellet is dried and resuspended in 50 µL of RNAse-free water. 
 
2.15.2 TISSUES 
 
2.15.2.1 FROZEN TISSUES 
Frozen tissues were cut with a cryostat to get 20-30 slides depending on the size of the frozen 
piece. The slides were homogenized using a Polytron homogenizer (Capitol scientific, Inc; Austin, TX). 
The homogenized samples were lysed by addition of 1 mL and the following steps are common to the 
protocol described in section 2.19.1.2. The RNA extracted by this method was purified again using the 
protocol described in section 2.19.1.1. 
 
2.15.2.2 FFPE TISSUES 
RNA form paraffin embedded tissues is usually not well conserved because the process of fixing the 
tissue sample and embedding it in paraffin can cause severe degradation of the RNA. The quality of the 
RNA from paraffin embedded tissues is usually much lower than RNA from frozen tissues. The RNA 
isolated from FFPE tissues use to be shorter (primarily as fragments of less than 300 bases in length), 
and the yields are lower than those obtained from the same mass of fresh tissue. However, RNA from 
FFPE tissues is still suitable for some applications such as RT-PCR. Paraffin blocks were cut in a 
microtome to get 20-30 sections of 10µm thickness depending on the size of the fixed piece. The 
sections were desparaffinized by incubating twice with 1 mL of xilol for 10 minutes at 65º C. Then the 
samples were centrifuged at 10,000 rpm for 10 minutes and sections were washed twice with 1 mL of 
absolute ethanol for 10 minutes at 65º C. The samples were centrifuged again for 10 minutes at 10,000 
rpm and the pellets were left drying at 65º C.  
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500 µL of lysis buffer (10mM Tris ph8, 0.1 mM EDTA ph8, 2%SDS) and 4 µL of 50 µg/µL of proteinase 
K were used to lyse the samples and incubated for 16 hours at 65º C with shaking. RNA was purified by 
addition of 500 µL of phenol:chloroform:isoamyl alcohol (25:24:1) and centrifugation at 10,000 rpm for 
10 minutes in a microfuge. The aqueous phase was collected, 500 µL of chloroform:isoamyl alcohol were 
added and the sample was centrifuged again at 10,000 rpm for 10 minutes. The aqueous phase was 
collected and 1 mL of isopropanol plus 1 µL of linear acrylamide were added to precipitate the RNA. The 
sample was stored at -20º C overnight and then centrifuged for 30 minutes at 4º C. The supernatant was 
discarded and the pellet was washed with 70% ethanol. The pellet was dried and resuspended in 30-50 
µL of RNAse-free water.  
 
2.16 RETROTRANSCRIPTION 
 
2.16.1 mRNA 
cDNA synthesis from RNA was performed using the SuperScript II Reverse Transcriptase enzyme 
(Invitrogen), following the instructions provided by the manufacturer. Briefly, 500 ng of RNA were mixed 
with 50 ng of random hexamers, 1 µL of 10 mM dNTPs mix and water was added to a final volume of 12 
µL. Then, after a 5-minutes denaturation step at 65º C the following components were added: 4 µl of 5X 
first strand buffer, 2 µL of 0.1 M DTT and 1 µL of ribonuclease inhibitor (RNAsin) at 40 U/µL and the 
mixture was incubated for 2 minutes at 25º C prior to adding 1 µL of 200 U/µL SuperScript 
retrotranscriptase. The samples were then put in a thermocycler with the following program: 
 
Temperature Time 
25º C 10 minutes 
42º C 50 minutes 
70º C 15 minutes 
4º C ∞ 
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2.16.2 MicroRNA 
cDNA synthesis from miRNAs raises several problems attributable to the structure of the miRNA. 
First, miRNAs are 22 nucleotides long on average. Thus designing primers with the necessary melting 
temperature is very difficult. A second problem is that miRNAs are synthesized as primary miRNAs (pri-
miRNAs) and processed to precursor miRNAs (pre-miRNAs) through Drosha-mediated cleavage (Lee et 
al., 2003). After export to the cytosol the pre-miRNA is then processed by Dicer to the mature miRNA 
(McManus and Sharp, 2002). However the only form that is biologically active is the mature miRNA and 
to measure its abundance is necessary to discriminate the mature form. 
In this work we have used TaqMan microRNA Assays to measure specifically the mature form of the 
miRNAs. The cDNA synthesis step is carried out with a specific primer for each miRNA. This primer 
contains a specific sequence that anneals on the miRNA in the 3’ end and a general sequence in the 5’ 
end that do not anneal on the miRNA. Instead, this general sequence forms a hairpin impedes the 
annealing to the immature forms. In the other hand, the primer yields a product much larger than the 
original miRNA allowing for an easier design of the PCR primers. 
The retrotranscription was carried out using the TaqMan® MicroRNA Reverse Transcription Kit 
(Applied Biosystems). Briefly, 1 µL of 2ng/µL RNA solution was mixed with 0.05 µL of 100 mM dNTPs, 
0.33 µL of 50 U/µL MultiScrib Reverse Transcriptase, 0.5 µL of Reverse Transcription Buffer, 0.063 µL of 
20 U/µL of RNAse inhibitor and 1 µL of the specific RT primer in a final volume of 5 µL. The samples were 
put in a thermocycler with the following program: 
Program Time (min) Temperature 
HOLD 30 16º C 
HOLD 30 42º C 
HOLD 5 85º C 
HOLD 
∞ 4º C 
  
2.17 REAL-TIME QUANTITATIVE PCR 
Quantification of RNA expression by RT-PCR was carried out in a similar manner for mRNA and 
miRNA but the volumes of each reagent differ slightly. For mRNA, 2 µL of cDNA (0.66 µL for miRNAs) 
were mixed with 7.5 µL (5 µL for miRNAs) of 2X Universal Master Mix (Applied Biosystems) and 0.75 µL 
(0.5 µL for miRNAs) of the specific 20X TaqMan Assay (Applied Biosystem) in a final volume of 15 µL (10 
µL for miRNAs). The PCR cycling conditions were standard: 95º C for 10 minutes (one step), 95º C for 15 
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seconds, and 60º C for 1 minute (40 cycles). The relative changes in gene expression were calculated by 
the ΔΔCt method using the Sequence Detection System (SDS) 2.1 software (Applied Biosystems). The 
ΔΔCt method gives the amount of target normalized to an endogenous reference and relative to a 
calibrator. The expression of each of the genes in all specimens was related to its expression in a 
reference RNA pool (Stratagene) used as a calibrator. The level of each transcript was quantified by the 
cycle at which the PCR amplification was in log phase where there was significant fluorescent signal (Ct) 
with HGUSB as the endogenous control (RNU19, RNU44 and RNU48 for miRNAs). All standards and 
samples were run in triplicate. 
2.18 GENE EXPRESSION MICROARRAYS 
Gene expression microarrays are powerful techniques, which allow the analysis of the expression of 
thousands of genes simultaneously. The past decade has witnessed a revolution in the field of 
expression profiling in cancer. Microarray technology has changed both the view of cancer and how 
research in molecular oncology can be conducted (Raetz and Moos, 2004). In this work the Whole 
Human Genome Microarray Kit (1x44K, Agilent Technologies) was used. 
 
2.18.1 cDNA SYNTHESIS FROM TOTAL RNA 
2μg of total RNA were mixed with 2μl of a 5,000-fold dilution of Agilent's Two-Color Spike-in RNA 
control and amplified using Agilent Low RNA Input Fluorescent Amplification Kit (Agilent Technologies, 
Inc., Santa Clara, CA). The mixture in a final volume of 6.5μl (total concentration at least 5ng/μl) was 
mixed with 5μl of T7 promoter primer. The primer and the template were denatured by incubating the 
reaction at 65º C for 10min and placing on ice for 5min. Following, 8.5μl of cDNA Master Mix was added 
and the samples were incubated first at 40OC in a circulating water bath for 2h and then at 65º C in a 
heating block for 15min to inactivate MMLV-RT. Following that time, the samples were incubated on ice 
for 5min.  
cDNA Master Mix composition: 4μl of 5X First strand buffer, 0.1M DTT 2μl, 10mM dNTP mix 1μl, 1μl 
of MMLV-RT and 0.5μl of RNaseOUT. 
 
2.18.2 FLUORESCENT cRNA SYNTHESIS: IN VITRO TRASNSCRIPTION AND 
INCORPORATION OF FLUOROCHROMES 
To each sample tube, either 2.4μl of 10mM cyanine 3-CTP (sample) or 2.4μl of 10mM cyanine 5-CTP 
(Stratagene Universal Human Reference RNA) was added and mixed. Following, to each sample, 57.6μl 
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of Transcription Master Mix was added an incubated in a circulated water bath at 40º C for 2h. 
Following amplification and labeling, each sample was assessed on the Nanodrop ND-1000 to measure 
yield and specific activity.  
Transcription Master Mix composition: 15.3μl of Nuclease-free water, 20μl of 4X Transcription 
buffer, 0.1M DTT 6μl, 8μl of NTP mix, 50% PEG 6.4μl, 0.5μl of RNase OUT, 0.6μl of Inorganic 
pyrophosphatase and 0.8μl T7 RNA Polymerase. 
 
2.18.3 HYBRIDIZATION 
cRNA target was prepared as follows: 0.75μg cyanine 3-labeled, linearly amplified sample cRNA was 
mixed with 0.75μg cyanine 5-labeled, linearly amplified reference pool cRNA, 50μl of 10X control targets 
and Nuclease-free water to final volume of 240μl. The hybridization solution was prepared by adding 
240μl of 2X target solution to 10μl of 25X fragmentation buffer. The mixture was incubated at 60º C in 
the heating block for 30min. Following, 250μl of 2X hybridization buffer (from In situ Hybridization kit) to 
the final volume of 500μl, mixed, spinned and 490μl of the hybridization solution was applied to 60-mer 
Agilent 44K (or 4X 44K) Human Whole Genome oligonucleotide microarrays and assembled in 
microarray hybridization chamber (G2534A).  
Once fully assembled, the chambers were loaded into the hybridization rotator rack and set to 
rotate at 4rpm. The hybridization was performed in a rotating oven at 60º C for 17h. All the washing 
steps were performed at room temperature. First the sandwiched slides were submerged in Wash 
Solution 1 to remove oligo microarray slide. The slides were washed for 1min in the Wash Solution 1 
with the magnetic stir. The slides were then transferred to the staining dish containing Wash Solution 2 
and washed for 1min. Following, the slides were transferred to the staining dish containing the Wash 
Solution 3 and washed for 30 seconds. All steps were performed in the dark. The dried slides were 
scanned with a G2565BA Microarray Scanner System (Agilent Technologies, Palo Alto, CA).  
Wash solution 1 composition: 6X SSPE, 0.005% N-Lauroylsarcosine, deionized nuclease free water. 
Wash solution 2 composition: 0.06X SSPE, 0.005% N-Lauroylsarcosine, deionized nuclease free 
water. 
The buffers 1 and 2 are passed through a 0.2μm sterile filtration unit before use. 
Wash solution 3 composition: The Agilent Stabilization and Drying Solution contains an ozone 
scavenging compound dissolved in acetonitrile.  
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2.19 MicroRNA EXPRESSION MICROARRAYS 
 
2.19.1 LABELING 
100 ng of total RNA were hybridized onto an Agilent 8x15K Human microRNA Microarray Kit for the 
detection of 470 human and 64 viral microRNAs, following the manufacturer’s instructions (Agilent 
Technologies). Briefly, this procedure consisted of a RNA dephosphorylation step where the mixture of 
100 ng RNA, 10X CIP Buffer and CIP (16 U/µl) was incubated at 37º C for 30min. Following, a 
denaturation step was performed through addition of DMSO to samples carried out at 100º C for 5min. 
Samples were then treated with T4 ligase (15 U/µl) and labeled with Cy3 at 16º C for 2 hours. The 
reaction was performed in a total volume of 20 µl. Subsequently, RNA was purified with Bio-spin 6 
columns (BioRad, Hercules, CA) and dried in a speed vacuum (45º C, 45 minutes).  
Ligation master mix composition: 10X T4 ligase Buffer 2 µl, 0.1% BSA 2 µl, pCp-Cy3 3 µl and T4 ligase 
diluted (15 U/µl) 1 µl. 
 
2.19.2 HYBRIDIZATION 
Labeled RNA was resuspended in the appropriate volume of hybridization mix (H2O 18 µl, blocking 
agent 4.5 µl and hybridization buffer 22.5 µl) to a final volume of 45 µl and incubated at 100º C for 5 
minutes, quickly cooled and pipetted into the 8X gasket, closed with the Agilent 8x15K Human miRNA 
platform, and locked with the appropriate support. Hybridization was carried out at 55º C for 20 hours 
at 20 rpm. After that time the slides were washed first with WB1 buffer and then with WB2 buffer. Both 
washing steps were performed at 37º C for 7 minutes each, with shaking. Finally, the array was 
submerged in acetonitrile for 1 minute and dried. The arrays were scanned for Cy3 fluorescence with a 
G2565BA Microarray Scanner System (Agilent Technologies, Palo Alto, CA). 
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2.20 BIOINFORMATIC TOOLS 
 
2.20.1 MICROARRAY DATA ANALYSIS 
 
2.20.1.1 GENE EXPRESSION MICROARRAYS 
The data were processed and normalized with the use of Feature Extraction (v.9.5.3.1) software 
(Agilent technologies). The data were subsequently combined and filtered for saturated and non-
uniformly stained flags using the combine program (http://combine.bioinfo.cnio.es/). Filtered data were 
analyzed with the T-Rex program included in the Gene Expression Pattern Analysis Suite 
(http://www.gepas.org/) (Montaner et al., 2006) calculating the Pearson correlation between identified 
SUZ12-target genes and SUZ12 expression. 
2.20.1.2 MICRORNA EXPRESSION MICROARRAYS 
Data from miRNA microarrays were extracted using Feature Extraction (v. 9.5.3.1) software (Agilent 
technologies). Following, the average values of the replicate spots of each miRNA were background 
subtracted, normalized, and subjected to further analysis. MicroRNA was normalized using Loess within 
array normalization and quantile between-array normalization. MicroRNAs were retained when present 
in at least 30% of samples, (meaning the miRNAs were measured as present in at least the smallest 
group in the dataset) and when at least 30% of the miRNA had fold change of more than 1.5 from the 
gene median. Following the data was analyzed using the bioinformatics tools included in the Gene 
Expression Pattern Analysis Suite (http://www.gepas.org/) (Montaner et al., 2006). T-test statistic was 
calculated with the T-Rex program included in the aforementioned package. 
 
2.20.2 GENE SET ENRICHMENT ANALYSIS 
The Gene Set Enrichment Analysis (GSEA) tool (http://www.broad.mit.edu/gsea/) (Subramanian et 
al., 2005) was used to explore functional gene sets, allowing the interpretation of complete gene-
expression data in relation to SUZ12 expression. The gene sets coregulated with SUZ12 expression were 
identified using Pearson correlation, with a minimum of 10 and a maximum of 500 genes in a gene set 
being required to qualify them for further analysis. The selected gene sets corresponded to Biocarta 
pathways (http://www.biocarta.com/), excluding those that were not relevant to either lymphoid cell 
biology or cancer. Gene sets with an FDR less than 0.25 were considered significant. 
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2.20.3 INGENUITY PATHWAYS 
We identified Functions/Pathways classification terms enriched for SUZ12-bound genes using 
Ingenuity Pathways Analysis (http://www.ingenuity.com). The probability associated with a biological 
process is a measure of its statistical significance with respect to the Functions/Pathways/Lists Eligible 
molecules for the dataset and a Reference Set of molecules that defines the molecules that could 
possibly have been Functions/Pathways/Lists Eligible. The probability is that associated with a right-
tailed Fisher's exact test 
 
2.21 TOTAL PROTEIN EXTRACTION 
Total protein extraction was performed by lysis with RIPA buffer (150mM NaCl, 1.0% IGEPAL® CA-
630, 0.5% sodium deoxycholate, 0.1% SDS, and 50mM Tris, pH 8.0; Sigma-Aldrich) supplemented with 
Complete Protease Inhibitor Cocktail (Roche, Basel, Switzerland). Briefly, 10
6
 cells were lysed by addition 
of 50 µL of RIPA with cocktail inhibitor for 20 minutes on ice. Cell debris was removed by 4º C 
centrifugation at top speed for 30 minutes in a microfuge. Proteins were quantified using the A, B and C 
reagents of the BioRad protein assay (BioRad, Hercules, CA) following the manufacturer’s instructions 
and using bovine seroalbumin (BSA) as a standard. Briefly, 1ml of Agent A was mixed with 20μl of Agent 
S. First, the adequate amount of either standard (BSA) or sample was applied to each well of 96-well 
plate, following 25μl of previously prepared mixture was added. Finally, 200μl of Agent B was added and 
the whole preparation was incubated for 15min at RT and measured at a wavelength of 750nm.  
2.22 HISTONE EXTRACTION 
Histones were isolated by acidic extraction in 0.25 M HCl and precipitation with acetone. Briefly, 10
6
 
cells were harvested and incubated overnight in 200 μl of 0.25 M HCl at 4ºC with shaking. For histone 
precipitation, eight volumes of acetone were added to the supernatant, and histones were pelleted by 
centrifugation and washed with acetone. Histones were air-dried and resuspended in 0.25 M HCl for 
subsequent immunoblot analysis. 
 
2.23 WESTERN BLOTTING 
The list of antibodies used for Western blot can be found in table 2.7. For Western blot, 15-40 µg of 
protein were subjected to electrophoresis on sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels 
using the acrylamide concentration adequate for the size of the detected proteins (15% for histones, 
12% for PARP, 10% for SUZ12 and BCL6) using Mini-Protean 3 system (BioRad). 
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Electrophoresis buffer 5X composition: TrisHCl 0.13M, glycine 0.95M, SDS 0.5%. 
Sample buffer (Laemmli buffer) 4X composition: 62.5mM TrisHCl pH 6.8, glycerol 20%, SDS 2%, 2-
mercaptoethanol 5%, bromophenol blue 0.025%. 
After the electrophoresis, the proteins were transferred to a nitrocellulose membrane (Hybond ECL; 
Amersham) using the Mini Trans-blot Cell system (BioRad). Transference conditions were 40 mA for 16 
hours at room temperature or 400 mA for 1.5 hours at 4º C. 
Transference buffer 10X composition: TrisHCl 0.025M, glycine 0.2M, 20% of methanol 
Membranes were blocked in PBS-T (phosphate-buffered saline with 0.1% Tween-20) for 1 hour with 
continuous shaking and sequentially immunoprobed with primary antibodies at adequate dilution. 
Antibody detection was carried out using fluorescent-labeled secondary antibodies (Alexa 680 and Alexa 
800, Rockland, Gilbertsville, PA, USA) and an Odyssey Infrared System Scanner (LI-COR Biosciences, 
Lincoln, NE, USA). Band intensities were quantified using the ImageJ 1.34S software (National Institute 
of Health, Bethesda, MD, USA). 
 
2.24 ANALYSIS OF THE PRESENCE OF THE EPSTEIN-BARR VIRUS (EBV)  
 
2.24.1 ANALYSIS BY PCR 
Analysis of the presence of the EBV genome in cell lines was carried out by standard PCR using 1 
unit of EcoStart Taq polymerase (Ecogen, Truro, England) and 100 ng of DNA in a reaction volume of 25 
µL as described in section 2.8. The PCR conditions are the followings: 
Temperature Time Step 
95º C 5 minutes Denaturation 
94º C 30 seconds Denaturation 
30 cycles 55º C 30 seconds Annealing 
72º C 30 seconds Extension 
72º C 10 minutes Final extension 
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The primer sequences are described below and gave an amplicon of 122 bp. The PCR products were 
analyzed by electrophoresis in a 2% agarose gel. 
Primer sequences (5’ à 3’): 
EBV1: CCA GAG GTA AGT GGA CTT TA 
EBV2: GAC CGG TGC CTT CTT AGG AG 
 
2.24.2 ANALYSIS BY IN SITU HYBRIDIZATION (ISH) 
EBV detection in FFPE tissue sections was carried out by the Histology and Immunohistochemistry 
Core Unit at the Spanish National Cancer Research Center (CNIO). EBV was detected by ISH using an 
Epstein Barr Virus encoded RNA (EBER) specific probe (Bond ISH EBER Probe; Vision BioSystem, Wetzlar, 
Germany). The probe was hybridized in a Bond-maX autostainer (Vision BioSystem), an automated IHC 
staining system.  
 
2.25 FLUORESCENCE IN SITU  HYBRIDIZATION (FISH)  
FISH was performed by the Molecular Cytogenetics Group at the CNIO. The technique was used to 
detect SUZ12 copy-number changes in malignant samples. To study SUZ12 amplification we used the 
Bacterial Artificial Chromosome clones RP11-290N17 and RP11-640N20 from the BACPAC resources 
center (Children's Hospital Oakland Research Institute, Oakland, CA), which spans the entire 17q11.2 
genomic region, and a commercial centromeric probe for chromosome 17 (Vysis Inc., Downers Grove, 
IL), which was used as a control for the ploidy level of chromosome 17. 
The probes were labeled using the Nick Translation kit (Abbot Inc., Abbott Park, IL) following the 
protocol provided by the manufacturer and purified with the QIAquick PCR Purification kit (Qiagen) as 
indicated by the manufacturer’s instructions. The probes were hybridized on FFPE tissue slides that 
were previously desparaffinized as follows: 
First, slides were incubated overnight at 65º C. Then the slides were treated with xilol for 10 
minutes (twice at 65º C in the oven), ethanol 100% for 5 minutes (twice), ethanol 80% for 5 minutes and 
ethanol 70% for 5 minutes and kept in distilled water. After this, the samples were boiled in pre-warmed 
EDTA 0,5mM pH 8 for 6-10 minutes and the slides were washed with 1X PBS. The last step is digestion 
with 40 µL of pepsin for 30 minutes at 37º C. The reaction was stopped by putting the slides in STOP 
solution (1X PBS, 50 mM Mg2Cl). Slides were washed with water and dehydrated by progressively 
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increasing the ethanol concentration in the washing solution (70% ethanol, 80% ethanol, 100% ethanol; 
3 minutes each). 
The protocol for hybridization is summarized here. A hybridization mix was prepared with the 
following components: 1 µL of the probe, 2 µL of sterile water and 7 µL of the proper buffer. In the case 
of SUZ12 probe Vysis LSI (Abbot Inc.) was used and Vysis CEP (Abbot Inc.) for the centromeric probe. 
This mix was heated at 96º C for 5 minutes and 10 µL of it were put in each slide and incubated 
overnight at 37º C. The following day, the slides were washed with 0.4X SSC, 0.3% NP-40 for 2 minutes 
at 75º C and later on with 2X SSC, 0.1% NP-40 for 5 minutes under agitation. A last wash with phosphate 
buffered detergent (PBD) at room temperature was performed. Chromosomes were revealed by 
addition of 10 µL of 4',6-diamidino-2-phenylindole (DAPI).  
Fluorescence signals were scored in each sample by counting the number of single-copy gene and 
centromeric signals in an average of 130 (60–210) well-defined nuclei. SUZ12 amplification was 
recognized if the SUZ12/chromosome 17 ratio was greater than 2 in at least 20% of tumor cells. A 
sample was considered to feature a SUZ12 gene gain if the SUZ12/chromosome 17 ratio was greater 
than 1.5 but less than 2 (Sholl et al., 2007; Singh et al., 2002). 
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RESULTS I 
Deregulated expression of the Polycomb-group protein SUZ12 target genes 
characterizes Mantle Cell Lymphoma 
  
Cancer is the result of a series of genetic and epigenetic alterations that lead to the 
uncontrolled proliferation of malignant cells. Polycomb proteins are known to be of 
great importance in different tumors. SUZ12, a component of the PRC2 complex, is 
essential for the H3K27me trimethylation mark that is catalized by EHZ2 and both 
are involved in embryonic stem cell differentiation. In spite of the discovery that 
EZH2 plays an oncogenic role in several tumors a similar causative role has not been 
demonstrated for SUZ12. Using tissue microarray in a large cohort of normal and 
tumor samples it has been found that EZH2 and SUZ12 are not expressed at the 
same time in many tumors and normal tissues. Whereas EZH2 seemed to be almost 
ubiquitously expressed, SUZ12 showed a much more limited pattern of expression 
restricted mainly to proliferating cells in normal tissues such as germinal centers in 
lymph nodes and cycling epithelial cells. Changes in expression associated with 
tumoral transformation were found for SUZ12, which exhibited increased expression 
in different types of tumors including mantle cell lymphomas. Moreover, 
amplification of the SUZ12 locus was found in some cases. Using MCL cell lines as a 
model, functional and genomic studies were performed. Knock down of SUZ12 by 
shRNA demonstrated that SUZ12 loss compromises cell viability and increases 
apoptosis. By chIP-on-chip it was found that SUZ12 targets genes that are essential 
in the pathogenesis of MCL, including ATM, CDKN2A, CHEK1, BCL10 and RB. A high 
number of SUZ12 target genes were involved in cell cycle and proliferation, DNA 
replication and repair, development, cell death and control of gene expression. This 
results support the hypothesis that the abnormal expression of SUZ12 accounts for 
some of the unexplained features of MCL, such as abnormal DNA repair and 
increased resistance to apoptosis. 
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Figure 3.1. SUZ12 220A/A3 antibody validation in cytospin slides of transfected HEK-293T 
cells. (A) The transfected HEK-293T cell line with SUZ12-cDNA showed specific staining with 
SUZ12 220A mAB. (B) However, the same cell line transfected with SOX4–cDNA was 
negative with SUZ12 220A mAB. 
3.1 SUZ12 AND EZH2 PROTEIN EXPRESSION IN NORMAL HUMAN TISSUES 
Taking into account the fundamental role of the PcG repressing complexes in cancer and 
the fact that the relevance as well as the function of the PRC2 member SUZ12 in cancer has 
not yet been clarified, we decided to investigate the potential role of SUZ12 in human tumors. 
With the aim of exploring a possible abnormal expression pattern of SUZ12 in human 
tumors, we first characterized the expression of this protein in normal tissues. As first step, in 
collaboration with the Monoclonal Antibodies Core Unit of the CNIO, we generated a 
monoclonal antibody (mAb) against SUZ12 (clone 220A/A3; described in the section 2.3.1) that 
was used in subsequent experiments. To confirm that 220A/A3 mAb recognized de human 
SUZ12 protein, immunohistochemistry on frozen cytospin preparations of V5-tagged human 
SUZ12 expressed in HEK-293T cells was performed. Labeling with the anti-V5 mAb confirmed 
the efficiency of transfection. A Cytospin preparation of V5-tagged human SOX4 protein was 
used as a negative control (Figure 3.1).The immunohistochemical results were confirmed by 
western blot using cell lysate of SUZ12 and SOX4-transfected cells. The specificity of the mAb 
generated was also demonstrated in the shRNA experiments described below using several 
shRNAs designed against the coding sequence of SUZ12 transcripts and comparing with an 
unrelated scramble control sequence. The antibody was found to be suitable for 
immunohistochemistry, immunofluorescence (data not shown), western blot detection, and 
chromatin immunoprecipitation. 
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Figure 3.2. Expression of SUZ12 in non-tumoral human tissues. SUZ12 protein is 
preferentially detected in proliferating cells of various non-tumoral human tissues such as 
proliferating cells of tonsil’s germinal center (A), proliferating cells of tonsil’s squamous 
epithelium (B), germinal cells of the testis (C), and hair follicle (D). (Objective 100x, 
immersion). (M: Mantle Zone; GC: Germinal Center) 
This antibody was used in a TMA that contained around 50 different normal tissues (154 
samples) as described previously (Sanchez-Beato et al., 2006). Since EZH2 is the molecular 
partner of SUZ12 that carries the enzymatic activity, we decided to characterize the expression 
of EZH2 as well. Strikingly, EZH2 expression was detected in a large proportion of tissues with 
very few exceptions, while SUZ12 was detected in a more limited number of samples and 
usually in proliferating cells such as centroblasts in reactive lymphoid tissue, germinal cells in 
the testis, and the epithelium of various organs (Figure 3.2 & 3.3; Table 3.1). 
 
 
 
 
 
3.2 SUZ12 AND EZH2 PROTEIN EXPRESSION IN HUMAN TUMORS 
At the same time, we also studied the expression of these two proteins in TMAs containing 
representative paraffin sections from 569 cases of different human tumors encompassing up 
to 69 different tumor types (Sanchez-Beato et al., 2006). Similar to normal tissues, the pattern 
of expression was different in human tumors for both proteins and we found no significant 
association between them. EZH2 was again more ubiquitously expressed in most tumors (489 
out of 521 -94%- were positive) although with different intensities, however SUZ12 expression 
was mainly detected in tumors arising from lymphoid, lung, vascular, germinal and skin tissues 
(250 out of 497 -50.3%- had detectable expression). In summary, SUZ12-positive cases used to 
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be also EZH2-positive but not vice versa. A small fraction of the tumors (16/497, 3.2%) showed 
expression of SUZ12 but not EZH2 suggesting that SUZ12 can have additional EZH2-
independent functions (Figure 3.3 & 3.4; table 3.2). 
SUZ12 was detected mainly in lymphomas (91%) (especially in MCL), germinal cell-derived 
tumors (70%) (seminomas, teratocarcinomas, and embryonic carcinomas), skin tumors (88%) 
(melanomas and skin carcinomas), vascular tumors (83%) and pulmonary neuroendocrine 
small-cell carcinomas (70%) (Figure 3.3; Table 3.2). Most of these tumors are characterized by 
the presence of a high growth fraction. 
 
  ORGAN CELL TYPE SUZ12 EZH2 Ki67 
CENTRAL NERVOUS 
SYSTEM 
Cerebral cortex 
neurons 0 1 0 
glia 0 1 0 
molecular layer 0 1 0 
Purkinje cells 0 1 0 
granular layer 0 1 0 
Basal nuclei 
neurons 0 1 0 
glia 0 1 0 
Brain stem 
neurons 0 1 0 
glia 0 1 0 
Choroid plexus   0 1 0 
DIGESTIVE TRACT 
Esophageal mucose 
basal 0 1 -1 
superficial 0 1 -1 
Gastric mucose 
glands 0 1 1 
crypts 0 1 0 
Small intestine-mucose 
glands 0 1 1 
villi 0 1 0 
Large intestine-mucose 
crypts 0 1 1 
surface epithelium 0 1 0 
Parotid 
glands 0 1 0 
ducts 0 1 0 
Liver 
hepatocytes 0 -1 0 
bile duct 0 1 0 
Pancreas 
acini 0 1 1 
duct 0 1 0 
Langerhans islets 0 1 0 
Gallbladder 
glands 0 1 1 
surface epithelium 0 1 0 
RESP. TRACT 
Larynx 
basal  0 1 1 
superficial 1 0 0 
Lung-pleura & bronchi 
bronchi -1 -1 -1 
pneumocytes 0 1 0 
ENDOCRINE 
SYSTEM 
Pituitary gland 
adenohypophisis 0 1 0 
neurohypophisis -1 -1 0 
Thyroid gland follicles 0 1 1 
Parathyroid gland chief cells 0 1 1 
Table 3.1. SUZ12, EZH2 and Ki67 expression in non-tumoral human tissues. 0: Negative 
expression. 1: positive expression. 1*: isolated cells. - 1: No data. 
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cortex 0 1 0 
medulla 0 1 0 
SKIN & SOFT 
TISSUES 
Skin 
basal  1 1 1 
spinous  1 1 0 
hair follicle 1 1 1 
Adipose tissue adipocytes 0 1 0 
Striated muscle   0 1 0 
LYMPHOID TISSUE 
Spleen 
red pulp 0 1 0 
germinal center cells 1 1 1 
marginal cells 0 1* 1 
Thymus 
epithelial cells 1* 1 0 
lymphocytes 1 1* 1 
Tonsil & Lymph node 
interfollicular cells 1* 1 1 
germinal center cells 1 1 1 
mantle cells 0 1* 1 
BREAST Breast 
ducts 0 1 0 
acini 0 -1 0 
stroma 0 1* 0 
GINECOLOGICAL 
TISSUES 
Ovary 
follicles -1 1 -1 
stroma 0 1 0 
Fallopian tubes   0 1 0 
Myometrium   0 1 0 
Proliferative endometrium  
glands 0 1 1 
stroma 0 1 1 
Secretor edometrium 
glands 0 1 1 
stroma 0 1 1 
Endocervix   0 1 -1 
Exocervix 
basal 0 1 1 
superficial 1 0 0 
  
Placenta 
syncytiotrophoblast 0 1 0 
cytotrophoblast 1 1 1 
Umbilical cord stroma 0 1* -1 
URINARY TRACT 
Kidney 
glomerulus 0 0 0 
tubule 0 1 0 
Bladder urothelium 0 1 -1 
Prostate 
glands 0 1 0 
stroma 0 1 0 
MALE & 
REPRODUCTIVE 
SYSTEM 
Testis 
germinal cells 1 1 1 
Sertoli cells 0 1 1 
Leydig cells 0 1* 0 
Epididymis ducts 0 1 0 
Seminal vesicles epithelium 0 1 0 
  Endothelium endotehlial cells 0 1 1 
 
3.3 COPY NUMBER CHANGES AT THE SUZ12 LOCUS 
SUZ12 gene has been described to suffer several cytogenetic abnormalities in some tumors 
such as recurrent translocations in endometrial stromal tumors (Koontz et al., 2001a) and a 
wide spectrum of cytogenetic abnormalities in other tumors (Douglas et al., 2004; Espinet et 
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al., 1999; Kraggerud et al., 2002; Onciu et al., 2001; Starczynowski et al., 2008). Therefore, we 
thought that amplification of the gene locus might be a mechanism that could explain the high 
level of expression of SUZ12 and we decided to study the copy number of the chromosomal 
region containing the SUZ12 gene in our series of tumors.  
To study copy number variations at the SUZ12 locus we performed FISH analysis in TMA 
paraffin sections, in collaboration with the Molecular Cytogenetics Group of the CNIO. The 
TMAs were the same as used for the immunohistochemical analysis. We used standard criteria 
for definition of amplification (ratio SUZ12/centromeric 17 > 2.0), copy gains (2>ratio 
SUZ12/centromeric 17 > 1.5) and trisomies (Sholl et al., 2007; Singh et al., 2002).  
We found five cases with amplification of SUZ12, and two cases with copy gains. These 
chromosomal aberrations affected several tumor types: mesothelioma (amplification in 1/10), 
melanoma (amplification in 1/10), skin basal cell carcinoma (gain in 1/10), thyroid follicular 
carcinoma (amplification in 1/8), leiomyosarcoma (gain in 1/6), MCL (amplification in 1/10) and 
ovary serous cystoadenocarcinoma (amplification in 1/6). The results are summarized in table 
3.2.  
SUZ12 protein expression in MCL was positive in 9 out of 10 samples while it was not 
detected in non-malignant mantle zone cells. This result together with the finding of one case 
with amplification of the SUZ12 locus that was associated to strong SUZ12 protein expression 
prompted us to extend the study to a larger cohort of cases for further validation.  
Additionally, SUZ12 expression was detected in lymphomas that derive from germinal 
center B-cells with a high growth fraction (BL and DLBCL), or was restricted to proliferating 
cells in chronic lymphocytic leukemia, follicular lymphoma and splenic marginal zone 
lymphoma cases (Figure 3.3 & 3.4) while MCL is a tumor characterized by lower or 
intermediate proliferation, and their normal cell counterparts, mantle zone cells, show 
undetectable levels of SUZ12 protein expression. 
 
3.4 SUZ12 IN MANTLE CELL LYMPHOMAS 
Therefore, we extended our previous observations and checked SUZ12 protein expression 
and gene locus alterations in an additional TMA containing 76 MCL cases. In total, 46 out of 81 
(56%) MCL cases (10 in the general multitumor TMA and 71 new evaluable cases in MCL-
specific TMA) showed SUZ12 protein expression (Table 3.3). 
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Figure 3.3. Expression of SUZ12 (A) and EZH2 (B) proteins in human tumors (T) and in 
corresponding normal tissue counterparts (N). Red color represents positive expression; 
blue indicates absence of expression. In the case of tumors, the length of red/blue bars 
is proportional to the percentage of positive/negative cases, respectively, for each 
tumor type. Grey indicates no sample. 
 
 
 
B 
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For FISH analysis, 67 new samples from the TMA gave evaluable results. In total, three MCL 
samples (the previous one and two cases in the new TMA) showed gene amplification (Figure 
3.4) and four cases had copy gains affecting SUZ12 locus. Strikingly, the three cases with 
amplification had more than 80% of SUZ12 positive cells and remarkably, two of them were 
diagnosed as aggressive (blastoid) variant MCL cases. In summary, around 9% of MCL cases 
had cytogenetic alterations at the SUZ12 locus. Additionally polysomy of chromosome 17 was 
found in twelve MCL samples. 
 
TUMORAL TYPE 
EZH2 
EXPRESSION 
SUZ12 
EXPRESSION 
SUZ12 
GAINS 
(AMP+GAIN) 
SUZ12 
AMPS 
SUZ12 
GAINS 
Chr 17 
POLY 
CENTRAL NERVOUS SYSTEM  48/48 9/48 --- --- --- --- 
Ependymoma  9/9 1/9 --- --- --- --- 
High grade astrocytoma  10/10 6/10 --- --- --- --- 
Low grade astrocytoma  9/9 0/9 --- --- --- --- 
Meningioma  10/10 0/10 --- --- --- --- 
Oligodendroglioma  10/10 2/10 --- --- --- --- 
GASTROINTESTINAL TRACT  87/97 12/95 --- --- --- --- 
Gastric signet ring 
adenocarcinoma  
10/10 4/9 --- --- --- --- 
Poorly differentiated gastric 
adenocarcinoma  
6/6 0/6 --- --- --- --- 
Well differentiated gastric 
adenocarcinoma  
9/10 0/9 --- --- --- --- 
Exocrine pancreatic 
adenocarcinoma  
5/5 0/5 --- --- --- --- 
Endocrine pancreatic tumor  5/5 0/5 --- --- --- --- 
Appendix carcinoid  3/3 0/3 --- --- --- --- 
Gallbladder adenocarcinoma  6/6 0/5 --- --- --- --- 
Colonic tubular adenoma  5/5 1/8 --- --- --- --- 
Liver cell carcinoma  9/9 0/7 --- --- --- --- 
Low grade villous colonic 
adenoma  
4/7 5/9 --- --- --- --- 
High grade villous colonic 
adenoma  
7/10 1/6 --- --- --- --- 
Poorly differentiated colorectal 
adenocarcinoma  
4/4 1/5 --- --- --- --- 
Well differentiated colorectal 
adenocarcinoma  
9/9 0/9 --- --- --- --- 
Table 3.2. Summary of SUZ12 and EZH2 expression, and SUZ12 locus (17q11.2) alterations in 
human tumors. Values are the number of positive samples for SUZ12 or EZH2 staining. 
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Mucinous colorectal 
adenocarcinoma  
5/8 0/9 --- --- --- --- 
RESPIRATORY TRACT  57/57 37/73 1/71 1 0 15 
Lung adenocarcinoma  9/9 4/9 0/10 0 0 3 
Parotid pleomorphic adenoma  9/9 1/10 0/10 0 0 0 
Squamous cell carcinoma of 
the larinx  
10/10 6/9 0/10 0 0 3 
Lung squamous cell carcinoma  10/10 7/9 0/10 0 0 2 
Lung undifferentiated large cell 
carcinoma  
9/9 2/10 0/10 0 0 4 
Lung neuroendocrine small cell 
carcinoma  
5/5 12/17 0/11 0 0 3 
Mesothelioma  5/5 5/9 1/10 1 0 0 
ENDOCRINE SYSTEM  52/56 31/48 1/52 1 0 6 
Parathyroid adenoma  10/10 9/9 0/10 0 0 3 
Pituitary adenoma  9/9 9/9 0/10 0 0 2 
Thyroid follicular carcinoma  8/8 3/7 1/8 1 0 0 
Thyroid medullar carcinoma  8/8 3/8 0/8 0 0 0 
Thyroid papillary carcinoma  8/10 2/5 0/10 0 0 1 
Adrenal cortex Carcinoma  1/3 1/1 --- --- --- --- 
Adrenal pheochromocytoma  8/8 1/8 0/6 0 0 0 
SKIN & SOFT TISSUE  45/62 45/63 3/64 1 2 4 
Capillary haemangioma  4/7 5/8 0/9 0 0 0 
Kaposi's sarcoma  9/10 10/10 0/10 0 0 0 
Skin squamous cell carcinoma  8/9 8/8 0/9 0 0 2 
Skin basal cell carcinoma  6/7 8/9 1/9 0 1 0 
Solitary fibrous tumor  3/4 2/4 0/3 0 0 0 
Leiomyosarcoma  5/6 3/6 1/6 0 1 1 
Atypical lipoma  2/3 0/3 0/2 0 0 0 
Liposarcoma  6/7 2/6 0/6 0 0 0 
Malignant melanoma  8/10 7/9 1/10 1 0 1 
LYMPHOMAS  131/146 100/140 7/121 3 4 16 
Follicular lymphoma  9/9 9/9 0/10 0 0 1 
Mantle cell lymphoma  70/81 46/81 7/77 3 4 12 
Chronic lymphocytic lymphoma  9/9 9/10 --- --- --- --- 
Splenic marginal zone 
lymphoma 
9/9 5/8 --- --- --- --- 
Diffuse large B-cell lymphoma  10/10 7/7 0/9 0 0 2 
Burkitt lymphoma  7/9 8/9 0/6 0 0 0 
Hodgkin lymphoma  8/9 8/8 0/10 0 0 0 
Peripheral T-cell lymphoma  9/10 8/8 0/9 0 0 1 
GYNECOLOGICAL & BREAST 
TISSUES  
77/78 46/73 1/73 1 0 8 
Ovary endometrioid 
adenocarcinoma  
9/9 4/9 0/9 0 0 0 
Ovary clear cell carcinoma  8/9 3/10 0/10 0 0 3 
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Ovary serous 
cystoadenocarcinoma  
10/10 5/8 1/8 1 0 0 
Ovary mucinous cystoadenoma  9/9 7/7 0/9 0 0 0 
Endometrial carcinoma  10/10 6/10 0/10 0 0 0 
Squamous cell carcinoma of 
the cervix  
10/10 7/9 0/10 0 0 4 
Breast ductal carcinoma  9/9 8/10 0/8 0 0 1 
Breast lobular carcinoma  8/8 6/7 0/5 0 0 0 
Uterus leiomyoma  4/4 0/3 0/4 0 0 0 
URINARY & MALE 
REPRODUCTIVE  SYSTEM  
45/46 19/45 0/45 0 0 11 
Prostate adenocarcinoma  9/9 0/8 0/8 0 0 0 
Clear cells renal cell carcinoma  9/9 0/9 0/10 0 0 1 
Embryonic carcinoma  4/5 4/5 0/5 0 0 2 
Seminoma  10/10 6/9 0/10 0 0 4 
Teratocarcinoma  3/3 3/5 0/4 0 0 2 
Bladder carcinoma  10/10 6/9 0/8 0 0 2 
 
These findings suggest that alterations in SUZ12 leading to the overexpression of the gene 
product are important in the pathogenesis of MCL. However, the percentage of cytogenetically 
altered cases does not account for the overexpression of SUZ12 in many MCL cases. In those 
cases with cytogenetically normal SUZ12 locus, other mechanisms may be responsible for 
SUZ12 overexpression.  
 
POS TMA TMA ORGAN TUMORAL TYPE Ki67 EZH2 SUZ12 FISH SUZ12 
2 216 lymph node Mantle Cell Lymphoma 2 1 1 NA 
3 216 lymph node Mantle Cell Lymphoma 2 1 1 NA 
5 216 lymph node Mantle Cell Lymphoma 2 1 1 3R/2G 
6 216 lymph node Mantle Cell Lymphoma 2 1 1 Poly 
9 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
10 216 lymph node Mantle Cell Lymphoma 0 0 0 NA 
11 216 lymph node Mantle Cell Lymphoma 1 NA 0 NA 
12 216 lymph node Mantle Cell Lymphoma 0 0 NA 2n 
13 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
14 216 lymph node Mantle Cell Lymphoma_Blastic variant 2 1 1 AMPL 
15 216 lymph node Mantle Cell Lymphoma_Blastic variant 2 1 1 AMPL 
16 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
17 216 lymph node Mantle Cell Lymphoma 1 1 1 3R/2G 
18 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
19 216 lymph node Mantle Cell Lymphoma 2 1 0 2n 
20 216 lymph node Mantle Cell Lymphoma 1 0 0 2n 
Table 3.3. SUZ12, EZH2 and Ki67 expression in MCL-specific TMA. NA: not available. 0: 
negative. 1 and 2: positive expression. AMPL: Amplification; 1N: haploid; 2N: diploid; 3r/2g: 
gain; Poly; polysomy. 
   
Results I 
81 
 
21 216 lymph node Mantle Cell Lymphoma 1 1 0 Poly 
23 216 lymph node Mantle Cell Lymphoma 2 1 1 Poly 
24 216 lymph node Mantle Cell Lymphoma 0 0 0 2n 
26 216 lymph node Mantle Cell Lymphoma 1 1 NA 2n 
27 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
28 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
29 216 lymph node Mantle Cell Lymphoma 1 1 0 Poly 
30 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
31 216 lymph node Mantle Cell Lymphoma 2 1 1 1n 
32 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
33 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
34 216 lymph node Mantle Cell Lymphoma 2 1 1 Poly 
35 216 lymph node Mantle Cell Lymphoma 2 1 1 NA 
36 216 lymph node Mantle Cell Lymphoma 1 0 0 2n 
37 216 lymph node Mantle Cell Lymphoma 2 1 0 Poly 
38 216 lymph node Mantle Cell Lymphoma 1 0 0 NA 
40 216 lymph node Mantle Cell Lymphoma 1 0 0 2n 
41 216 lymph node Mantle Cell Lymphoma 2 1 0 2n 
42 216 lymph node Mantle Cell Lymphoma 0 0 0 2n 
43 216 lymph node Mantle Cell Lymphoma 1 0 0 2n 
44 216 lymph node Mantle Cell Lymphoma 1 1 1 2n 
46 216 lymph node Mantle Cell Lymphoma NA NA NA 2n 
47 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
49 216 lymph node Mantle Cell Lymphoma 0 NA 0 2n 
50 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
51 216 lymph node Mantle Cell Lymphoma 0 0 0 NA 
52 216 lymph node Mantle Cell Lymphoma 0 0 NA Poly 
53 216 lymph node Mantle Cell Lymphoma NA NA NA 3R/2G 
55 216 lymph node Mantle Cell Lymphoma 0 NA 1 poly 
56 216 lymph node Mantle Cell Lymphoma_Blastic variant 2 1 1 2n 
57 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
58 216 lymph node Mantle Cell Lymphoma 2 1 0 2n 
59 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
60 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
61 216 lymph node Mantle Cell Lymphoma 2 1 1 NA 
62 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
63 216 lymph node Mantle Cell Lymphoma_Blastic variant 2 1 1 Poly 
64 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
65 216 lymph node Mantle Cell Lymphoma 2 1 1 Poly 
66 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
67 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
68 216 lymph node Mantle Cell Lymphoma 1 1 1 2n 
69 216 lymph node Mantle Cell Lymphoma 1 1 1 2n 
70 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
71 216 lymph node Mantle Cell Lymphoma 1 1 1 Poly 
72 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
73 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
74 216 lymph node Mantle Cell Lymphoma 2 1 0 2n 
75 216 lymph node Mantle Cell Lymphoma 2 1 0 2n 
76 216 lymph node Mantle Cell Lymphoma 1 1 0 NA 
77 216 lymph node Mantle Cell Lymphoma 2 1 0 2n 
78 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
79 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
80 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
81 216 lymph node Mantle Cell Lymphoma 2 1 1 Poly 
82 216 lymph node Mantle Cell Lymphoma 2 1 1 2n 
83 216 lymph node Mantle Cell Lymphoma 2 1 1 1n 
84 216 lymph node Mantle Cell Lymphoma 1 1 0 2n 
85 216 lymph node Mantle Cell Lymphoma 1 1 0 3R/2G 
86 216 lymph node Mantle Cell Lymphoma 1 1 1 2n 
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Figure 3.4. SUZ12 in B-cell lymphomas. (A) SUZ12 and Ki67 expression in different types of B-cell lymphoma, showing the correlation between the 
strength of SUZ12 expression and proliferation index. (B) However, in MCL samples, a tumor with a relatively low proliferation index, some cases showed 
increased SUZ12 expression, in contrast to the absence of its expression from normal mantle zone cells (Figure 1A), which are the benign counterpart of 
MCL. C) SUZ12 gene amplification detected by FISH in an SUZ12-positive MCL case. Several copies of SUZ12 (in red) are detected, compared with only 
two centromeric copies for chromosome 17 (in green). Objective 100X, immersion. 
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3.5 MicroRNA LOSSES MAY ACCOUNT FOR UPREGULATION OF SUZ12 IN SOME 
MCL CASES 
Although cytogenetic alterations are an important mechanism of aberrant gene expression, 
SUZ12 locus cytogenetic abnormalities do not fully explain the gene overexpression seen in 
most of the cases.  
A potential role for microRNAs in regulating the expression of multiple oncogenes and 
tumor suppressor genes has been demonstrated (Croce, 2008). Therefore we decided to 
investigate microRNAs putatively regulating SUZ12 by studying their expression level in MCL 
cases.  
To this end we used the MicroCosm Targets tool (formerly miRBase Targets; 
http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/), which contains 
computationally predicted targets for microRNAs across many species using the miRanda 
algorithm (Griffiths-Jones, 2004; Griffiths-Jones et al., 2006; Griffiths-Jones et al., 2008). The 
MicroCosm analysis proposed hsa-miR-27b*, hsa-miR-126, hsa-miR-200b, hsa-miR-210, hsa-
miR-323-3p, hsa-miR-429, and hsa-miR-573 as putative regulators of SUZ12 expression. 
Therefore, we looked for the expression of these miRNAs in a group of 24 MCL cases and 
MCL-derived cell lines (Jeko-1 and Z138) using data generated in our laboratory with the 
Human miRNA Microarray platform from Agilent Technologies. As controls, we used reactive 
lymphoid tissue for MCL cases, and sorted IgD+ cells for cell lines. Probes for hsa-miR-323-3p 
and hsa-miR-27b* were not included in the chip. 
Expression of two of the five miRNAs included in the array showed lower levels than control 
samples in nearly all MCL cases studied (Figure 3.5).  
We found that hsa-mir-126 and hsa-miR-200b genes were downregulated in MCL cases 
relative to reactive lymphoid tissues (FDR < 0.01), and hsa-miR-200b was also downregulated 
in MCL-derived cell lines compared with IgD cells (p = 0.002). Hsa-mir-210 was not significantly 
deregulated in MCL with respect to control samples, and hsa-mir-429 and hsa-mir-573 were 
not detected in any normal or tumor sample.  
These data suggest an alternative mechanism that would explain SUZ12 overexpression in 
those cases that do not harbor cytogenetic abnormalities. However, further functional studies 
will be needed to mechanistically confirm our hypothesis. 
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3.6 SUZ12 DEFICIENCY COMPROMISES MCL VIABILITY 
Having in mind a possible oncogenic role for SUZ12 in MCL we wondered if SUZ12 was 
really needed for MCL cells to survive. Thus, to further asses the significance of SUZ12 
overexpression in MCL we performed an RNAi analysis using a lentiviral (HIV)-based RNA 
interference vector in two MCL-derived cell lines: Jeko-1 and Z138. The vector, as described in 
section 2.8 harbors the EGFP gene under the regulation of the UBC promoter allowing for the 
selection of infected cells by FACS. 
Two sequences (shSUZ12.783 and shSUZ12.2076) successfully knocked SUZ12 down in both 
cell lines with a residual expression of less than 20% (Figure 3.6A). Additionally, specificity of 
the shRNAs was assessed by measuring the levels of trimethylation at lysine 27 of histone H3 
(H3K27me3), a hallmark of the PRC2 complex activity. Taking into account that SUZ12 is 
required for the methyltransferase activity of EZH2 (Cao and Zhang, 2004), SUZ12 knock down 
should abrogate this mark. Levels of H3K27me3 were significantly affected 72 hours 
(decreased around 50% or less) after the infection with the lentivirus carrying shRNAs against 
SUZ12 compared with controls (Figure 3.6B). 
To determine whether the inhibition of SUZ12 had any effect on the survival of MCL derived 
cell lines, we followed several strategies. First we studied the growth potential of these cells 
compared with control cells. To this end we designed a strategy based on competitive 
Figure 3.5. Loss of expression of miRs regulating SUZ12 in MCL and MCL-derived cell lines. 
(A) Relative levels of hsa-mir-200b (A) and hsa-mir-126 (B) in tumoral MCL samples vs. 
normal controls (FDR < 0.01 for both miRs) and MCL-derived cell lines JEKO and Z138, (p = 
0.002 for hsa-mir-200b, and not significant for hsa-mir-126) compared with normal 
controls. For MCL, the normal control used was reactive lymphoid tissue, and for cell lines 
IgD+ isolated cells. (MCL-CL: MCL-derived cell lines; RLT: reactive lymphoid tissue). 
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proliferation similar to that previously described (see section 2.10.2) (Ivanova et al., 2006). 
When we infected Jeko-1 and Z138 with lentivirus carrying shRNAs against SUZ12 or scramble 
controls, we could observe a decrease in the infected EGFP-positive population only in those 
experiments in which we used shRNAs against SUZ12 (Figure 3.6C). This decrease was slight 
but constant along the time, meaning that although SUZ12 deficiency does not have a 
dramatic effect on cell viability, it is necessary for the long-term survival of these cells. In 
addition, we tested the effects of SUZ12 silencing on cell growth directly through 
measurement of cell number by trypan blue exclusion counting. For that, we previously sorted 
the EGFP-positive fraction. The results show that SUZ12-deficient cells grew less than cells 
either expressing a scramble control or infected with the empty vector (Figure 3.6D). This was 
mainly due to an increase in apoptosis, because cell cycle analysis by FACS in these GFP+-
sorted cells showed either slight but not significant decrease in G2/M or increase in SubG1 
phase in cells deficient for SUZ12 (Figure 3.7C). Thus we decided to study levels of apoptosis by 
means of annexin V staining. Levels of apoptosis augmented in Jeko-1 and Z138 cells upon 
silencing of SUZ12 (Figure 3.7B). Apoptosis was also demonstrated by Western blot using 
antibodies against PARP that were able to detect the cleavage of this protein upon apoptosis 
induction (Figure 3.7A). PARP was more efficiently cleaved in cells lacking SUZ12. We could 
observe that one of the hairpins was more efficient killing the cells. This efficiency correlated 
well with the levels of H3K27me3 suggesting that the effect on cell survival is mediated by the 
loss of this epigenetic mark. Actually, we could not detect PARP cleavage in Jeko-1 with the 
less efficient hairpin, although this probably occurred due to a matter of sensitivity of the 
antibody, since we still observed a mild increase in apoptosis by annexin V staining. 
 
3.7 IDENTIFICATION AND FUNCTIONAL CLASSIFICATION OF SUZ12 GENOMIC 
TARGET GENES IN MCL 
SUZ12 is known to exert its function on the Polycomb-PRC2 complex through the direct 
repression of many target genes. Although some genome-wide mapping of SUZ12 targets has 
been previously performed (Boyer et al., 2006; Bracken et al., 2006; Lee et al., 2006; Squazzo 
et al., 2006), it has been demonstrated that SUZ12 targets vary among developmental states, 
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Figure 3.6. (A) (left) Anti-SUZ12 immunoblot of Jeko-1 and Z138 cell lines transduced either with the 
empty vector, a scrambled sequence or with two different hairpins against SUZ12. Band signals 
were normalized with tubulin as a loading control (right). (B) Depletion of SUZ12 affects the function 
of the PRC2 complex as assessed by immunoblot using an antibody against histone H3 
trimethylation at lysine 27 (left). Total histone H3 was used to normalize band signals (right). (C) 
Expression of EGFP that marks transduced cells was tracked over time in order to observe 
differences in viability between cells transduced either with the empty vector or with a scramble 
control and cells transduced with two different hairpins against SUZ12. (D) GFP+-sorted Jeko1 and 
Z138 proliferation was assessed by counting viable cells using trypan blue exclusion along the time. 
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tissues and cell types (Squazzo et al., 2006). To look for potential targets that could explain the 
role of SUZ12 in MCL we performed chromatin immunoprecipitation (ChIP) and subsequent 
hybridization on Agilent’s Human Promoter Microarray (ChIP-on-chip) with the Z138 MCL-
derived cell line. 
 
Figure 3.7. (A) Immunoblot showing specific cleavage of poly (ADP-ribose) polymerase 
(cPARP) in SUZ12-deficient cells after sorting. (B) Flow cytometric analysis of apoptosis 
using double staining of Annexin V and propidium iodide after cell sorting. (C) Flow 
cytometric analysis of cell cycle in Jeko1 and Z138 cells after GFP+-sorting. Representative 
examples of three different measurements for each cell line are shown. 
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Figure 3.8. Validation of SUZ12 target genes by semi-
quantitative ChIP. Single-locus semi-quantitative PCR on 
ChIP samples was performed on several SUZ12 candidate 
target genes, with SUZ12 and H3K27me3 antibodies. Mouse 
IgG was used as a negative control. 
For ChIP experiments the SUZ12 antibody described here (clone 220A/A3) and SUZ12 
commercial antibodies (Upstate, 07-379) were used. Triplicates of the immunoprecipitated 
DNA were amplified using GenomePlex’s Whole Genome Amplification kit. Triplicates were 
then mixed, labeled, and hybridized against the input DNA on the Human Promoter chip.  
After data extraction, normalization and processing, we found 17,605 (3.6%) bound probes 
(peak p < 0.01) corresponding to 1,806 genes. As a second filter we used a normalized log2 
ratio above 1 to consider the genes to be potential SUZ12 targets. We found 1,424 gene 
promoters that passed both criteria including gene promoters of known SUZ12 target genes 
such as CDKN2A, GADD45G, BMP2, and WNT (Bracken et al., 2006; Kotake et al., 2007; Lee et 
al., 2006).  
However, the chromatin immunoprecipitation technique has some caveats. First, the 
binding capacity of agarose beads usually overwhelms the amount of antibody used giving high 
backgrounds that can mask the results. Second, these procedures give, at best, relative 
enrichment of DNA fragments and not absolute purification (Kuo and Allis, 1999).  
 
Thus, to determine the accuracy of SUZ12 target gene discovery, single-locus semi-
quantitative PCR was performed on immunoprecipitated material with SUZ12 and H3K27me3 
antibodies on 18 candidate SUZ12 target genes. These target genes included genes with known 
relevance in MCL or lymphoma pathogenesis such as ATM, BCOR or VAV; genes which play a 
role on significant processes associated with cancer such as apoptosis or DNA repair (BIRC2, 
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GADD45G) and genes related to transcriptional regulation, a process in which SUZ12 is 
supposed to play a critical role (JMJD2, E2F5). GADD45G (a previously described target, (Lee et 
al., 2006)) was used as the positive control (Figure 3.8). 
 With this method, eleven out of eighteen targets were validated with both antibodies, 
SUZ12 and H3K27me3, including ATM, CBX2, VAV3, JMJD2 and BIRC2. These data support the 
idea that SUZ12 is not only present at these loci but also is functionally active, since the 
H3K27me3 mark can be found at the same loci.  
 
 
To determine whether SUZ12 controls the expression of essential pathways in the survival 
of MCL cells as suggested by the functional experiments we decided to explore the functions of 
SUZ12 target genes using the Ingenuity Pathway Analysis (IPA) program. Only 658 out of 1,424 
genes identified by chIP-on-chip had annotated functions in the IPA database and could 
therefore be functionally classified. Functional classification showed an enrichment of genes 
controlling gene expression, cell cycle and proliferation, DNA replication and repair and 
development (Figure 3.9). These findings are consistent with other studies (Bracken et al., 
2006; Lee et al., 2006) and can explain the role of SUZ12 in cancer.  
Figure 3.9. Functional classification of SUZ12-targeted genes. Functions of SUZ12 target 
genes were analyzed using the IPA program. 658 out of 1,424 genes identified by ChIP-on-
chip have annotated functions in the IPA database. The number of genes identified as 
belonging to each category is included. The probability is that associated with a right-tailed 
Fisher's exact test. 
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Among the SUZ12 target genes that were sorted as having a role in gene expression we 
mainly found transcription factors and regulators, such as E2F5, POU domain proteins, and 
SUV39H1, and enzymes regulating transcription and translation, such as DNA and RNA 
polymerases, jumonji domain (JMJD) proteins, and several eukaryotic translation initiation 
factors (EIFs). It is interesting that we found members of the E2F family of transcription factors 
between SUZ12 target genes because several E2F proteins regulate and interact with 
Polycomb proteins, suggesting a feed-back regulatory loop between E2F factors and Polycomb 
proteins (Nowak et al., 2006; Sanchez-Beato et al., 2004; Wu et al., 2010b). 
Regulation of development is one of the main functions of the PcG proteins. Thus it is not 
surprising that we found a lot of development regulators among SUZ12, some of which have 
been previously described as SUZ12 targets in ES cells. These include Sry-related HMG box 
(SOX) and Forkhead box (FOX) family genes; POU domain transcription factors, including 
POU2F3 a known tumor suppressor gene that is aberrantly silenced by hypermethylation in 
cancer (Zhang et al., 2006); and BMP2. 
Another interesting finding was the presence of SUZ12 at the promoter of several miR 
genes, two of which have been identified as SUZ12 targets (hsa-mir-124a and hsa-mir-183 (Lee 
et al., 2006; Marson et al., 2008). Some of these miRs have a known role in cancer and 
differentiation such as hsa-miR-148a (Lujambio et al., 2008) and hsa-miR-223 (Stamatopoulos 
et al., 2009).  
Indeed, the most noteworthy finding was many of the most significant genes among the 
SUZ12 targets were genes with known roles in the pathogenesis of MCL. Some of the genes, 
like CDKN2A, were previously known to be SUZ12 target genes, but many others have not 
been previously described as SUZ12 targets. The list of target genes related to MCL 
pathogenesis included genes regulating cell cycle (CDKN2A and other INK4 family genes, 
several cyclins and cyclin dependent kinases, CHEK1, MAD2L1, and BUB3), DNA damage and 
repair genes (ATM, GADD45, several DNA polymerases and topoisomerases, MLH1, XRCC 
family genes, and ERCC family genes), apoptosis regulators (BCL2 and BCL2 regulator proteins, 
BID, several BIRC family members, and others). We also found members of NF-κB pathway 
(BCL10, NF-ΚB2, and IKBKG) to be regulated by SUZ12. The fine tuning of the NF-κB pathway is 
altered in several cancers (Karin et al., 2002). 
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3.8 GENE EXPRESSION PROFILING IN SUZ12 DEFICIENT MCL CELLS AND IN MCL 
SAMPLES 
To really assess the effect of SUZ12 in the gene expression pattern of MCL and elucidate 
and validate the relevance of the results obtained by chIP-on-chip we decided to look for 
potential gene expression changes associated to the levels of SUZ12 expression. To this end we 
performed gene expression profiling in Z138 cell line after SUZ12 silencing and in an additional 
series of MCL patients, using whole genome expression microarrays. 
3.8.1 CHANGES IN SUZ12 TARGETS AFTER SUZ12 SILENCING IN THE Z138 MCL-
DERIVED CELL LINE 
As a first step we analyzed differentially expressed genes in SUZ12-silenced cells. For that 
we compared the gene expression profile of cells transduced with lentiviruses encoding for 
shRNAs against SUZ12 (shSUZ12.783 and shSUZ12.2076) with the gene expression profile of 
cells transduced with lentiviruses that did not encode for any shRNA. We decided not to use a 
scramble shRNA in these experiments as a control to exclude the possible off-target effects of 
the scramble sequence that could mask the effects of SUZ12 on some genes and also give 
several false positives.  
After SUZ12 silencing in the Z138 cell line, some SUZ12 targets were actually unrepressed. 
140 transcripts, belonging to the group of SUZ12-target genes, showed an upregulation or 
downregulation of at least 0.6 (log2 scale) after 3 or 5 days and were considered to be 
significantly deregulated after SUZ12 silencing. Among the genes that were differentially 
expressed we found some genes belonging to pathways altered in MCL such as CDKN2A and 
GADD45G as well as genes involved in development, such as BMP2 and several GATA binding 
proteins or differentiation factors like MLLT3 and CBX2 (Figure 3.10). 
 
3.8.2 GENE EXPRESSION PROFILE IN MCL SAMPLES 
With the aim of examining the impact of SUZ12 expression in MCL samples, we decided to 
explore the gene expression changes associated to SUZ12 expression in human samples. Thus 
we hybridized an additional series of 24 MCL cases onto Agilent’s whole human genome 
microarrays. Then, we looked for genes which expression was inversely or directly correlated 
with SUZ12 expression and were found to be SUZ12 targets by chIP-on-chip. Using these kind 
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of analysis we could observe that 188 of 642 known genes suitable for the analysis (30%) were 
significantly correlated with SUZ12 expression (Pearson R > ±0.4, FDR < 0.15). The correlation 
of most of these genes with SUZ12 expression was inverse being more downregulated in those 
cases with more SUZ12 expression and upregulated in those cases that did not express SUZ12 
(126 inversely correlated with SUZ12 expression vs. 62 with a direct correlation) (Figure 3.11).  
Among these target genes we could find genes involved in spindle checkpoint function such 
as BUB3 and MAD2L1, DNA repair (XRCC6), apoptosis (TP53RK, BNIP2, BIRC2 and TMBIM4), 
NF-κB pathway (NKAP) and regulators of transcription and translation (SMARCAD1, JMJD2D, 
EIF1B, EIF4A2, FOXJ2 and E2F5). 
 
3.9 PATHWAYS COREGULATED WITH SUZ12 IN MCL 
All these analysis give an idea of the direct targets that are under the control of SUZ12. 
However, the impact of SUZ12 in tumor cells is composed by the direct as well as indirect 
effects of its expression. Thus, in order to determine the general characteristics of the tumors 
associated to the expression of SUZ12, we explored the gene expression profile of MCL 
samples taking into account all the genes for the analysis and not only those genes that 
appeared as direct targets of SUZ12. 
We focused our attention in identifying functional pathways coregulated with the 
expression of SUZ12. To this end we performed a gene set-enrichment analysis (GSEA) of 
SUZ12 expression with all the genes in MCL malignant samples, not restricted to SUZ12 targets 
identified by ChIP, using GSEA software (http://www.broad.mit.edu/gsea/). GSEA is a 
computational method that determines whether an a priori defined set of genes shows 
statistically significant, concordant differences between two biological states. In this case the 
biological state was the expression of SUZ12 taken as a continuous variable. 
This analysis revealed a direct correlation with pathways associated with proliferation, such 
as cell cycle (including E2F1 and several cyclins and CDKs) and caspase-apoptosis pathways 
(including BCL2) enforcing the idea that high expression of SUZ12 is associated to more 
aggressive variants and an inverse correlation with the proteasome pathway (Table 3.4). We 
also found an inverse correlation with the MAPK pathway, which might be contradictory with 
previous results, however, some specific genes included in this pathway such as JUN, FOS, 
MAPK4, MAPK7, and BRAF showed stronger expression in SUZ12-expressing tumors.  
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Figure 3.10. SUZ12 target gene expression was affected in SUZ12-silenced cell lines. Gene-
expression profiling was performed in duplicate 3 and 5 days after SUZ12 depletion in Z138, with 
two different shRNAs (2076 and 783) vs. empty vector. The heat map represents expression levels 
for each sample. A total of 140 significant genes (Log2 (Cy5/ Cy3) cut-off =+/- 0.6 in at least three 
samples) were ranked by Euclidean squared distance. 
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Figure 3.11. SUZ12 target gene expression in MCL samples. (A) Relative expression levels of 
126 inversely correlated SUZ12 genes in MCL tumoral samples (FDR < 0.15). (B) Relative 
expression levels of 62 directly correlated SUZ12 genes in MCL tumoral samples (FDR < 0.15). 
Pearson correlation coefficients between identified SUZ12-target genes and SUZ12 expression 
were calculated using the T-Rex program available from the GEPAS site (v. 3.1). 
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Gene sets positively correlated with SUZ12 
expression 
   
NAME SIZE ES NES p-val FDR  
MITOCHONDRIA PATHWAY 21 0.5952 2.4673 0.0000 0.0053 
CELL CYCLE PATHWAY 21 0.5622 2.3809 0.0000 0.0075 
ARAP PATHWAY 19 0.5528 2.1412 0.0020 0.0283 
CASPASE PATHWAY 21 0.5233 2.1399 0.0040 0.0213 
CA2+ CAM PATHWAY 12 0.6362 1.9820 0.0043 0.0513 
D4GDI PATHWAY 11 0.6060 1.8114 0.0169 0.1118 
Gene sets negatively correlated with SUZ12 
expression 
   
NAME SIZE ES NES p-val FDR  
MAPK PATHWAY 83 -0.4378 -3.4409 0.0000 0.0000 
PROTEASOME PATHWAY 19 -0.7375 -2.8678 0.0000 0.0000 
GH PATHWAY 26 -0.4999 -2.2277 0.0000 0.0395 
IL1R PATHWAY 29 -0.4244 -2.0417 0.0080 0.0779 
CHREBP PATHWAY 15 -0.5951 -2.0912 0.0038 0.0832 
CK1 PATHWAY 12 -0.6534 -2.0431 0.0056 0.0916 
ARF PATHWAY 16 -0.5428 -1.9669 0.0056 0.1074 
RARRXR PATHWAY 14 -0.5157 -1.7385 0.0177 0.1367 
RAB PATHWAY 10 -0.5956 -1.7550 0.0220 0.1392 
ERK PATHWAY 30 -0.3620 -1.7652 0.0203 0.1402 
AKAP-CENTROSOME 
PATHWAY 
10 -0.6027 -1.7413 0.0198 0.1413 
TPO PATHWAY 22 -0.4373 -1.8955 0.0096 0.1444 
PPARA PATHWAY 51 -0.2753 -1.7689 0.0249 0.1465 
CYTOKINE PATHWAY 15 -0.5077 -1.7904 0.0183 0.1473 
PDGF PATHWAY 26 -0.3973 -1.7772 0.0149 0.1479 
VEGF PATHWAY 26 -0.3992 -1.7929 0.0135 0.1557 
TOLL PATHWAY 32 -0.3657 -1.8513 0.0134 0.1642 
GATA3 PATHWAY 13 -0.5419 -1.7935 0.0080 0.1678 
TOB1 PATHWAY 16 -0.4963 -1.7958 0.0189 0.1797 
P38MAPK PATHWAY 37 -0.3407 -1.8065 0.0132 0.1876 
Table 3.4. Pathways coregulated with SUZ12 expression in MCL. GSEA identifies statistically 
significant functionally relevant pathways (p < 0.05, FDR < 0.25) associated with a high level 
of expression of SUZ12. ES: enrichment score. NES: normalized enrichment score. p-val: 
Nominal probability. FDR: false discovery rate. 
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RESULTS II 
 Epstein Barr Virus microRNAs repress BCL6 expression in diffuse large B cell 
lymphoma.  
 
Epstein Barr Virus (EBV) is able to transform B cells by disrupting the normal B-
cell differentiation program leading to the development of different types of B-
cell lymphoma. BCL6 is a key transcriptional repressor during normal B-cell 
differentiation required for germinal centre development that has been shown 
to repress NF-kB in DLBCL. In some B-cell lymphomas the expression of BCL6 is 
opposite to the EBV infection, however the mechanism of this phenomenon 
and its biological meaning remain elusive. In this study, 22 viral microRNAs 
were found to be upregulated specifically in EBV-positive cases of DLBCL. By 
applying the miRanda algorithm 10 out of these 22 microRNAs were predicted 
to potentially target BCL6. To explore this possibility immunohistochemical 
analysis and in situ hybridization were carried out on 149 cases of DLBCL. The 
data showed an almost perfect inverse correlation between BCL6 protein 
expression and EBV infection even in the absence of LMP1 protein expression. 
From the list of 10 microRNAs, ebv-ebv-miR-BART3, ebv-ebv-miR-BART7, ebv-
ebv-miR-BART9 and ebv-ebv-miR-BART17-5p were selected for further 
functional validation. Thus we transfected synthetic microRNAs and measured 
the luciferase activity in our reporter system. At least three of the assayed 
microRNAs were able to decrease luciferase activity of the reporter. Then the 
effect of these microRNAs over the endogenous BCL6 protein was investigated 
in lymphoid BCL6-expressing cell lines by Western blot. The four microRNAs 
were able to downregulate the levels of endogenous BCL6 in several DLBCL cell 
lines. Inhibition of these microRNAs with synthetic microRNA inhibitors let to 
the upregulation of BCL6 in an EBV-positive cell line. In summary, EBV-positive 
DLBCL cases express a restricted set of viral microRNAs. Several of these 
microRNAs can potentially target the BCL6 gene highlighting the importance of 
BCL6 downregulation in the context of EBV B-cell transformation. Functional 
studies demonstrate that at least three of these microRNAs are able to 
downregulate BCL6 expression. We hypothesize that BCL6 downregulation 
might be necessary for DLBCL cells to survive in the context of EBV-induced NF-
κB pathway activation. 
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3.10 EBV microRNA EXPRESSION IN DLBCL CASES 
EVB is a lymphotropic virus that is associated to the development of several lymphoid 
malignancies. The discovery that EBV encodes several miRNAs has prompted research in this 
area. However, the understanding of the effect of these miRNAs and how they work is still very 
poor. Thus, we decided to study a possible oncogenic role for EBV miRNAs in DLBCL. As a first 
step, we studied the miRNA expression profile in 36 samples of DLBCL (33 negative for EBV and 
3 positive) using a microRNA microarray platform that contains 15,000 probes for 470 human 
and 64 human viral miRNAs.  
 
 
 Even though we had just 3 positive samples, the pattern of expression of viral miRNAs was 
very homogenous (Figure 3.12). 22 EBV-encoded miRNAs were found to be upregulated 
specifically in EBV-positive cases of DLBCL (Corrected p-value < 0.05, Table 3.5). These 22 
miRNAs were the product of 15 pre-miRNAs (Table 3.5). EBV miRNAs are grouped in two 
different clusters: one in the intronic regions of the BART gene (ebv-miR-BART1 to ebv-miR-
BART-20) and the other in the untranslated regions (UTRs) of the BHRF1 gene (ebv-miR-BHRF1-
1 to ebv-miR-BHRF1-3) (Cai et al., 2006; Grundhoff et al., 2006; Pfeffer et al., 2004). All the 
differentially expressed miRNA genes belonged to the BART cluster. 
Figure 3.12. Gene clustering demonstrates a very homogenous pattern of expression of EBV-
encoded miRNAs in EBV-positive DLBCL patients. 
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SystematicName p-value Corrected p-value 
ebv-miR-BART3-3p 2.23E-15 1.94E-13 
ebv-miR-BART6-3p 4.46E-15 1.94E-13 
ebv-miR-BART8-5p 6.71E-15 1.95E-13 
ebv-miR-BART14-3p 1.09E-14 2.36E-13 
ebv-miR-BART9 2.30E-14 4.01E-13 
ebv-miR-BART1-3p 1.01E-13 1.47E-12 
ebv-miR-BART1-5p 5.68E-13 7.05E-12 
ebv-miR-BART5 1.28E-10 1.40E-09 
ebv-miR-BART17-5p 7.19E-10 6.95E-09 
ebv-miR-BART14-5p 8.80E-10 7.65E-09 
ebv-miR-BART10 4.42E-09 3.50E-08 
ebv-miR-BART8-3p 9.48E-09 6.87E-08 
ebv-miR-BART4 9.29E-08 6.22E-07 
ebv-miR-BART11-3p 1.31E-07 8.13E-07 
ebv-miR-BART17-3p 2.42E-07 1.40E-06 
ebv-miR-BART7 4.22E-07 2.30E-06 
ebv-miR-BART6-5p 1.09E-05 5.60E-05 
ebv-miR-BART20-3p 1.76E-05 8.50E-05 
ebv-miR-BART3-5p 1.87E-05 8.56E-05 
ebv-miR-BART12 2.66E-04 0.001158242 
ebv-miR-BART16 0.002387877 0.009442969 
ebv-miR-BART11-5p 0.008477309 0.03206634 
 
Among these miRNAs we could find ebv-miR-BART5 which has been described to target the 
p53 up-regulated modulator of apoptosis (PUMA) (Choy et al., 2008), a proapoptotic protein 
belonging to the “BH3-only” group of the Bcl-2 family, promoting in this way the survival of the 
host cell. We also found the expression of ebv-miR-BART1-5p, ebv-miR-BART16 and ebv-miR-
BART17-5p which have been described to target the viral LMP1 transcript suppressing protein 
expression (Lo et al., 2007). These miRNAs also promote cell survival since LMP1 
overexpression can be growth-inhibitory (Liu et al., 2002; Lu et al., 1996).  
Table 3.5. EBV-encoded miRNAs that show significant differential expression between EBV-positive 
and EBV-negative DLBCL cases. 
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 Surprisingly, we did not find expression of two important viral miRNAs: ebv-miR-BART2 that 
down-regulates the viral DNA polymerase BALF5 and inhibits the transition from latent to lytic 
cycle (Barth et al., 2008) and ebv-miR-BART22 which down-regulates LMP2A allowing the virus 
to escape from host immune surveillance (Lung et al., 2009). With the few exceptions that 
Figure 3.13. BCL6 is not expressed in EBV positive cases of Diffuse Large B-Cell 
Lymphoma even in the absence of LMP1 protein expression, suggesting other regulatory 
mechanisms. A) Immunohistochemical staining of two cases of DLBCL showing opposite 
pattern of BCL6 expression and EBV infection. B) Statistical analysis on a series of 149 
DLBCL patients. 
A 
B 
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have been commented before, the function as well as the viral or cellular targets of most viral 
miRNAs discovered here remain unknown. 
 
3.11 EBV INFECTION CORRELATES WITH THE ABSENCE OF BCL6 PROTEIN 
It has been observed that in several lymphomas, the expression of BCL6, a key transcription 
repressor that is essential for germinal center reaction and is frequently translocated or 
hypermutated in DLBCL (Pasqualucci et al., 2003), and the presence of the EBV genome are 
mutually exclusive occurrences (Capello et al., 2003; Carbone et al., 1997). In these studies, 
BCL6 expression was inversely correlated with LMP1 expression, and some evidences suggest 
that LMP1 can cause down-regulation of BCL6 but other possible mechanisms have not been 
studied.  
Thus to extend previous observations and to explore the possibility that EBV can repress 
BCL6 in DLBCL cases we performed an immunohistochemical analysis and in situ hybridization 
on 149 samples of DLBCL to detect BCL6 expression and EBV-encoded EBERs expression in 
these cases. Expression of EBERs was used as a marker of EBV positivity because it has been 
described that EBERs are expressed in all EBV latency types (Kuppers, 2003). 
From the 149 cases, 34 were found to be EBV positive and 115 were found to be EBV 
negative. When we looked at the results with the BCL6 antibody, we found an almost perfect 
inverse correlation between BCL6 expression and the presence of EBV (p<0.001, Figure 3.13). 
Only one out of 34 (2.94%) EBV-positive cases expressed BCL6, however 87 out of 115 
(75.65%) EBV-negative cases expressed BCL6.  
We also checked the expression of LMP1 viral antigen. Noteworthy, although the 
expression of LMP1 in our series was variable, many of the DLBCL cases studied were LMP1 
negative (Figure 3.13). In these cases, the absence of BCL6 cannot be explained by a putative 
LMP1-mediated repression of BCL6 and additional mechanisms can be proposed. 
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3.12 MicroRNA TARGET PREDICTION 
Our data in human DLBCL samples suggest that EBV down-regulates BCL6 by a LMP1-
independent mechanism. Having in mind the restricted cluster of EBV-encoded miRNAs 
expressed by EBV-positive DLBCL patients, we hypothesized that some viral miRNAs could 
account for this phenomenon. To test this hypothesis we decided to look for EBV-encoded 
miRNAs that could potentially down-regulate BCL6 protein expression. Thus, we extracted 
BCL6 3’UTR and EBV-encoded miRNAs sequences from public databases (Ensembl, 
http://www.ensembl.org; and miRBase, http://www.mirbase.org/) and applied the miRanda 
bioinformatic algorithm V3 (http://cbio.mskcc.org/microrna_data/miRanda-sept2008.tar.gz).  
With this approach we identified 21 hits with a score threshold over 50 and an energy 
threshold below -20 Kcal/mol (Table 3.6). The 21 hits corresponded to 18 different mature 
miRNAs, three of which presented more than one possible binding site. In order to have a 
clearer picture, we filtered the list of predicted miRNAs with the list of differentially expressed 
genes in DLBCL patients (Table 3.5). In common, we identified 10 miRNAs that matched both 
criteria (Table 3.6). 
 
Query Ref Score Energy 
(kCal/Mol) 
Quey
Pos 
RefPos Align
Len 
ebv-miR-BART18-5p BCL6_3UTR 148 -21 1 22 887 911 24 
ebv-miR-BART3 BCL6_3UTR 146 -23.59 3 23 121 145 23 
ebv-miR-BART17-5p BCL6_3UTR 145 -20.4 1 23 368 393 26 
ebv-miR-BART9 BCL6_3UTR 143 -21.3 1 24 898 919 25 
ebv-miR-BART10* BCL6_3UTR 133 -21.61 1 22 111 142 32 
ebv-miR-BART19-5p BCL6_3UTR 129 -20.38 3 24 270 297 26 
ebv-miR-BART14* BCL6_3UTR 126 -22.56 3 23 126 148 21 
ebv-miR-BART11-5p BCL6_3UTR 122 -20.89 1 24 860 886 26 
ebv-miR-BART2-5p BCL6_3UTR 122 -20.39 2 23 286 306 21 
ebv-miR-BART5 BCL6_3UTR 122 -22.92 2 25 856 883 27 
ebv-miR-BART16 BCL6_3UTR 120 -21.61 1 24 863 886 23 
ebv-miR-BART1-3p BCL6_3UTR 114 -20.95 3 23 135 156 20 
ebv-miR-BART10* BCL6_3UTR 114 -21.37 1 22 408 429 21 
ebv-miR-BART12 BCL6_3UTR 114 -20.02 1 23 980 998 22 
ebv-miR-BART7* BCL6_3UTR 113 -20.27 1 17 132 153 16 
ebv-miR-BART15 BCL6_3UTR 104 -21.84 1 22 286 311 25 
ebv-miR-BART11-5p BCL6_3UTR 102 -22.57 6 25 106 132 22 
Table 3.6. List of viral miRNAs that are predicted to target BCL6 as calculated using the 
miRanda algorithm. Bold indicates miRNAs that are differentially expressed in EBV-positive 
patients. 
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ebv-miR-BART20-3p BCL6_3UTR 100 -22.02 2 23 989 1021 32 
ebv-miR-BART10* BCL6_3UTR 99 -20.89 2 22 146 167 22 
ebv-miR-BART7 BCL6_3UTR 99 -21.62 3 22 153 170 19 
ebv-miR-BART7 BCL6_3UTR 76 -26.34 1 21 123 143 20 
There are several miRNA target prediction algorithms published that look for potential 
miRNA targets. All the algorithms follow very similar rules such as near-perfect sequence 
match between the first 8 nucleotides of the 5’ end of the miRNA (the so-called “seed region”), 
conservation of the binding site between related species and thermodynamic parameters. 
However, the consequences of varying so many parameters are that many times there is little 
overlap between different predictions making it difficult to distinguish true targets from false 
positive (Alexiou et al., 2009).  
 
 
Even though a site is predicted by several programs, it is possible that the miRNA does not 
really bind to the target site and a site predicted by just one algorithm can be potently bound 
by a defined miRNA. Nonetheless it is widely accepted that targets predicted by more than one 
algorithm have more chances to be true targets than those predicted by just one algorithm. 
Hence we also tested if other algorithms predicted that EBV-encoded miRNAs could potentially 
regulate BCL6. To this end we performed an additional bioinformatic analysis to complement 
the results obtained with miRanda using three target prediction programs: TargetScan 
Figure 3.14. Venn diagram showing the overlap between the predictions of different 
algorithms. 13 out of 18 miRNAs predicted by miRanda were also predicted by other 
methods. 
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(http://www.targetscan.org/), PITA (http://genie.weizmann.ac.il/pubs/mir07/32bit_exe_pita_ 
prediction.tar.gz) and another algorithm developed at CNIO’s bioinformatic Unit called 
SequenceMatch. With these three algorithms we could confirm the majority of the results 
obtained with miRanda. 13 out of 18 miRNAs predicted with miRanda were also predicted by 
at least one of the complementary algorithms that we have used (Figure 3.14).  
Consequently, we selected four miRNAs for further validation. These miRNAs were selected 
according to the following parameters: 1) The miRNAs presented a good score in the miRanda 
algorithm and 2) the miRNAs were differentially expressed between EBV-positive and EBV-
negative cases of DLBCL. In this way, we selected ebv-miR-BART3, ebv-miR-BART9 and ebv-
miR-BART17-5p.We also selected ebv-miR-BART7 because, although it does not present one of 
the highest scores in the miRanda algorithm, this program predicts two binding sites for the 
miRNA in the 3’ UTR of BCL6, increasing the probability of being a bona fide regulator of BCL6 
protein expression. The potential pairing between the selected EBV-encoded miRNAs and the 
3’ UTR of BCL6 is shown in Figure 3.15. 
 
3.13 EXPRESSION OF SELECTED microRNAS IN DLBCL PATIENTS 
Before continuing with mechanistic experiments, we wanted to validate the results of the 
microarray in another series of patients by RT-PCR. As a first step we measured the levels of 
expression of 5 miRNAs in 40 samples of this new cohort of DLBCL patients (15 EBV-positive 
and 25 EBV-negative) to ensure that viral miRNAs were expressed. The selected miRNAs for 
validation were the four we selected before plus ebv-miR-BART10*, that was selected for 
three reasons: first, miRanda algorithm gave a good score for this miRNA; second, there were 
two binding sites predicted for the miRNA in the 3’ UTR of BCL6 and third, although the miRNA 
Figure 3.15. Representation of the theoretical binding of selected miRNAs to the 3’UTR of 
BCL6 using the RNAhybrid software. 
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probe was not printed onto the microarray platform, DLBCL patients showed differential 
expression of the complementary strand of the pre-miR, the ebv-miR-BART10, suggesting that 
ebv-miR-BART10* could be also expressed at high levels. 
Thus, we applied RT-PCR to measure the amount of ebv-miR-BART3, ebv-miR-BART7, ebv-
miR-BART9, ebv-miR-BART10*, ebv-miR-BART17-5p transcripts in DLBCL samples. As expected, 
the selected miRNAs were expressed by EBV-positive cases (Figure 3.16). Intriguingly, although 
the difference in expression between positive and negative cases was roughly around 100-fold 
we still could detect expression of viral miRNAs in several EBV-negative cases by this 
technique. 
 
 
This unexpected result could be due to a technical limitation of the method used here. 
However, the fact that some cases were EBV-negative does not mean that EBV was also absent 
from non-malignant cells. In fact, since EBV infected cells are very rare (approximately 1–50 
per million of B cells (Khan et al., 1996)) it is difficult to study EBV in healthy virus carriers. The 
presence of non-malignant EBV-positive cells in EBV-negative cases of DLBCL could account for 
the low although detectable expression of viral miRNAs in these patients. Moreover, the ebv-
Figure 3.16. RT-PCR was carried out on 40 DLBCL samples using probes for five different 
microRNAs. Black bars indicate mean and standard deviation. 
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miR-BART10* was expressed in EBV-positive patients at very low levels when compared to 
other miRNAs and in contrast with the complementary strand (ebv-miR-BART10) that showed 
high expression by microarray analysis. 
 
 
 
  
Figure 3.17. The opposite pattern between BCL6 expression and EBV infection is not 
maintained in DLBCL cell lines. A) Western Blot against BCL6 in several DLBCL and Burkitt 
cell lines. Tubulin was used as a loading control. B) Quantification of BCL6 protein 
expression in DLBCL cell lines of Activated B-Cell (ABC) and Germinal Centre B-Cell (GCB) 
types and Burkitt Lymphoma cell lines. Yellow bars indicate EBV-positive cell lines. 
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3.14 BCL6 PROTEIN AND microRNA EXPRESSION IN CELL LINES 
We wanted to see if this inverse correlation between EBV presence and expression of BCL6 
was also observed in cell lines. We performed immunoblot analysis in a panel of DLBCL cell 
lines (Figure 3.17). We also included 4 BL cell lines because in BL it has been described 
compatibility between BCL6 expression and EBV presence (Ferry, 2006). We used the EBV-
negative cell lines to give an idea of the normal levels of BCL6 in each lymphoma type.  
 
 
 In BL-derived cell lines, two EBV-positive cell lines (Namalwa and Raji) showed moderate 
levels of BCL6 and the EBV-positive cell line Akata expressed high levels of BCL6 when 
compared with the EBV-negative cell line, Ramos (Figure 3.17). In DLBCL cell lines, one of the 
Figure 3.18. RT-PCR analysis of five EBV-encoded miRNAs in DLBCL and BL cell lines 
demonstrate that levels of BCL6 protein expression (lower panel) correlate with levels of 
miRNA expression (upper panel). Expression data is represented in a logarithmic scale and 
has been normalized using the Ramos EBV-negative cell line as background signal. 
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EBV-positive cell lines (DoHH-2) showed the lowest levels of BCL6 in the entire panel but the 
other EBV-positive cell line (Farage) presented the highest levels of BCL6 expression, even 
higher than the BL-derived cell lines (Figure 3.17). Therefore, the phenomenon that we 
observe in human samples is not conserved in cell lines. 
To look for a reason that could explain the lack of correlation in cell lines, we decided to 
study the expression of EBV-encoded miRNAs in these cell lines in order to elucidate if the 
expression of BCL6 still kept an inverse correlation with the levels of viral miRNAs. We 
measured the expression of ebv-miR-BART3, ebv-miR-BART7, ebv-miR-BART9, ebv-miR-
BART10*, ebv-miR-BART17-5p transcripts in EBV-positive DLCBL and BL cell lines by RT-PCR.  
Our results show that the relative expression of the five miRNAs still correlates in an inverse 
fashion with the levels of BCL6 expression. Consequently, the Farage cell line which showed 
the highest levels of BCL6 expression, expressed very low levels of viral miRNAs; BL-derived cell 
lines expressed moderate levels of miRNAs, being Akata the one with lower expression; and 
DoHH-2 expressed the highest levels of EBV-encoded miRNAs (Figure 3.18). 
 
3.15 MULTIPLE VIRAL microRNAS REPRESS BCL6 IN DLBCL 
The variability in the results of the different target prediction programs also evidences one 
of the main caveats of the bioinformatic approach. The use of bioinformatic prediction is 
reduced to the generation of hypothesis but must be empirically validated. Our hypothesis is 
supported not only by the bioinformatic predictions but also by the data obtained at the level 
of miRNA expression in human tumors and the inverse correlation between BCL6 levels and 
the expression of EBV-encoded miRNAs. 
 
3.15.1 ASSESMENT OF THE INTERACTION BETWEEN EBV-ENCODED microRNAS 
AND THE 3’ UTR OF BCL6 
Therefore, to functionally validate the putative BCL6-regulatory role of these miRNAs we 
amplified the 3’ UTR of BCL6 by PCR and cloned the fragment into the pGL3-Control vector. We 
called the resulting vector pGL3-BCL6. The pGL3-Control vector is a plasmid that contains the 
luc+ gene encoding for the firefly luciferase protein under the control of the SV40 promoter, 
resulting in the constitutive expression of the luc+ gene. The luc+ gene does not have a 3’ UTR 
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and only the SV40 polyadenylation signal is added after the coding sequence. This allow the 
researcher to clone the 3’ UTR of interest at the 3’ end of the luc+ gene generating useful tools 
for the study of the miRNA function. 
The following step was to co-transfect the pGL3-BCL6 vector with synthetic Pre-miR miRNA 
precursor molecules and a vector that contains the Rluc gene encoding for the Renilla 
luciferase as a transfection control. The amount of miRNA to transfect was selected based in 
the optimization with a positive control, the hsa-miR-1 that is able to down-regulate the PRK9 
gene. A 50 nM concentration resulted in optimal results for this miRNA and this gene. 
As controls we used first, the pGL3-Control vector that does not harbor the 3’ UTR of BCL6 
to account for the unspecific effects of each miRNA not related to the presence of the BCL6 3’ 
UTR and second a commercial non-targeting control called Pre-miR Negative Control #1. 
 
 
With this approach we could identify a significant reduction in luciferase signal with three 
of the four miRNAs assayed (Figure 3.19). Ebv-miR-BART3, ebv-miR-BART9 and ebv-miR-
BART17-5p reduced the luciferase signal around 60%, however the reduction in the signal for 
Figure 3.19. Some predicted miRNAs can downregulate BCL6. Cotransfection of several 
miRNAs with a luciferase reporter with (pGL3-BCL6) or without (pGL3-Co) the 3’UTR of BCL6 
led to specific inhibition for miRNAs ebv-miR-BART3, ebv-miR-BART9 and ebv-miR-BART17-
5p 
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ebv-miR-BART7 was around 20% a value that was similar to the one obtained when we 
transfected the negative control. We did not explore the effect of the ebv-miR-BART10* 
because the low expression of this miRNA indicates that the functional miRNA in patients is the 
complementary strand, ebv-miR-BART10. 
Additionally, we also decided to study if these miRNAs could have a collaborative effect to 
regulate BCL6. To this end we also co-transfected the four miRNAs at a concentration of 10 nM 
each. With this mix we obtained a reduction of luciferase signal around 80% (Figure 3.19) 
supporting the hypothesis that these miRNAs can collaborate to repress the same target. The 
combination of different miRNAs resulted in potent inhibition, especially if we take into 
account that ebv-miR-BART7 seemed not to be able to reduce the luciferase signal. 
Anyway, in order to avoid possible artifacts derived from the forced co-expression of the 
3’UTR and the miRNAs we tested our hypothesis on the endogenous protein. 
 
3.15.2 EFFECTS OF microRNAS ON ENDOGENOUS BCL6 PROTEIN  
In order to validate the results obtained with the luciferase assays, we investigated the role 
of EBV-encoded miRNAs on the endogenous BCL6 protein. We first selected several lymphoid 
cell lines that expressed BCL6 because we thought these models would be more closely related 
to the situation in the patient than using a cell line derived from non-lymphoid tissues. 
However, lymphoid cell lines have the disadvantage of being very difficult to transfect. 
Therefore we used a high-efficiency electroporation device called Microporator (see section 
2.14.1.3) that allows the transfection of lymphoid cell lines with minimum levels of cell death. 
We transfected each miRNA at a final concentration of 50 nM and looked for changes in 
BCL6 protein expression 48 hours after the transfection. With this approach we could observe 
a decrease of BCL6 protein levels with several miRNAs; however the results were not the same 
in all cell lines (Figure 3.20).  
The first striking result was that ebv-miR-BART7 was able to reduce BCL6 expression in most 
cell lines used. There are two possible explanations: on one hand the effects of ebv-miR-BART7 
on the endogenous protein might be indirectly mediated by second players and not due to a 
direct interaction between the miRNA and the 3’ UTR of BCL6; on the other hand, these 
contradictory results may account for the differences in the cellular context of each cell line. 
This is also suggested by the variability in the results between different cell lines. 
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We used three different DLBCL-derived cell lines (DB, SU-DHL-4 and SU-DHL-6) and one BL-
derived cell line (Ramos). In the three DLBCL-derived cell lines transfection of the viral miRNAs 
ebv-miR-BART3, ebv-miR-BART9 and ebv-miR-BART17-5p led to a significant reduction in the 
levels of BCL6 protein 48 hours after transfection (Figure 3.20). In contrast, ebv-miR-BART7 
was able to reduce BCL6 protein expression only in SU-DHL-4 and SU-DHL-6 48 hours after 
transfection of the miRNA while it had little or no effect in the DB cell line. 
 In the case of the Ramos cell line, transfection of the miRNAs led to significant reduction of 
BCL6 protein levels in the case of ebv-miR-BART7, ebv-miR-BART9 and ebv-miR-BART17-5p 
while the cells showed no response to ebv-miR-BART3 overexpression 48 hours after 
transfection. 
 
3.15.3 INHIBITION OF ENDOGENOUS EBV-ENCODED microRNAS AUGMENTS THE 
EXPRESSION OF BCL6 PROTEIN 
Finally, we also investigated whether inhibition of EBV-encoded miRNAs could increase the 
expression f BCL6. This is important for two reasons. First, the fact that EBV-encoded miRNAs 
can regulate the protein levels of BCL6 does not necessarily mean that this is the main 
mechanism of BCL6 down-regulation in vivo. Second, our results have shown that the EBV has 
different and redundant mechanisms to inhibit BCL6 protein expression. Thus, increasing the 
levels of BCL6 in EBV-positive cells might have an important biological effect. 
To this end, we used anti-miR miRNA inhibitors against the ebv-miR-BART3, ebv-miR-
BART7, ebv-miR-BART9 and ebv-miR-BART17-5p and transfected two EBV-positive DLBCL-
derived cell lines (DoHH-2 and Farage). The anti-miRs are small, chemically modified single-
stranded RNA molecules designed to specifically bind to and inhibit the activity of endogenous 
mature miRNA molecules.  
In this case, using a positive control (anti-miR hsa-let7c miRNA inhibitor which inhibits hsa-
let7c and induces upregulation of HMGA2) we established an optimum concentration of 200 
nM. The results with the two EBV-positive cell lines were very different. On one hand, 
inhibition of EBV-encoded miRNAs in DoHH-2 cell line, which expresses high levels of miRNAs 
and almost undetectable levels of BCL6, did not led to any upregulation in the BCL6 protein 
expression either when we inhibited each miRNA alone or in combination (Figure 3.20). On the 
other hand, inhibition of EBV-encoded miRNAs in the Farage cell line, which expresses low 
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levels of viral miRNAs and high levels of BCL6, induced a moderate increase in the levels of 
BCL6 when ebv-miR-BART9 or ebv-miR-BART17-5p was inhibited but not when we inhibited 
either ebv-miR-BART3 or ebv-miR-BART7 alone. When we inhibited the four miRNAs with a 
mixture of anti-miRs at 50 nM concentrations each, we obtained similar results than inhibiting 
ebv-miR-BART9 or ebv-miR-BART17-5p alone at 200 nM concentrations (Figure 3.20).  
The differences between cell lines can be explained in different ways. First, the almost 
undetectable levels of BCL6 in the DoHH-2 cell line could mean that the gene is regulated by 
other mechanisms such as the presence of transcription repressors in the promoter of the 
gene or absence of activators. Second, we cannot forget that DoHH-2 is the cell line that 
expresses highest levels of EBV-encoded miRNAs. Hence, inhibition of four miRNAs could not 
be enough to allow the re-expression of BCL6 if other BCL6-targetting miRNAs are at very high 
concentrations. The increased expression of BCL6 in the Farage cell line after miRNA inhibition 
did not result in any evident effect on cell viability. However we have experimentally tested 
that the effect of the synthetic RNAs that we transfect does not last more than 72 hours. This 
short time window is enough to see effects in the levels of expression but might not be enough 
to see effects on cell viability, especially in a cell line that already expresses BCL6 and in which 
the increase in BCL6 protein expression after miRNA inhibition is not dramatic. 
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Figure 3.20. (A)Transfection of the DLBCL cell lines with several miRNAs led to a decreased 
BCL6 expression. BCL6 signal was normalized using tubulin (lower panel). (B) Transfection of 
anti-miRNA inhibitors led to a moderate upregulation of BCL6 in the Farage cell line. DoHH-2 
cell line showed no response to miRNA inhibition. BCL6 signal was normalized using tubulin 
(lower panel) 
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Cancer is a complex disease that follows a multi-step model to develop. This multi-step 
model encompasses both genetic and epigenetic alterations that finally lead to the 
development of cancer. 
These alterations provide advantages to the tumor cell that allow it to acquire self-
sufficiency to growth signals, insensitivity to anti-growth signals, limitless replicative potential, 
resistance to apoptosis, capacity to sustain angiogenesis and ability to invade tissues and 
metastasize (Hanahan and Weinberg, 2000). There is increasing evidence that an additional 
characteristic is the acquisition of stem cell properties. This has led to cancer stem cells (CSCs) 
being postulated as the origin of some tumors. This is supported by the fact that tumors are 
composed of a heterogeneous population of cells while being derived from a single clone. 
Ongoing mutagenesis can only explain part of this process. Thus, many genes and pathways 
that are active in embryonic stem cells are altered in cancer cells (Taipale and Beachy, 2001). 
A CSC can be generated in two ways: the tumor-initiating cell (TIC) with stem cell properties 
may arise from a stem cell that loses the capacity to regulate its mitotic potential, in contrast it 
could be a downstream progenitor (or committed progenitor) cell that acquires the ability to 
self-renew through some molecular alterations. In fact, a recent report suggests that both of 
these occur (Roesch et al., 2010). 
Although a broad spectrum of genetic alterations has been studied in human cancer, it is 
well documented that progression from normal to malignant cells also involves epigenetic 
changes, including extensive DNA methylation at promoter-associated CpG islands, an 
aberrant pattern of histone modifications and changes in the expression of microRNAs. 
Chromatin structure is crucial for the regulation of DNA accessibility and thus for the 
regulation of gene expression. Furthermore, an altered chromatin structure provokes altered 
gene patterns and genomic instability that can be propagated to daughter cells, causing 
cellular transformation to a malignant status (Jones and Baylin, 2002) 
In the present work we provide new insights into the epigenetic mechanisms that lead to 
development of lymphomas. We focused our attention in the Polycomb group of proteins and 
microRNAs.  
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4.1 SUZ12 AND THE PATHOGENESIS OF MANTLE CELL LYMPHOMA 
SUZ12 is one of the core components of the PRC2. The other core components are EZH2 
and EED and other components that can be molecular partners of SUZ12 are RbAp48, RbAp46, 
PHF1, AEBP2, SIRT1, HDAC1 and HDAC2 amongst others. 
EZH2 has been implicated in several human malignancies such as prostate carcinoma 
(Bachmann et al., 2006; Varambally et al., 2002), breast carcinoma (Bachmann et al., 2006; 
Bracken et al., 2003; Puppe et al., 2009), melanoma (Leung et al., 2004), bladder cancer 
(Bracken et al., 2003; Raman et al., 2005), glioma (Suva et al., 2009), endometrial carcinoma 
(Bachmann et al., 2006), lymphomas (Bracken et al., 2003; Visser et al., 2001), colon carcinoma 
(Bracken et al., 2003), glioblastoma (Bracken et al., 2003), Ewing tumor (Burdach et al., 2009), 
several lymphomas (Morin et al., 2010), myeloid malignancies (Ernst et al., 2010; Nikoloski et 
al., 2010) and acute myeloid leukemia (Paul et al.).  
However, although some studies have demonstrated overexpression of SUZ12 in colon 
and breast tumors (Kirmizis et al., 2003; Kirmizis et al., 2004), its real relevance in human 
cancer is yet to be established. 
In the first part of this work, we present various results that point to the importance of 
SUZ12, independently of EZH2, in tumorigenesis in general and MCL pathogenesis in particular.  
First, we have studied the expression pattern of SUZ12 and EZH2 in normal human tissues 
with two different objectives. On one hand, this is important to have a baseline to study 
tumors. Comparing the expression between normal tissues and tumors gives information 
about which patterns of expression are associated to malignant transformation. On the other 
hand, the study of SUZ12 in normal samples can give an idea of the processes in which SUZ12 
may be important.  
EZH2 was widely detected in most human normal tissues with very few exceptions such as 
superficial cells of the larynx. This point to an essential function of EZH2 in most tissues and 
this may be due to the fact that EZH2 is the only PRC2 component that carries 
methyltransferase activity. 
However, the expression pattern of SUZ12 was quite different. This may indicate two 
things: first, that SUZ12 is dispensable for some of the functions of PRC2. However, it has been 
described that SUZ12 is essential for the methyltransferase activity (Pasini et al., 2004). This 
could mean that EZH2 has functions independent of its methyltransferase activity. A second 
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possibility is that other proteins could partially substitute the absence of SUZ12. Up to our 
knowledge, it is not known of any protein that could substitute for SUZ12 function. 
The expression pattern of SUZ12 in normal tissues indicate that SUZ12 regulates or is 
regulated by the cell cycle, since SUZ12 expression was mainly restricted to proliferating cells 
such as germinal centers in reactive lymphoid tissue, thymic cortex, epithelial basal cells and 
germinal cells in the testis. All these tissues are characterized by their regenerative capacity, 
suggesting a role for SUZ12 in tissue homeostasis and in cell cycle and proliferation. This 
regenerative capacity of the tissues could also mean that SUZ12 expression is essential for cells 
that act as progenitors. It has been published that several Polycomb proteins increase their 
expression when stem cells begin to differentiate and become committed progenitors (Lessard 
et al., 1998), so we cannot rule out that the expression of SUZ12 in these tissues could be 
related to an ongoing differentiation process. 
Analysis of malignant samples again showed a very different pattern of expression for the 
two PRC2 components that we have studied. EZH2 was expressed in all cancer types analyzed 
and only few tumors showed loss of expression in a percentage of cases. Strikingly, all the 
tumor types derived from the skin showed loss of expression in a small fraction of tumors, 
indicating that these tumors might be tolerant to depletion in some PcG components or might 
have alternative oncogenic mechanisms that can render the cells resistant to a lack of EZH2 
expression. 
Another finding in human tumors may indicate that the PcG complexes may suffer tissue-
dependent changes. The presence of tumors that express SUZ12 but not EZH2 can be an 
indication that SUZ12 can have EZH2-independent functions under some circumstances. This 
notion is also supported by the fact that superficial cells of the larynx do express SUZ12 but not 
EZH2, so the EZH2-independent functions of SUZ12 may be also physiological. 
We found overexpression of SUZ12 in several tumors, including germinal cell-derived 
tumors, tumors from the gastrointestinal tract, astrocytomas, squamous cell carcinomas of the 
larynx, melanomas, skin basal cell carcinomas, lung neuroendocrine small-cell carcinoma, 
pituitary and parathyroid adenomas, breast carcinomas and other gynecological tumors and B 
and T cell lymphomas. A significant proportion of B-cell lymphomas arise from proliferating 
germinal center B-cells, called centroblasts. These cells normally express SUZ12 so we cannot 
exclude the possibility that SUZ12 expression in lymphomas may reflect the differentiation 
status of the cell that gave rise to the tumor. However in MCL, we have found high expression 
of SUZ12 in contrast with its absence in the non-malignant mantle zone cells in reactive lymph 
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node. Thus, overexpression of SUZ12 in MCL is a cancer-specific feature. In short, our results 
extend previous observations of the strong expression of SUZ12 in human tumors (Kirmizis et 
al., 2003; Kirmizis et al., 2004). 
Altered expression of a protein is not sufficient for considering it causally involved in the 
tumorigenesis. It could be that the altered expression is just a marker of the disease but the 
underlying oncogenic mechanism could be unrelated to the protein investigated. However, 
genetic or genomic abnormalities that target directly the gene indicate that the phenomenon 
is not only a surrogate of other oncogenic mechanisms but has a sense by itself.  
Thus our findings of SUZ12 locus (17q11.2) amplification and copy gains associated with 
protein overexpression in several tumors such as mesothelioma (amplification in 1/10), 
melanoma (amplification in 1/10), skin basal cell carcinoma (gain in 1/10), thyroid follicular 
carcinoma (amplification in 1/8), leiomyosarcoma (gain in 1/6), ovary serous 
cystoadenocarcinoma (amplification in 1/6) and especially in MCL (3/77 amplifications and 
4/77 gains), along with the presence of SUZ12 translocations in endometrial stromal sarcomas 
(Koontz et al., 2001a; Oliva et al., 2007), support the hypothesis that SUZ12 has an oncogenic 
function and contributes to tumor formation and maintenance. 
It is interesting to note that amplification of SUZ12 locus was more frequently found in 
aggressive variant cases of MCL (two out of four cases showed gene amplification by standard 
criteria). The gene locus amplification was associated with the highest levels of SUZ12 
expression. This could mean that SUZ12 is not only important for MCL pathogenesis but its 
expression also correlates to aggressiveness of the disease. This phenomenon has already 
been described for other PRC2 members such as EZH2 which expression is correlated to the 
aggressiveness of the tumor in prostate cancer (Varambally et al., 2002). 
Another interesting issue that focused our attention in MCL is that SUZ12 overexpression 
was mainly found in lymphomas that derive from germinal center B cells and are characterized 
by a high growth fraction (like diffuse large B cell lymphomas) or was restricted to proliferating 
cells in other lymphoid tumors such as chronic lymphocytic leukemia, follicular lymphoma, and 
splenic marginal zone lymphoma.  
MCL seems to be an exception because it is a tumor characterized by lower or 
intermediate proliferation rate, which do not derive from germinal center B cells and still 
expresses high levels of SUZ12 in the majority of cases.  
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Our findings became even more interesting when we looked at the expression of miRNAs 
in MCL cases. It has been estimated that at least one-third of the genome may be regulated by 
microRNAs (Lewis et al., 2005; Lim et al., 2005). MicroRNA deregulation has been proposed as 
a general mechanism of carcinogenesis.  
Our data suggest that loss of expression of hsa-miR-126 and hsa-miR-200b may account 
for the overexpression of SUZ12 in many MCL patients, revealing an even greater complexity 
of the genetic mechanisms that drive carcinogenesis than previously appreciated. However we 
are aware that the data provided in this issue is only correlative and the hypothesis that these 
two miRNAs regulate SUZ12 must be experimentally confirmed by using in vitro manipulated 
cell lines. Anyway, the data obtained from the MicroCosm database indicate that there are 
very few miRNAs with the potential of inhibiting SUZ12 expression, a fact that increases the 
probability that hsa-miR-126 and hsa-miR-200b are bona fide regulators of SUZ12. 
Given the especial characteristics of MCL in relation with SUZ12 expression in the tumor 
and in the normal counterpart and the finding of genomic abnormalities involving the SUZ12 
locus we decided to use MCL to depict the role of SUZ12 in tumorigenesis and its putative 
oncogenic function. This has been further supported by the functional assays described here 
and the integrative genomic analysis performed in cell lines and malignant samples.  
To functionally validate the oncogenic role of SUZ12 in MCL, we have silenced SUZ12 
expression by RNAi in two different MCL-derived cell lines, and we have evaluated the effect of 
SUZ12 depletion on levels of H3K27me3, cell proliferation, apoptosis, and cell survival. The 
clear decrease in H3K27me3 after SUZ12 silencing demonstrated that SUZ12 knockdown 
affects the function of the PRC2 in accordance with previous reports (Pasini et al., 2004).  
Moreover this suggests that, SUZ12 is necessary for EZH2-methyltransferase activity in 
different conditions and models so, if EZH2 have SUZ12-independent functions as commented 
before, these might not rely on the methyltransferase activity of SUZ12. However it is still 
possible that EZH2-mediated methyltransferase activity can be restored by other factors in 
SUZ12 deficient cells in some uncommon situations. 
When we studied viability of SUZ12 deficient cells, we could observe that SUZ12 
knockdown resulted in an increased apoptosis, as demonstrated by annexin V and PARP 
cleavage analysis.  
The increase in apoptosis was maintained over time leading to a progressive reduction in 
the SUZ12 deficient population as assessed by cell counting and competition assays. Thus, 
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SUZ12 knock down compromises cell viability and leads to big decrease in cell number over 
time. These results indicate that SUZ12 expression contributes to cell survival in MCL through 
the inhibition of apoptosis and supporting cell proliferation.  
SUZ12 is known to exert its function on the Polycomb-PRC2 complex through the direct 
repression of many target genes. The identification of SUZ12 direct targets and the discovery 
of genes/pathways co-regulated by SUZ12 are essential to understand their role and relevance 
in MCL. Although other studies have already tackled this question (Bracken et al., 2006; Lee et 
al., 2006) in other models, it has been demonstrated that SUZ12 targets vary among different 
cell types (Squazzo et al., 2006).  
Therefore, we decided to identify SUZ12 targets that could mediate the effect on MCL-
derived cell line viability and explain their role in MCL pathogenesis. We have approached this 
question by combining ChIP-on-chip for SUZ12-target identification with gene expression 
profiling of these targets in SUZ12-silenced cells and MCL samples.  
We have found several genes related to apoptosis among SUZ12 targets (including BCL2, 
BID, cFLIP and several BIRC family members). The fact that some apoptosis-related SUZ12 
targets were anti-apoptotic, may lead to the assumption that SUZ12 can have a pro-apoptotic 
function rather than inhibiting apoptosis. However, the phenotypic effect seen in MCL cell 
lines after SUZ12 knock down supports the notion that, overall SUZ12 overexpression results in 
inhibition of apoptosis.  
We also found that SUZ12 targets several genes related to cell proliferation (several INK4 
family genes, cyclins, and CDKs). Again, the presence of cyclins and CDKs seems contradictory 
with a putative oncogenic role of SUZ12; however several cyclins and CDKs are tissue or cell 
type specific and some of them are dispensable depending on the cell (Santamaria et al., 
2007). In contrast, SUZ12 targets the CDK inhibitors CDKN2A, CDKN2B, CDKN2C and CDKN2D 
which is supports the idea of an oncogenic role for SUZ12. 
More arguments that favor our hypothesis are the discovery that SUZ12 targets several 
genes related to checkpoint regulation (CHK1, BUB3, MADL2, GADD45, and CDK6) and DNA 
damage and repair (ATM, GMNN, and MLHL1) inhibiting two of the key signaling pathways 
that suppress tumor development. 
SUZ12 also targets several transcription factors and genes involved in development and 
differentiation in MCL cells, which is in accordance with previous results (Bracken et al., 2006; 
Lee et al., 2006; Squazzo et al., 2006).  
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Several of these targets are genes of relevance in MCL (Figure 4.1). For instance, CDKN2A, 
ATM, BCL10, and RBL1, identified here as being SUZ12 targets, are frequently deleted or lost in 
MCL (reviewed in (Jares et al., 2007)). This means that SUZ12 is collaborating to the 
inactivation of these genes by epigenetic mechanisms. Other important pathways in MCL such 
as the NF-κB pathway are targeted by SUZ12 (BLIMP1, IKBKG, and NFKB2) indicating an 
abnormal regulation of this key pathway. 
Many of these genes have been previously described as SUZ12 targets in other cell lines 
(e.g. BMP2, CDKN2A, SOX3, and GADD45G), but many others not and could be specific of MCL. 
This is the case for many interesting genes such as ATM, BIRC family genes, BTK, BUB3, 
MAD2L1, and RBL1, among others, some of which have been validated by classic ChIP 
suggesting that they are bona fide SUZ12-targets, and possibly specific to MCL cells. Moreover, 
SUZ12 targets several miRNAs, some of which were already known to be involved in cancer.  
Many of these genes were confirmed to be inversely correlated with SUZ12 expression in 
MCL samples, such as BIRC2, TMBIM4, XRCC6, JMJD2D, MAD2L1 and BUB3, among others. 
Some SUZ12 target genes that do not correlate with SUZ12 expression in MCL cases might be 
repressed by other mechanisms in SUZ12-negative cases. Some SUZ12 targets were also re-
expressed after SUZ12 knockdown in a MCL cell line. The fact that some of the SUZ12 targets 
remained unaltered after SUZ12 depletion has several possible explanations. For instance, 
many SUZ12 targets may require not only the depletion of SUZ12 but also additional events 
like DNA demethylation or the presence of an activator to be expressed again (Bracken et al., 
2006; Sparmann and van Lohuizen, 2006).  
All these findings strongly indicate that SUZ12 collaborates in deregulating the expression 
or function of many important pathways controlling MCL pathogenesis and SUZ12 
overexpression may account for some of the still unexplained features of MCL, including 
abnormal DNA repair, increased resistance to apoptosis. 
 Interestingly, some studies highlight the ability of some drugs to interfere with the PRC2 
complex. Tan et al. (Tan et al., 2007) reported how DNZep, a drug that disrupts the function of 
the PRC2 complex, can induce apoptosis in cancer cells but not in normal cells. The drug also 
induced the re-expression of several genes involved in development and differentiation 
(Miranda et al., 2009). The re-expression of these genes can be indicative that cancer cells are 
losing self-renewal capacity. 
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Some studies also point to the fact that some histone deacetylase inhibitors (HDACi), such 
as LBH589 and LAQ824, can also deplete the PRC2 complex in malignant cells in acute myeloid 
leukemia (AML) (Fiskus et al., 2006). Combination of DNZep with HDACi has been also tested in 
AML with good results (Fiskus et al., 2009). 
 
4.2 REGULATION OF BCL6 BY EBV-ENCODED microRNAS 
EBV is a lymphotropic virus that has been implicated in the development of several 
lymphoid malignancies. The oncogenic potential of many of the proteins encoded by the virus 
has been extensively studied (Klein et al., 2010). These investigations has led to the discovery 
that the latent membrane protein LMP1 and the nuclear antigens EBNA-2, -3, -5 and -6 are 
essential for immortalization of B lymphocytes (Kaye et al., 1993). However the EBV also 
expresses several RNAs that do not translate into proteins. On one hand, the Epstein Barr-
Figure 4.1. SUZ12 regulates the expression or function of multiple important pathways 
controlling MCL pathogenesis. Genes identified as SUZ12 targets by ChIP-on chip in red. 
Genes marked with * suffer translocation or overexpression in MCL cases. Genes 
underlined are frequently deleted in MCL. 
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encoded RNAs (EBERs) and on the other hand several miRNAs that are grouped in two clusters: 
the BHRF and the BART clusters. The biological significance as well as the oncogenic potential 
of these miRNAs has been poorly investigated. 
Thus we have investigated the role of EBV-encoded miRNAs in DLBCL where the role of EBV 
is not well defined. 
First we have analyzed the pattern of expression of EBV-encoded miRNAs in a series of 36 
patients (33 negative and 3 positive) and we have found a very constant pattern of expression 
in the positive cases. The EBV-positive cases did not express all the viral miRNAs but only a 
group of 22 miRNAs that were the product of 15 pre-miRNAs. None of the miRNAs belonged to 
the BHRF1 cluster, a finding that confirms previous publications that propose that the highest 
levels of these miRNAs are reached during the lytic cycle (Pfeffer et al., 2004).  
Among the EBV-encoded miRNAs that were differentially expressed in these DLBCL cases; 
we found some miRNAs that has been described to exert a protective function for the host 
cell. Three of these miRNAs, ebv-miR-BART1-5p, ebv-miR-BART16 and ebv-miR-BART17-5p, 
target the viral antigen LMP1 (Lo et al., 2007) and avoids the growth inhibitory effect of the 
overexpression of this protein (Liu et al., 2002; Lu et al., 1996). Another miRNA, ebv-miR-
BART5 has a cellular target, PUMA and its inhibition promotes host survival. In both cases it 
seems clear that one of the main advantages that confer the virus to the host cell is to impede 
cell death. 
BCL6 is the most frequently involved oncogene in the pathogenesis of DLBCL, where it is 
hypermutated or translocated in a high number of cases (Pasqualucci et al., 2003; Ye, 2000). 
BCL6 is a key repressor that orchestrates many of the events occurring during the germinal 
center reaction. However, EBV positive cells seem, in most cases, not to participate in the 
germinal center reaction (Araujo et al., 1999). BCL6 can be downregulated in vitro by 
transfection of the viral LMP1 protein (Kuppers, 2003), but we have studied the relationship 
between BCL6 and EBV in a series of 149 patients of DLBCL and we have found an inverse 
correlation even in the absence of LMP1 expression. The reason why many of these DLBCL did 
not express LMP1 remains unknown, but we have found the expression of the LMP1-targetting 
miRNAs ebv-miR-BART1-5p, ebv-miR-BART16 and ebv-miR-BART17-5p in these lymphomas. 
Therefore, BCL6 must be down-regulated in these cases by other means. We wanted to test 
the hypothesis that the down-regulation of BCL6 in DLBCL could be due to the expression of 
BCL6-targetting miRNAs by the virus. As a first step we have performed a bioinformatic 
  
Discussion 
126 
 
prediction using the miRanda algorithm. This prediction rendered 21 binding sites in the 3’ UTR 
of BCL6 for 18 EBV-encoded miRNAs. In spite of the stringent thermodynamic criterion that we 
have used (-20 Kcal/mol) we found a high number of miRNAs. This might be a reflection of a 
redundant or a synergistic system. From this list, 10 miRNAs were found differentially 
expressed in the first series of 36 DLBCL patients and therefore we selected four miRNAs for 
functional validation based on bioinformatic parameters.  
However, in the miRNA microarray we had just 3 EBV-positive cases so we decided to study 
the expression of these four miRNAs plus the ebv-miR-BART10* that had very good score in 
miRanda but was not included in the microarray, in 40 patients (15 positive and 25 negative) 
included in the second series of 149 patients by RT-PCR. We found that all the miRNAs 
analyzed were expressed in the EBV-positive cases. Notably the expression of ebv-miR-
BART10* was around 10-fold less than the other miRNAs probably indicating that this strand is 
not entering into the RISC complex and is being targeted for degradation. 
 A striking finding is that we still could detect the expression of several of these miRNAs in 
EBV-negative cases (although at a much lower level). There are several possible explanations 
for this. The most obvious is that RT-PCR technique applied to miRNAs has some limitations. 
We used TaqMan probes that use a looped RT primer to increase melting temperature of the 
primer and to avoid amplification of immature miRNA sequences. However, due to the short 
extension of miRNAs the design of the primers is difficult and may not be as favorable as in the 
case of mRNA. The unexpected observations indicated here might be not important in cells 
expressing the target miRNA because the transcript will efficiently compete with the unspecific 
background. However, if the miRNA is not present, unspecific amplification could be giving 
some signal. Another possibility is that there are EBV-positive non-malignant cells in the 
biopsies that we have used and, although they are uncommon, we still can detect the 
expression of EBV-encoded miRNAs originated in these cells.  
Tumor cell lines are not always adequate models and very often do not resemble some of 
the features of the original tumors. However, our results of miRNA levels in cell lines explain 
why the phenomenon observed in patients is not reproduced in cell lines. In cell lines, the 
presence of EBV does not always result in high expression of the miRNAs. Hence, BCL6 is not 
repressed in those cell lines with low levels of EBV-encoded miRNAs. These results also offer a 
possible explanation of why EBV does not induce down-regulation of BCL6 in BL. Nevertheless 
it remains to be demonstrated that EBV-positive BL patients express lower levels of these 
miRNAs than EBV-positive DLBCL patients. 
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Using luciferase assays we have demonstrated that at least three of these miRNAs (ebv-
miR-BART3, ebv-miR-BART9 and ebv-miR-BART17-5p) can decrease BCL6 protein expression. 
This has been also confirmed in BCL6 positive cell lines by measuring the effect of the miRNAs 
on BCL6 protein levels. The results at the protein level differed slightly from the results 
obtained in the luciferase assays, especially with ebv-miR-BART7. This could reflect an indirect 
effect of this miRNA (which also makes sense) or, more probably, a cell context-dependent 
phenomenon that could be related to target-site accessibility. 
 Moreover, using anti-miR miRNA inhibitors, we could increase the expression of BCL6. It is 
interesting that we could not re-express BCL6 in the DoHH-2 cell line, which expresses the 
highest levels of miRNAs and the lowest levels of BCL6 protein. In this cell line, BCL6 might be 
transcriptionally inactive because it is being regulated at a different level (i.e. by a co-
repressor) or that the concentration of anti-miR that we have used is not enough to inhibit the 
high levels of EBV-encoded miRNAs in this cell line.  
 
The reason by which EBV-encoded miRNAs down-regulate BCL6 remains unknown. However, 
we could speculate that it is a mechanism to allow the activation of the NF-κB pathway. BCL6 
Figure 4.2. EBV activates NF-κB pathway directly (full line arrow) or indirectly (dashed line 
arrow) through latent membrane proteins (LMP1 and LMP2A) as a survival mechanism. At 
the same time it inhibits BCL6 to avoid NF-κB repression. 
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represses NF-κB in normal and pathogenic conditions (Perez-Rosado et al., 2008). However, 
several of the viral proteins such as LMP1 and LMP2A can activate directly or indirectly the NF-
κB pathway to promote the survival of the host cell (Figure 4.2) (Cahir-McFarland et al., 2004; 
Cahir McFarland et al., 1999; Keller et al., 2006; Kung and Raab-Traub, 2010; Merchant et al., 
2001; Mosialos et al., 1995; Song and Kang, 2010). Thus to down-regulate BCL6 is a pre-
requisite for the virus in order to survive in the host cell. 
This could have therapeutic implications. Taking into account that BCL6 functions as an 
oncogene in DLBCL, the presence of the EBV and the down-regulation of BCL6 indicate that, in 
infected cells, BCL6 confers disadvantages for the tumor cells. Thus inhibiting EBV-encoded 
miRNAs in these cells to increase the levels of BCL6 could be toxic for the cell. Moreover, in 
EBV-negative DLBCL cases and cell lines, inhibition of BCL6 by a small-molecule inhibitor leads 
to the suppression of tumor growth in xenograft models and to cell death in primary DLBCLs 
from human patients (Cerchietti et al., 2010).  
 
4.3 PERSPECTIVES 
In summary, in this work we have shown in first place that alterations in the PRC2 complex 
are common in human cancer and can be relevant in the pathogenesis of the tumors. It would 
be interesting to study the expression pattern of the third PRC2 core component, EED, because 
given the fact that EZH2 and SUZ12 act as oncogenes in many tumors, it is plausible that EED 
also exerts an oncogenic effect under some conditions. Moreover, we have seen a very 
different expression pattern for SUZ12 and EZH2 but we still do not know if the EED expression 
pattern is more similar to EZH2, to SUZ12 or has a distinct pattern.  
Second, we have demonstrated that the oncogenic virus EBV takes advantage of the 
host’s molecular machinery and hijacks the miRNA pathway to induce the regulation of BCL6. 
Although here we have only explored the relationship with BCL6, many other cellular targets 
may be affected by EBV infection and be relevant to its oncogenic potential. Thus, it would be 
interesting to study the effect of these miRNAs at the proteome level using quantitative 
proteomic profiling (Khan et al., 2010) in order to elucidate the exact role of these miRNAs in 
DLBCL. Moreover, the therapeutic implications of our discoveries also deserve further 
investigation in the adequate models.  
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1. SUZ12 and EZH2, although being both core components of the PRC2, are not expressed 
simultaneously in normal tissues and tumors. EZH2 was ubiquitously expressed in almost every 
tissue, while SUZ12 showed a most restricted expression pattern, associated to proliferation. 
2. SUZ12 is altered in human cancers, including lymphoid, pulmonary cancer, vascular 
tumor, germ-cell tumors, and skin tumors. The alterations include protein overexpression as 
well as copy number changes. 
3. SUZ12 loss interferes with the H3K27me3 mark and induces a decrease of cell viability 
in mantle cell lymphoma derived cell lines. 
4. Genome-wide mapping of SUZ12 gene targets suggests that SUZ12 controls several 
important functions such as apoptosis, proliferation, checkpoint regulation and DNA damage 
and repair. 
5. Epstein Barr virus-positive diffuse large B cell lymphoma samples express a restricted 
cluster of EBV-encoded miRNAs, located within the BART cluster and most of them with 
unknown function.  
6. Epstein Barr virus and BCL6 expression are mutually exclusive phenomena in diffuse 
large B-cell lymphoma 
7. Several of the EBV-encoded miRNAs that are expressed in EBV-positive DLBCL samples 
target BCL6 and inhibit its expression. In vitro studies demonstrate the ability of several EBV-
encoded miRNAs to collectively modulate BCL6 expression. 
  
 
  
    
Conclusiones 
132 
 
1. Aunque SUZ12 y EZH2 son ambos miembros centrales del complejo PRC2, no siempre 
se expresan de manera simultánea en tejidos normales y tumores. La expresión de EZH2 se 
detectó en prácticamente todos los tejidos y tumores, mientras que SUZ12 presentó un patrón 
asociado a proliferación. 
2. SUZ12 se encuentra alterado en cáncer, incluyendo tumores linfoides, pulmonares, 
vasculares, germinales y de piel. Estas alteraciones incluyen aumentos en los niveles de 
expresión y variaciones en el número de copias. 
3. La deficiencia de SUZ12 interfiere con la modificación epigenética H3K27me3 y 
produce un descenso en la viabilidad celular de líneas celulares derivadas de linfoma de células 
del manto. 
4. La identificación a nivel genómico de los genes diana de SUZ12 sugiere que SUZ12 
controla funciones importantes tales como apoptosis, proliferación, regulación de puntos de 
control y daño y reparación del ADN. 
5. Muestras de pacientes de linfoma difuso de células B grandes positivos para el virus de 
Epstein Barr expresan un grupo restringido de microARNs codificados por el virus, localizados 
en el grupo BART, la mayoría de los cuales tiene función desconocida. 
6. La presencia del virus de Epstein Barr y la expresión de BCL6 son fenómenos 
recíprocamente excluyentes en linfoma difuso de células B grandes. 
7. Varios de los microARNs codificados por el virus y que son expresados en muestras de 
pacientes de linfoma difuso están dirigidos contra BCL6 e inhiben su expresión. Estudios in 
vitro demuestran la capacidad de varios microARNs codificados por el virus para regular 
colectivamente los niveles de expresión de BCL6. 
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